Neptune Wellness Solutions (NEPTF) 40-F 28 Jun 18 2018 FY Annual report (Canada) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Mar. 31, 2018shares
Document And Entity Information [Abstract]
Document Type	40-F
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Trading Symbol	NEPT
Entity Registrant Name	Neptune Technologies & Bioressources Inc.
Entity Central Index Key	1,401,395
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding	78,804,212

Consolidated Statements of Fina

Consolidated Statements of Financial Position	Mar. 31, 2018CAD ($)	Mar. 31, 2017CAD ($)
Current assets:
Cash and cash equivalents (note 24)	$ 24,287,107	$ 15,802,363
Restricted short-term investment (note 24)	2,350,000
Trade and other receivables (note 5)	5,590,847	13,559,469
Tax credits receivable (note 18)	49,597	139,932
Prepaid expenses	372,944	684,261
Inventories (note 6)	5,261,329	13,242,735
Other financial asset (note 21 (a)(iii))	19,090
Total current assets	37,930,914	43,428,760
Restricted short-term investments (note 24)	60,000	2,745,000
Property, plant and equipment (note 7)	41,880,847	45,864,367
Intangible assets (note 8)	5,236,363	11,947,693
Goodwill (note 8)	6,750,626	6,750,626
Tax credits recoverable (note 18)	152,464	152,464
Deferred tax assets (note 18)		265,461
Other assets (notes 13 and 21 (a)(i))	6,585,740	65,745
Total assets	98,596,954	111,220,116
Current liabilities:
Trade and other payables (note 9)	6,747,889	9,993,019
Loans and borrowings (note 10)	4,661,356	7,192,315
Deferred revenues	109,954	549,675
Total current liabilities	11,519,199	17,735,009
Deferred lease inducements	267,101	326,456
Long-term payable (note 11)	249,714	795,072
Deferred tax liabilities (note 18)	27,170
Loans and borrowings (note 10)		15,739,229
Unsecured convertible debentures		1,406,365
Other financial liabilities (note 21 (a)(ii) and (iii))		417,747
Total liabilities	12,063,184	36,419,878
Equity:
Share capital (note 12)	128,483,507	127,201,343
Warrants (note 12 (e))	648,820	648,820
Contributed surplus	36,355,549	33,335,136
Accumulated other comprehensive income (loss)	525,559	(427,350)
Deficit	(79,479,665)	(97,010,523)
Total equity attributable to equity holders of the Corporation	86,533,770	63,747,426
Non-controlling interest (note 13)		7,435,948
Subsidiary warrants, options and other equity (note 13)		3,616,864
Total equity attributable to non-controlling interest		11,052,812
Total equity	86,533,770	74,800,238
Commitments and contingencies (note 23)
Total liabilities and equity	$ 98,596,954	$ 111,220,116

Consolidated Statements of Earn

Consolidated Statements of Earnings and Comprehensive Income - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement Of Earnings And Comprehensive Income Loss [Abstract]
Revenue from sales (note 4)	$ 26,168,469	$ 45,734,361
Royalty revenues	1,477,113	1,083,022
Total revenues	27,645,582	46,817,383
Cost of sales (note 6)	(18,944,321)	(34,015,571)
Other cost of sales - impairment loss on inventories (notes 4 et 6)	(2,376,969)
Cost of sales (note 6)	(21,321,290)	(34,015,571)
Gross margin	6,324,292	12,801,812
Research and development expenses	(12,395,671)	(7,248,873)
Research tax credits and grants (note 18)	(1,751,952)	2,408,377
Research and development, net	(14,147,623)	(4,840,496)
Selling, general and administrative expenses	(14,708,250)	(17,060,852)
Other income - royalty settlement (note 14)		15,301,758
Other income - net gain on sale of assets (note 4)	23,702,312
Income from operating activities	1,170,731	6,202,222
Gain on loss of control of subsidiary (note 13)	8,783,613
Finance income	227,465	66,536
Finance costs (note 16)	(2,446,279)	(2,772,146)
Change in fair value of derivative assets and liabilities and loss on sale of available-for-sale investment (note 21)	(36,347)	(263,135)
Income (loss) from non-operating activities	(2,255,161)	(2,968,745)
Income before income taxes	7,699,183	3,233,477
Income tax recovery (expense) (note 18)	1,640,200	(2,353,628)
Net income	9,339,383	879,849
Other comprehensive income (loss) (that may be reclassified subsequently to net income)
Unrealized gains (losses) on available-for-sale investments (notes 13 and 21 (a)(i))	544,834	(104,705)
Net change in unrealized gains on derivatives designated as cash flow hedges (note 21 (a)(iii))	26,388	29,751
Reclassification to net income of accumulated realized gain on available-for-sale investment (note 21 (a)(i))	381,687
Total other comprehensive income (loss)	952,909	(74,954)
Total comprehensive income	10,292,292	804,895
Net income attributable to:
Equity holders of the Corporation	17,530,858	6,913,228
Non-controlling interest (note 13)	(8,191,475)	(6,033,379)
Net income	9,339,383	879,849
Total comprehensive income attributable to:
Equity holders of the Corporation	18,483,767	6,838,274
Non-controlling interest (note 13)	(8,191,475)	(6,033,379)
Total comprehensive income	$ 10,292,292	$ 804,895
Basic and diluted income per share	$ 0.22	$ 0.09
Basic weighted average number of common shares (note 19)	78,599,208	77,945,548
Diluted weighted average number of common shares (note 19)	79,359,296	78,145,887

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - CAD ($)	Total	Acasti	Share Capital	Warrants	Contributed Surplus	Contributed SurplusAcasti	Available-for-Sale Investment	Cash Flow Hedges	Deficit	Total Attributable to Equity Holders of the Corporation	Total Attributable to Equity Holders of the CorporationAcasti	Subsidiary Warrants, Options and Other Equity	Subsidiary Warrants, Options and Other EquityAcasti	Non-controlling Interest	Non-controlling InterestAcasti	Total Attributable to Non-controlling Interest	Total Attributable to Non-controlling InterestAcasti
Beginning balance, shares at Feb. 29, 2016			77,968,587
Beginning balance at Feb. 29, 2016	$ 66,924,881		$ 127,201,343	$ 648,820	$ 29,871,114		$ (315,347)	$ (37,049)	$ (103,923,751)	$ 53,445,130		$ 5,548,482		$ 7,931,269		$ 13,479,751
Net income (loss) for the period	879,849								6,913,228	6,913,228				(6,033,379)		(6,033,379)
Other comprehensive (loss) income for the period	(74,954)						(104,705)	29,751		(74,954)
Total comprehensive income	804,895						(104,705)	29,751	6,913,228	6,838,274				(6,033,379)		(6,033,379)
Contributions by and distribution to equity holders
Share-based payment transactions (note 17)	2,014,902				1,340,324					1,340,324		674,578				674,578
Total contributions by and distribution to equity holders	2,014,902				1,340,324					1,340,324		674,578				674,578
Change in ownership interests in subsidiaries that do not result in a loss of control
Expiry of Acasti options and call-options (note 13 (i))						$ 3,059,035					$ 3,059,035		$ (3,059,035)				$ (3,059,035)
Acasti public offering (note 13 (vi))		$ 4,746,653				(935,337)					(935,337)		143,932		$ 5,538,058		5,681,990
Acasti issue of unsecured convertible debentures, net of deferred income tax expense of $129,362 (note 13 (vi))		308,907											308,907				308,907
Total changes in ownership interest in subsidiaries	5,055,560				2,123,698					2,123,698		(2,606,196)		5,538,058		2,931,862
Total transactions with equity holders	7,070,462				3,464,022					3,464,022		(1,931,618)		5,538,058		3,606,440
Ending balance, shares at Mar. 31, 2017			77,968,587
Ending balance at Mar. 31, 2017	74,800,238		$ 127,201,343	648,820	33,335,136		(420,052)	(7,298)	(97,010,523)	63,747,426		3,616,864		7,435,948		11,052,812
Net income (loss) for the period	9,339,383								17,530,858	17,530,858				(8,191,475)		(8,191,475)
Other comprehensive (loss) income for the period	952,909						926,521	26,388		952,909
Total comprehensive income	10,292,292						926,521	26,388	17,530,858	18,483,767				(8,191,475)		(8,191,475)
Contributions by and distribution to equity holders
Share-based payment transactions (note 17)	2,283,756				1,623,145					1,623,145		660,611				660,611
Liability settled in shares, shares			630,681
Liability settled in shares (note 12 (b))	$ 848,070		$ 848,070							848,070
DSU released, shares	55,944		55,944
DSU released (note 12 (c))			$ 80,000		(80,000)
Share options exercised, shares			149,000
Share options exercised (note 12 (d))	$ 256,616		$ 354,094		(97,478)					256,616
Loss of control of subsidiary (note 13)	(2,233,973)											(2,739,050)		505,077		(2,233,973)
Total contributions by and distribution to equity holders, shares			835,625
Total contributions by and distribution to equity holders	1,154,469		$ 1,282,164		1,445,667					2,727,831		(2,078,439)		505,077		(1,573,362)
Change in ownership interests in subsidiaries that do not result in a loss of control
Expiry of Acasti options and call-options (note 13 (i))						1,466,459					1,466,459		$ (1,466,459)				(1,466,459)
Exercise of warrants (note 13 (ii))	384,250				155,720					155,720		(71,966)		300,496		228,530
Fees related to past financing of Acasti (note 13 (iii))		$ (154,463)				$ (52,452)					$ (52,452)				$ (102,011)		$ (102,011)
Convertible debenture interest settled in shares (note 13 (iv))	56,984				5,019					5,019				51,965		51,965
Total changes in ownership interest in subsidiaries	286,771				1,574,746					1,574,746		(1,538,425)		250,450		(1,287,975)
Total transactions with equity holders, shares			835,625
Total transactions with equity holders	1,441,240		$ 1,282,164		3,020,413					4,302,577		$ (3,616,864)		$ 755,527		$ (2,861,337)
Ending balance, shares at Mar. 31, 2018			78,804,212
Ending balance at Mar. 31, 2018	$ 86,533,770		$ 128,483,507	$ 648,820	$ 36,355,549		$ 506,469	$ 19,090	$ (79,479,665)	$ 86,533,770

Consolidated Statements of Cha5

Consolidated Statements of Changes in Equity (Parenthetical)	13 Months Ended
	Mar. 31, 2017CAD ($)
Acasti | Unsecured Convertible Debentures
Acasti issue of unsecured convertible debentures, deferred income tax expense	$ 129,362

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows (used in) from operating activities:
Net income for the period	$ 9,339,383	$ 879,849
Adjustments:
Depreciation of property, plant and equipment	2,617,646	2,741,670
Amortization of intangible assets	924,236	1,075,130
Stock-based compensation	2,283,756	2,014,902
Impairment loss on inventories (note 6)	2,376,969	256,913
Gain on loss of control of subsidiary (note 13)	(8,783,613)
Recognition of deferred revenues	(549,671)	(397,440)
Amortization of deferred lease inducements	(59,355)	(64,303)
Net finance expense	2,255,161	2,968,745
Realized foreign exchange gain (loss)	(345,781)	155,840
Net gain on sale of assets, excluding transaction costs and severances (note 4)	(25,544,261)
Charge on settlement of liability	90,385
Income taxes expense (recovery) (note 18)	(1,640,200)	2,353,628
Tax credits recoverable (note 18)	1,932,831	(1,966,757)
Adjustments to reconcile profit (loss)	(15,102,514)	10,018,177
Changes in operating assets and liabilities (note 20)	7,515,995	(1,575,745)
Income taxes paid		(629,001)
Cash flows from (used in) operating activities	(7,586,519)	7,813,431
Cash flows from investing activities:
Maturity of short-term investments	519,000	23,341,837
Acquisition of short-term investments	(184,000)	(15,737,245)
Proceeds on sale of assets (note 4)	43,075,587
Proceeds on sale of investment (note 21 (a)(i))	104,110
Interest received	227,465	66,066
Acquisition of property, plant and equipment	(1,267,364)	(2,942,276)
Acquisition of intangible assets	(3,783,669)	(1,715,464)
Cash reduction related to loss of control of Acasti (note 13)	(2,666,122)
Cash flows from (used in) investing activities	36,025,007	3,012,918
Cash flows used in financing activities:
Payment of debt issuance transaction costs	490,000	(1,040,000)
Repayment of loans and borrowings (note 20 (c))	(19,389,098)	(7,654,363)
Increase in long-term debt, net of finance costs		3,666,311
Interest paid	(873,305)	(2,219,320)
Penalty on debt reimbursement (note 20 (c))	(263,483)
Settlement of derivative swap agreements (note 20 (c))	(58,999)
Issuance of shares costs (note 12 (b))	(9,930)
Proceeds from exercise of options (note 12 (d))	256,616
Cash flows from (used in) financing activities	(19,885,019)	(366,349)
Foreign exchange gain (loss) on cash and cash equivalents held in foreign currencies	(68,725)	(130,564)
Net increase in cash and cash equivalents	8,484,744	10,329,436
Cash and cash equivalents as at April 1, 2017 and March 1, 2016	15,802,363	5,472,927
Cash and cash equivalents as at March 31, 2018 and 2017	24,287,107	15,802,363
Cash and cash equivalents is comprised of:
Cash	5,784,810	12,808,173
Cash equivalents	18,502,297	2,994,190
Acasti
Cash flows used in financing activities:
Payment of debt issuance transaction costs	(40,305)
Issuance of shares costs (note 12 (b))	(380,765)
Proceeds from Acasti warrants	$ 384,250
Net proceeds from Acasti public offering (note 13 (ii)) and private placement		$ 6,881,023

Reporting Entity

Reporting Entity	12 Months Ended
	Mar. 31, 2018
Disclosure Of Reporting Entity [Abstract]
Reporting entity	1. Reporting entity: Neptune Technologies & Bioressources Inc. (the "Corporation" or "Neptune") is incorporated under the Business Corporations Act Companies Act Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Corporation formulates and develops turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com . Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extracts and formulations in high potential growth segments such as medical and wellness cannabinoid-based products.

Basis of Preparation

Basis of Preparation	12 Months Ended
	Mar. 31, 2018
Disclosure Of Basis Of Preparation [Abstract]
Basis of preparation	2. Basis of preparation: (a) Statement of compliance: These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements were approved by the Board of Directors on June 5, 2018. (b) Basis of measurement : The consolidated financial statements have been prepared on the historical cost basis, except for the following: • Share-based compensation transactions which are measured pursuant to IFRS 2, Share-based payment (note 3 (l)(ii)); • Available-for-sale financial assets which are measured at fair value (notes 13 and 21 (a)(i)); • Derivative hedging financial instrument which is measured at fair value (note 21 (a)(iii)); and • Derivative warrant liabilities which were measured at fair value until deconsolidation of Acasti (note 21 (a)(ii)). Certain of the Corporation’s accounting policies and disclosures require the determination of fair value, for both financial and non-financial assets and liabilities. In establishing fair value, the Corporation uses a fair value hierarchy based on levels as defined below: • Level 1: defined as observable inputs such as quoted prices in active markets. • Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable. • Level 3: defined as inputs that are based on little or no little observable market data, therefore requiring entities to develop their own assumptions. (c) Functional and presentation currency: These consolidated financial statements are presented in Canadian dollars, which is the Corporation and its subsidiaries’ functional currency. (d) Use of estimates and judgments: The preparation of consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates are based on management’s best knowledge of current events and actions that the Corporation may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements include the following: • Determining that the goodwill recorded on the acquisition of the Biodroga operations should be fully associated with these operations and therefore that none should be allocated to the sale of assets (note 4); • Assessing the recognition of contingent liabilities, which requires judgment in evaluating whether there is a probable outflow of economic benefits that will be required to settle matters subject to litigation (note 23); and • Assessing the criteria for recognition of tax assets (note 18). Assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year include the following: • Estimating the recoverable amount of non-financial assets (note 3 (f)(ii)). 1

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Mar. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Significant accounting policies	3. Significant accounting policies: The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, and have been applied consistently by the Corporation’s subsidiaries. (a) Basis of consolidation: ( i ) Business combinations and related goodwill: Business combinations are accounted for using the acquisition method as at the acquisition date, when control is transferred. The consideration transferred for the acquisition of a business is the fair value of the assets transferred, and any liability and equity interests issued by the Corporation on the date control of the acquired company is obtained. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are generally measured initially at their fair values at the acquisition date. The Corporation measures goodwill as the fair value for the consideration transferred including the recognized amount of any non-controlling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured at the acquisition date. If this consideration is lower than the fair value of the net assets of the business acquired, the difference is recognized immediately in the consolidated statement of earnings and comprehensive loss as a gain from a bargain purchase. Restructuring, transaction costs other than those associated with the issue of debt or equity securities, and other direct costs of a business combination are not considered part of the business acquisition transaction and are expensed as incurred. Subsequent recognition of goodwill: After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but tested for impairment at least annually and upon occurrence of an indication of impairment. The impairment testing process is described in the appropriate section of these accounting policies. Subsidiaries: Subsidiaries are entities controlled by the Corporation. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Control exists when the Corporation is exposed to, or has the right to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. (ii) Transactions eliminated on consolidation: Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. (iii) Subsidiary warrants, options and other equity: Subsidiary warrants, options and other equity are comprised of equity-classified warrants, rights and options issued by the subsidiary, as well as options and rights issued by the Corporation over the subsidiary’s equity instruments. Because they do not represent outstanding participating non-controlling interests, they are recorded at cost and remain presented as a sub-component of non-controlling interest until such time they are exercised or expire. (iv) Acquisitions and dispositions of non-controlling interests while retaining control: Acquisitions and dispositions of non-controlling interests while retaining control are accounted for as transactions with equity holders in their capacity as equity holders; therefore, no goodwill is recognized as a result of acquisitions and no gain or loss is recognized in connection with dispositions. Upon acquisition or disposition of non-controlling interests while retaining control, the Corporation adjusts non-controlling interests to reflect the relative change in its interest in the subsidiary’s equity, before giving effect of the elimination of the intra-group balances. Any difference between the amount by which non-controlling interest is adjusted and the fair value of consideration paid or received is recognized directly in equity attributable to shareholders of the Corporation. The fair value of consideration paid includes the cost of any subsidiary warrants, options and other equity exercised as part of the operation. Subsidiary warrants, options and other equity that expire unexercised are transferred to equity attributable to shareholders of the Corporation. (v) Attribution of profit or loss: Profit or loss of the subsidiaries is attributed to the Corporation’s shareholders and to non-controlling interests based on their respective share of participating equity instruments in each subsidiary outstanding during the period. This allocation is made giving effect to subsidiary profit and loss and before the elimination of intra-group balances. (b) Financial instruments: ( i ) Non-derivative financial assets: The Corporation has the following non-derivative financial assets: cash and cash equivalents, restricted short-term investments, trade and other receivables and other assets. Financial assets and liabilities are offset and the net amount presented in the consolidated statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Loans and receivables Loans and receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses. Loans and receivables comprise cash and cash equivalents, trade and other receivables and restricted short-term investments. Cash and cash equivalents comprise cash balances and highly liquid investments purchased three months or less from maturity. Bank overdrafts that are repayable on demand form an integral part of the Corporation’s cash management and are included as a component of cash and cash equivalents for the purpose of the consolidated statements of cash flows. Available-for-sale financial assets Available-for-sale financial assets are non-derivative financial assets that are designated as available-for-sale or are not classified in any of the other categories of financial assets. These assets are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at fair value and changes therein, are recognized in other comprehensive income (loss) and presented in accumulated other comprehensive income (loss) in equity. When an available-for-sale financial asset is derecognized, the gain or loss accumulated other comprehensive income (loss) in equity is reclassified to income or loss. The Corporation’s available-for-sale financial asset is comprised only of quoted equity securities and is presented as Other Assets. (ii) Non-derivative financial liabilities: The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire. The Corporation has the following non-derivative financial liabilities: loans and borrowings, trade and other payables and long-term payables. Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method. (iii) Share capital: Common shares are classified as equity. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. (iv) Compound financial instruments: Compound financial instruments are instruments that can be converted to share capital at the option of the holder, and the number of shares to be issued is fixed. The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not remeasured subsequent to initial recognition. (v) Derivative financial instruments and hedge accounting: Derivative financial instruments: The Corporation has issued liability-classified derivatives over its own equity. Embedded derivative is separated from the host contract and accounted for separately if the economic characteristics and risks of the host contract and the embedded derivative are not closely related, a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative, and the combined instrument is not measured at fair value through profit or loss. Derivatives and separable embedded derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives and separable embedded derivatives are measured at fair value, and all changes in their fair value are recognized immediately in profit or loss. Hedge accounting: Derivatives that qualify as hedging instruments must be designated as either a “cash flow hedge”, when the hedged risk is a variability in the future cash flows of the hedged item, or a “fair value hedge”, when the hedged risk is a variability in the fair value of the hedged item. Any derivative instrument that does not qualify for hedge accounting is marked-to-market at each reporting date and the gains or losses are included in income. Cash flow hedges: For derivative financial instruments designated as cash flow hedges, the effective portion of changes in their fair value is recognized in other comprehensive income in the consolidated statement of comprehensive income and presented in the cash flow hedges reserve in equity. Any ineffectiveness is recognized in income immediately as it arises in the same consolidated statement of earnings and comprehensive loss account as the hedged item when realized. Should a cash flow hedging relationship become ineffective or the hedging relationship be terminated, previously unrealized gains and losses remain within the cash flows hedges reserve until the hedged item is settled and any future changes in value of the derivative are recognized in income prospectively. When the hedged item is realized, amounts recognized in the cash flow hedge reserve are reclassified to the same consolidated statement of earnings and comprehensive loss account or reclassified to the related non-financial asset in which the hedged item is recorded. If the hedged item ceases to exist before the hedging instrument expires, the unrealized gains or losses within the cash flow hedge reserve are immediately reclassified to income. Use of derivative financial instruments: Derivative financial instruments are utilized, from time to time, by the Corporation in the management of its foreign currency exposures and interest-rate market risks. These derivative financial instruments are used as a method for meeting the risk reduction objectives of the Corporation by generating offsetting cash flows related to the underlying position in respect of amount and timing of forecasted foreign currency cash flows and interest payments. The Corporation uses interest rate swap agreements to lock-in a portion of its debt cost and reduce its exposure to the variability of interest rates by exchanging variable rate payments for fixed rate payments. The Corporation has designated its interest rate swaps as cash flow hedges for which it uses hedge accounting. When it utilizes derivatives in hedge accounting relationships, the Corporation formally documents and designates all of its eligible hedging relationships. This process involves associating all derivatives to specific assets and liabilities on the consolidated statement of financial position or with forecasted or probable transactions. The Corporation also formally assesses the effectiveness of hedging relationships at inception and on an on-going basis. (vi) Other equity instruments: Warrants, options and rights over the Corporation’s equity issued outside of share-based payment transactions that do not meet the definition of a liability instrument are recognized in equity. (c) Inventories: Inventories are measured at the lower of cost and net realizable value. The cost of raw materials, supplies and spare parts is based on the weighted-average cost method. The cost of finished goods and work in progress includes expenditures incurred in acquiring the inventories, production or conversion costs, sub-contractors costs and other costs incurred in bringing them to their existing location and condition, as well as production overheads based on normal operating capacity. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. (d) Property, plant and equipment: ( i ) Recognition and measurement: Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labour, any other costs directly attributable to bringing the assets to a working condition for their intended use, the costs of dismantling and removing the items and restoring the site on which they are located and borrowing costs on qualifying assets. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. When parts of an item of property, plant and equipment have significantly different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized in net profit (loss). (ii) Subsequent costs: The cost of replacing a part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property, plant and equipment are recognized in profit or loss as incurred. (iii) Depreciation: Depreciation is calculated over the depreciable amount, which is the cost of an asset less its residual value. Depreciation is recognized in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item of property, plant and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows: Asset Method Period/Rate Building and building components Straight-line 20 to 40 years Laboratory, R&D and plant equipment Straight-line 10 to 20 years Furniture and office equipment Declining balance 20% to 30% Computer equipment Straight-line 2 to 5 years Depreciation methods, useful lives and residual values are reviewed at each financial year-end and adjusted prospectively, if appropriate. (e) Intangible assets: ( i ) Research and development: Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditure is recognized in profit or loss as incurred. Capitalized development expenditure is measured at cost less accumulated amortization and accumulated impairment losses. (ii) Other intangible assets: Non-compete agreements Non-compete agreements were valued as part of business acquisitions and are amortized on a straight-line basis over a period of 3 Customer relationships Customer relationships were acquired as part of business acquisitions and are amortized on a straight-line basis over a period of 10 Patent costs Patents for technologies that are no longer in the research phase are recorded at cost. The patent costs include legal fees to obtain patents and patent application fees. When the technology is still in the research phase, those costs are expensed as incurred. Patent costs are amortized on a straight-line basis over a period of 20 years. License agreements License agreements are mainly comprised of a license agreement acquired separately or as part of business acquisitions and are amortized on a straight-line basis between a period of 12 or 13 years from the acquisition date according to the licence agreement. Trademarks Trademarks have indefinite useful lives considering that they can be renewed at a minimal cost and are not amortized. They are tested for impairment annually, or more frequently if events or changes in circumstances indicate that they might be impaired. Any impairment is recognized in profit or loss. (iii) Subsequent expenditure: Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred. (iv) Amortization: Amortization is calculated over the cost of the asset less its residual value. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, other than trademarks, from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are described above. (f) Impairment: ( i ) Financial assets (including receivables): A financial asset not carried at fair value through profit or loss is assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, restructuring of an amount due to the Corporation on terms that the Corporation would not consider otherwise, indications that a debtor or issuer will enter bankruptcy, or the disappearance of an active market for a security. The Corporation considers evidence of impairment for receivables at both a specific asset and collective level. All individually significant receivables are assessed for specific impairment. All individually significant receivables found not to be specifically impaired are then collectively assessed for any impairment that has been incurred but not yet identified. Receivables that are not individually significant are collectively assessed for impairment by grouping together receivables with similar risk characteristics. In assessing collective impairment, the Corporation uses historical trends of the probability of default, timing of recoveries and the amount of loss incurred, adjusted for management’s judgment as to whether current economic and credit conditions are such that the actual losses are likely to be greater or less than suggested by historical trends. An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. Impairment losses on available-for-sale financial assets are recognized by reclassifying the losses accumulated in accumulated other comprehensive income to profit or loss. The amount reclassified is the difference between the acquisition cost and the current fair value, less any impairment loss previously recognized in profit or loss. (ii) Non-financial assets: The carrying amounts of the Corporation’s non-financial assets, and other than inventories, tax credits receivable and recoverable and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. For intangible assets that have indefinite useful lives or that are not yet available for use, the recoverable amount is estimated each year at the same date. The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the ''cash-generating unit'', or ''CGU''). An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill: Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired. Impairment is determined for goodwill by assessing the recoverable amount of each CGU to which the goodwill relates. The Corporation defines its CGUs based on the way it internally monitors and derives economic benefits from the acquired goodwill. Impairment losses for a CGU is first allocated to reduce goodwill. An impairment loss in respect of goodwill is not reversed in future periods. (g) Provisions: A provision is recognized if, as a result of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost. ( i ) Onerous contracts: A provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract. (ii) Contingent liability: A contingent liability is a possible obligation that arises from past events and of which the existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not within the control of the Corporation; or a present obligation that arises from past events (and therefore exists), but is not recognized because it is not probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation, or the amount of the obligation cannot be estimated reliably . (h) Revenue: ( i ) Sale of goods: Revenue from the sale of goods in the course of ordinary activities is measured at the fair value of the consideration received or receivable, net of returns. Revenue is recognized on delivery when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. The Corporation considers delivery to have occurred upon shipment, or in some cases, upon reception by the customer. If it is probable that discounts will be granted and the amount can be measured reliably, then the discount is recognized as a reduction of revenue as the sales are recognized. (ii) Royalty revenues: Royalties are earned under the terms of the applicable agreement and are generally recognized on this basis. Royalty revenues are recognized when it is probable that the economic benefits associated with the transaction will be received and the amount can be measured reliably. ( i ) Government grants: Government grants, consisting of grants and investment tax credits, are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Corporation has met or will meet the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset. (j) Lease payments: Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease. Contingent lease payments are accounted for in the period in which they are incurred. (k) Foreign currency: Transactions in foreign currencies are translated to the respective functional currency at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on retranslation are recognized in profit or loss. (l) Employee benefits: ( i ) Short-term employee benefits: Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Corporation has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably. (ii) Share-based payment transactions: The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in contributed surplus and subsidiary warrants and options, as applicable, over the period that the employees unconditionally become entitled to the awards. The grant date fair value takes into consideration market performance conditions when applicable. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. The fair value of the share-based payment transactions is measured based on valuation models. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility), weighted average expected life of the instruments (based on contractual life, tranche vesting term and general option holder behaviour), expected dividends, and the risk-free interest rate (based on government bonds). Service and non-market performance conditions attached to the transactions, if any, are not taken into account in determining fair value. (iii) Termination benefits: Termination benefits are recognized as an expense when the Corporation is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to (m) Finance income and finance costs: Finance income comprises interest income on funds invested. Interest income is recognized as it accrues in profit or loss, using the effective interest method. Finance costs comprise interest expense and accretion on borrowings, unwinding of the discount on provisions, financing costs, penalty on debt reimbursement, impairment losses recognized on financial assets and bank charges. Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognized in profit or loss using the effective interest method. Foreign currency gains and losses are reported on a net basis. The Corporation recognizes interest income as a component of investing activities and interest cost as a component of financing activities in the consolidated statements of cash flows. (n) Income tax: Income tax expense comprises current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to a business combination, or items recognized directly in equity or in other comprehensive income. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, and differences relating to investments in subsidiaries and jointly contr

Sale of Assets

Sale of Assets	12 Months Ended
	Mar. 31, 2018
Disclosure Of Sale Of Assets [Abstract]
Sale of assets	4. Sale of assets: On August 7, 2017, Neptune and Aker BioMarine Antarctic AS (“Aker BioMarine”) concluded an agreement whereby Aker BioMarine acquired Neptune’s intellectual property, list of customers and krill oil inventory for a cash consideration of $43,075,587 (US$34 million) paid at closing. Under this agreement, Neptune exits bulk krill oil manufacturing and distribution activities and Aker BioMarine becomes exclusive krill oil supplier to Neptune’s solutions business. An amount of $11,175,466 of such proceeds was used for debt reimbursement and to pay the penalty on early repayment of $263,483 concurrent with the sale transaction and an additional $2,391,673 of debt was repaid on October 6, 2017. The assets sold were included in the Nutraceutical segment. The disposal of the krill oil manufacturing and distribution activities allows the Corporation to accelerate its efforts to position the Corporation in attractive growth opportunities and product lines such as the medical and wellness cannabis oil extraction project, in line with its growth strategy. The krill oil manufacturing and distribution sales were $3.2 million during the year ended March 31, 2018 ($21.5 million for the thirteen-month period ended March 31, 2017) and the gross margin, excluding the impairment loss on inventories of $2.4 million, was $1.2 million during the year ended March 31, 2018 ($6.2 million for the thirteen-month period ended March 31, 2017 The Sherbrooke facility was not part of the transaction and it will be used for the development of unique extractions targeted towards high potential growth segments such as the cannabis industry. A large number of our employees saw their employment end as part of this transaction. A small team of people continues to work on special projects including the medical and wellness cannabis project at the facility as well as activities relating to exiting the bulk krill oil business. As the Sherbrooke facility was not part of the transaction, it did not qualify as discontinued operations for accounting purposes. Furthermore, management assessed the recoverable amount of the Sherbrooke facility and no revaluation of the useful life and no impairment of the plant and related equipment were recorded for the year ended March 31, 2018. The following table presents a reconciliation of the net gain on sale of assets for the year ended March 31, 2018 and the full impact of the sale transaction and concurrent debt reimbursements on the net income of the Corporation: August 7, 2017 Total transaction proceeds $ 43,075,587 Inventory sold (11,185,572 ) Net intangible assets sold (5,791,710 ) Write-off of assets, severance costs, transaction costs and costs for activities relating to exiting the bulk krill oil business (i) (2,395,993 ) Net gain on sale of assets as presented in the consolidated statement of earnings $ 23,702,312 Impairment loss in inventories – presented in cost of sales (note 6) (2,376,969 ) Penalty on reimbursement, loss on financing fees and reversal of accretion from non-interest bearing debt reimbursed – presented in finance costs (note 16) (920,429 ) Total impact of the transaction on the net income before tax $ 20,404,914 (i) Including non-cash write-off of assets of $554,044, employee severance of $1,063,790 and transaction costs of $497,811.

Trade and Other Receivables

Trade and Other Receivables	12 Months Ended
	Mar. 31, 2018
Trade And Other Current Receivables [Abstract]
Trade and other receivables	5. Trade and other receivables: March 31, March 31, 2018 2017 Trade receivables $ 4,926,632 $ 7,390,701 Sales taxes receivable 215,184 153,652 Accrued and other receivables 426,488 6,015,116 Grants receivables 22,543 — $ 5,590,847 $ 13,559,469 The Corporation’s exposure to credit and currency risks related to trade and other receivables is presented in note 21 (b).

Inventories

Inventories	12 Months Ended
	Mar. 31, 2018
Classes Of Inventories [Abstract]
Inventories	6. Inventories: March 31, March 31, 2018 2017 Raw materials $ 3,358,264 $ 5,539,437 Work in progress 474,057 3,154,833 Finished goods 675,031 3,807,455 Supplies and spare parts 753,977 741,010 $ 5,261,329 $ 13,242,735 For the year ended March 31, 2018 Finished goods and work in progress inventories with a carrying value of $11,185,572 was sold to Aker BioMarine during the year ended March 31, 2018 (note 4). Furthermore, the impairment loss on inventories of $2,376,969, was recorded for the year ended March 31, 2018 on raw materials after the sale of assets transaction and is all related to the nutraceutical segment. See note

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Mar. 31, 2018
Disclosure Of Property Plant And Equipment [Abstract]
Property, plant and equipment	7. Property, plant and equipment: Building Laboratory, Furniture and building R&D and plant and office Computer Land components equipment equipment equipment Total Cost: Balance at February 29, 2016 $ 228,630 $ 23,009,625 $ 26,073,781 $ 499,159 $ 281,766 $ 50,092,961 Additions – 6,231 2,953,611 9,710 88,820 3,058,372 Disposals – – (8,995 ) (45,102 ) – (54,097 ) Balance at March 31, 2017 228,630 23,015,856 29,018,397 463,767 370,586 53,097,236 Additions – 147,263 1,182,102 – 86,555 1,415,920 Loss of control of Acasti (note 13) – – (3,299,059 ) (18,407 ) (13,759 ) (3,331,225 ) Balance at March 31, 2018 $ 228,630 $ 23,163,119 $ 26,901,440 $ 445,360 $ 443,382 $ 51,181,931 Accumulated depreciation: Balance at February 29, 2016 – 1,721,529 2,358,964 258,377 206,426 4,545,296 Disposals – – (8,995 ) (45,102 ) – (54,097 ) Depreciation for the thirteen-month period – 899,412 1,743,346 57,439 41,473 2,741,670 Balance at March 31, 2017 – 2,620,941 4,093,315 270,714 247,899 7,232,869 Loss of control of Acasti (note 13) – – (529,344 ) (13,070 ) (7,017 ) (549,431 ) Depreciation for the year – 830,850 1,712,516 37,820 36,460 2,617,646 Balance at March 31, 2018 $ – $ 3,451,791 $ 5,276,487 $ 295,464 $ 277,342 $ 9,301,084 Net carrying amounts: March 31, 2017 $ 228,630 $ 20,394,915 $ 24,925,082 $ 193,053 $ 122,687 $ 45,864,367 March 31, 2018 228,630 19,711,328 21,624,953 149,896 166,040 41,880,847 From the balance of property, plant and equipment, an amount of $1,152,814 (2017 - $172,142) represents assets which are not yet in service as at March 31, 2018. Depreciation expense has been recorded in the following accounts in the consolidated statements of earnings and comprehensive income: March 31, March 31, 2018 2017 (12 months) (13 months) Cost of sales $ 1,067,629 $ 2,264,748 Research and development expenses 1,321,145 229,541 Selling, general and administrative expenses 228,872 247,381 $ 2,617,646 $ 2,741,670

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Mar. 31, 2018
Disclosure Of Intangible Assets And Goodwill [Abstract]
Intangible assets and goodwill	8. Intangible assets and goodwill: Non-compete Customer License agreements relationships Patents agreements Trademarks Total Cost: Balance at February 29, 2016 $ 400,000 $ 4,100,000 $ 1,544,467 $ 1,552,334 $ 150,289 $ 7,747,090 Additions — — 2,126 6,182,604 12,937 6,197,667 Balance at March 31, 2017 400,000 4,100,000 1,546,593 7,734,938 163,226 13,944,757 Additions — — — 772 3,844 4,616 Sale to Aker BioMarine (note 4) — — (1,185,773 ) (5,553,524 ) (167,070 ) (6,906,367 ) Balance at March 31, 2018 $ 400,000 $ 4,100,000 $ 360,820 $ 2,182,186 $ — $ 7,043,006 Accumulated depreciation: Balance at February 29, 2016 $ 22,000 $ 68,200 $ 814,174 $ 17,560 $ — $ 921,934 Amortization for the thirteen- month period 143,000 443,300 108,400 380,430 — 1,075,130 Balance at March 31, 2017 165,000 511,500 922,574 397,990 — 1,997,064 Sale to Aker BioMarine (note 4) — — (576,458 ) (538,199 ) — (1,114,657 ) Amortization for the year 132,111 409,267 14,704 368,154 — 924,236 Balance at March 31, 2018 $ 297,111 $ 920,767 $ 360,820 $ 227,945 $ — $ 1,806,643 Net carrying amounts: March 31, 2017 $ 235,000 $ 3,588,500 $ 624,019 $ 7,336,948 $ 163,226 $ 11,947,693 March 31, 2018 102,889 3,179,233 — 1,954,241 — 5,236,363 Amortization expense of $924,236 have been recorded in the Selling, general and administrative expenses in the consolidated statements of earnings and comprehensive income for the year ended March 31, 2018 ($1,075,130 for the thirteen-month period ended March 31, 2017). An impairment test of goodwill is performed on an annual basis, or more frequently if an impairment indicator is triggered. Impairment is determined by assessing the recoverable amount of the group of CGUs to which goodwill is allocated and comparing it to the CGUs’ carrying amount. For the purpose of impairment testing, goodwill is allocated to the Biodroga operations CGU of the nutraceutical segment which represents the lowest level within the Corporation at which the goodwill is monitored for internal management purposes. The Corporation performed its annual impairment testing of goodwill as at March 31, 2018. The recoverable amount of Biodroga operations CGU was determined using the value-in-use basis (as at March 31, 2017, the recoverable amount was determined using fair value less cost to sell of the nutraceutical group of CGUs based on quoted market prices, using level 1 inputs in the fair value hierarchy), and was determined to be higher than the carrying value, as such goodwill was not impaired. The value-in-use of the CGU was estimated using discounted cash flow forecasts with a discount rate of 18.2%. The discount rate represents the weighted average cost of capital ("WACC") for comparable companies operating in similar industries as the CGU, based on publicly available information. Determination of the WACC requires separate analysis of the cost of equity and debt, and considers a risk premium based on an assessment of risks related to the projected cash flows of the CGU. Cash flows were projected based on past experience, actual operating results and the three-year business plan including a terminal growth rate of 2.0%. The assumptions used by the Corporation in the cash flow forecast discounting model are classified as Level 3 in the fair value hierarchy, signifying that they are not based on observable market data. The model is particularly sensitive to the future expected cash flows in the upcoming periods, should these not be realized, an impairment loss may be needed in future periods.

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Mar. 31, 2018
Trade And Other Current Payables [Abstract]
Trade and other payables	9. Trade and other payables: March 31, March 31, 2018 2017 Trade payables $ 2,425,617 $ 4,344,557 Accrued liabilities and other payables 2,773,043 3,757,436 Employee salaries and benefits payable 1,549,229 1,891,026 $ 6,747,889 $ 9,993,019 The Corporation’s exposure to currency and liquidity risks related to trade and other payables is presented in note 21 (b).

Loans and Borrowings

Loans and Borrowings	12 Months Ended
	Mar. 31, 2018
Borrowings [Abstract]
Loans and borrowings	10. Loans and borrowings: This note provides information about the contractual terms of the Corporation’s loans and borrowings, which are measured at amortized cost. March 31, March 31, 2018 2017 Loans and borrowings: Loan, bearing interest at prime rate plus 2.5% (plus 3.25% before October 14, 2016), secured through a first-ranking mortgage on all movable assets of Biodroga current and future, corporeal and incorporeal, and tangible and intangible, reimbursable in monthly principal payments of $89,286 and a final payment of $3,314,276 on December 2018. The interest risk of the loan is mitigated by an interest rate swap. The Corporation has reserved $2,350,000 of short-term investments as pledge for the loan. Amounts received are net of transaction costs of $197,789. $ 3,891,077 $ 5,429,852 Balance of purchase price due to previous owners of Biodroga bearing interest at 5% until December 2018, reimbursable in quarterly principal payments of $93,750 from March 2016 to September 2018, with a final payment of $74,096. An amount of $2,501,016 bearing interest at 7% was reimbursed during the year. Payments under these agreements are only payable if covenants on the loan at prime plus 2.5% above are respected. 261,596 3,202,612 Authorized bank line of credit of $1,800,000 bearing interest at prime rate plus 1%, expiring on August 31, 2018. 490,000 — Finance lease liabilities, interest rate from 6.25% to 7.13%, payable in monthly instalments of $2,345, maturing in November 2018 and March 2019. 18,683 44,644 Secured loan from Investissement Québec (“IQ”), principal balance authorized of $12,500,000, bearing interest at 8%, reimbursed during the year. — 8,347,506 Loan, principal amount of 2.1 million GBP ($3,822,000), bearing interest at 12%, reimbursed during the year. — 3,562,814 Refundable contribution obtained from a federal program, principal balance authorized of $3,500,000, without collateral or interest, reimbursed during the year. — 2,344,116 4,661,356 22,931,544 Less current portion of loans and borrowings 4,661,356 7,192,315 Loans and borrowings $ — $ 15,739,229 Interest of $986,986 ($2,592,659 for the thirteen-month period ended March 31, 2017) was recognized during the year ended March 31, 2018 on loans and borrowings. Some of the proceeds resulting from the transaction with Aker BioMarine were used to completely reimburse the loan from IQ, the loan in GBP and the refundable contribution obtained from a federal program, and also to reduce balance of purchase price during the year ended March 31, 2018. See note 4. The Corporation’s exposure to liquidity risks related to loans and borrowings is presented in note 21 (b).

Long-term Payable

Long-term Payable	12 Months Ended
	Mar. 31, 2018
Long Term Payable [Abstract]
Long-term payable	11. Long-term payable: On September 30, 2016, Neptune through its subsidiary Biodroga entered into an exclusive, worldwide and royalty bearing commercial agreement with Ingenutra Inc. for its patented and clinically studied MaxSimil specialty ingredient. The agreement provides Neptune with the right to manufacture, distribute and sell MaxSimil in the nutraceutical field. As at September 30, 2016, Neptune has recorded an intangible asset of US$850,000 ($935,804 at the discounted fair value) and a long-term payable of the same amount. In connection with this agreement, Neptune must also pay royalties based on sales, using this specialty ingredient. Minimum annual volumes must be reached for the duration of the agreement of 11 years (refer to note 23 (a)(i)). A royalty fee of $372,592 has been recorded for the year ended March 31, 2018 ($115,870 for the thirteen-month period ended March 31, 2017). As at March 31, 2018, the short-term and long-term payable to Ingenutra Inc. are respectively $558,045 and $249,714 (2017 - $215,095 and $795,072).

Capital and other components of

Capital and other components of equity	12 Months Ended
	Mar. 31, 2018
Disclosure Of Share Capital Reserves And Other Equity Interest [Abstract]
Capital and other components of equity	12. Capital and other components of equity: (a) Share capital: Authorized capital stock: Unlimited number of shares without par value: ➣ Common shares Preferred shares, issuable in series, rights, privileges and restrictions determined at time of issuance: ➣ Series A preferred shares, non-voting, non-participating, fixed, preferential and non-cumulative dividend of 5% of paid-up capital, exchangeable at the holder’s option under certain conditions into common shares (none issued and outstanding). (b) Liability settled in shares: On May 9, 2017, Neptune issued 630,681 common shares of the Corporation at a price of $1.35 per common share as final payment of a liability of $858,000 (US$ 625,000). Total issue costs related to this transaction amounted to $9,930 and were record against share capital. (c) DSUs released: During the year ended March 31, 2018, Neptune issued 55,944 common shares of the Corporation to members of the Board of Directors for past services, the amount recorded was at the grant date fair value of the underlying shares of $1.43 per common share. (d) Share options exercised: During the year ended March 31, 2018, Neptune issued 149,000 common shares of the Corporation at a weighted average exercise price of $1.72 per common share for a total cash consideration of $256,616. (e) Warrants: The warrants of the Corporation are composed of the following as at March 31, 2018 and 2017: March 31, March 31, 2018 2017 Number Number outstanding outstanding and exercisable Amount and exercisable Amount Warrants IQ financing (i) 750,000 $ 648,820 750,000 $ 648,820 ( i ) Exercise price of $3.37 per share and expiring on December 12, 2019.

Non-controlling Interests ("NCI

Non-controlling Interests ("NCI")	12 Months Ended
	Mar. 31, 2018
Disclosure Of Significant Investments In Subsidiaries [Abstract]
Non-controlling interests ("NCI")	13. Non-controlling interests ("NCI"): Before Acasti’s public financing which occurred on December 27, 2017, Neptune owned 33.96% of Acasti’s shares and had determined it had de facto control over and therefore consolidated Acasti. After the financing, the ownership interest of the Corporation in Acasti went down to 20.39% and 12.12% on a fully diluted basis (34.45% and 23.28% as at March 31, 2017). Therefore, management has determined that the Corporation lost the de facto control of the subsidiary. On January 22, 2018, Acasti issued additional overallotment shares pursuant to its December 27, 2017 financing, which brought the Corporation’s ownership interest to 19.78%. Following these events, the Corporation concluded it does not have significant influence over Acasti and accounts for the investment in Acasti at fair value as an available-for-sale financial asset with changes in fair value recognized in Other comprehensive income. On December 27, 2017, the Corporation ceased consolidating Acasti and derecognized the assets and liabilities of its former subsidiary and the non-controlling interest in Acasti. The Corporation recognized its remaining non-controlling investment in Acasti at the fair value as at that date. The Corporation has 5,064,694 common shares of Acasti. The fair value of the investment in Acasti was determined to be $6,079,271 or $1.20 per share as at December 27, 2017. This investment was measured using Acasti’s stock market price, a level 1 input. The difference between the fair value of the investment and the book value of Acasti’s net assets and related non-controlling interest was recognized in the statement of earnings as a gain on loss of control of $8,783,613. The Corporation ceased to consolidate Acasti’s results from that date. Acasti represents the Cardiovascular segment (note 25). The following table presents a reconciliation of the gain on loss of control for the year ended March 31, 2018: December 27, 2017 Investment in Acasti at fair value $ 6,079,271 Non-controlling interest 2,233,973 Acasti's assets before deconsolidation (7,143,171 ) Acasti's liabilities before deconsolidation 7,613,540 Gain on loss on control of Acasti $ 8,783,613 The loss of control is a non-cash transaction excluded from the consolidated statement of cash flows, except for the cash reduction related to the cash position of Acasti on the date of loss of control. As at March 31, 2018, the investment in Acasti is presented in “Other assets” in the consolidated statement of financial position. The fair value of the investment is $6,585,740 or $1.30 per share as at March 31, 2018, determined using Acasti’s stock market price, a level 1 input. The change in fair value since the loss of control amounted to a gain of $506,469 which is recorded in other comprehensive income. Prior to this transaction, changes in ownership interest in the subsidiary that did not result in a loss of control were accounted for as equity transactions. The differences between the considerations received and the non-controlling interest adjustments were recognized in equity. During the year ended March 31, 2018, prior to the loss of control on December 27, 2017, the Corporation’s participation in Acasti changed as follows: (i) Acasti options and call-options expired, which impacted the non-controlling interest for an amount of ($1,466,459); (ii) Acasti issued shares resulting from the exercise of Series 2017 – Broker warrants, which impacted the non-controlling interest for an amount of $228,530; (iii) Acasti settled financing fees related to past financing, which impacted the non-controlling interest for an amount of ($102,011); (iv) Acasti issued shares to settle convertible debentures interest, which impacted the non-controlling interest for an amount of $51,965. During the thirteen-month period ended March 31, 2017, the Corporation’s participation in Acasti changed as follows: (v) Acasti options and call-options expired, which impacted the non-controlling interest for an amount of $3,059,035. (vi) Public offering 2017: On February 21, 2017, Acasti closed a public offering issuing 3,930,518 units of Acasti at a price of $1.45 per unit for gross proceeds of $5,699,251. The transaction costs associated with the Public Offering amounted to $1,190,730. The proceeds and transaction costs were considered as proceeds from change in ownership interest in subsidiary. Concurrent with the Public Offering, Acasti issued $2,000,000 aggregate principal amount of unsecured convertible debentures maturing February The impact of the Acasti public offering on the non-controlling interest amounted to $5,681,990. The impact of the private placement on the non-controlling interest amounted to $308,907.

Other Income

Other Income	12 Months Ended
	Mar. 31, 2018
Disclosure Of Other Income [Abstract]
Other income	14. Other income: On September 30, 2016, Neptune and Aker BioMarine (“Aker”) entered into a broad patent cross-licensing agreement, thus ending all outstanding litigation between both companies. The agreement provided continued access for Aker to Neptune’s composition patents for the duration of the patents, in consideration of an upfront royalty payment of US$10 million payable over a period of 15 months. Neptune acquired rights to use Aker’s select krill oil-related patent portfolio for the duration of the patents in consideration of an upfront royalty payment of US$4 million payable over the same 15-month period. On March 31, 2017, Neptune and Enzymotec Ltd (“Enzymotec”) entered into a broad patent cross-licensing agreement, thus ending all outstanding litigation between both companies. The agreement provided continued access for Enzymotec to Neptune’s krill-related patents for the duration of the patents, in consideration of an upfront royalty payment of US$1.63 million. The agreement provided also continued access for Neptune to Enzymotec’s krill-related patents with no consideration. Neptune has recorded a royalty settlement income of $2,184,758. The amount was received on March 31, 2017.

Personnel Expenses

Personnel Expenses	12 Months Ended
	Mar. 31, 2018
Personnel Expenses [Abstract]
Personnel expenses	15. Personnel expenses: March 31, March 31, 2018 2017 (12 months) (13 months) Salaries and other short-term employee benefits $ 9,833,691 $ 12,196,987 Severance 813,365 83,879 Share-based compensation 2,283,756 2,014,902 $ 12,930,812 $ 14,295,768

Finance Costs

Finance Costs	12 Months Ended
	Mar. 31, 2018
Disclosure Of Finance Income And Costs [Abstract]
Finance Costs	16. Finance costs: March 31, March 31, 2018 2017 (12 months) (13 months) Interest charges and other finance costs $ (1,061,588 ) $ (2,764,389 ) Interest expense on unsecured convertible debentures (275,140 ) — Penalty on reimbursment, loss on financing and discounted fees on debt reimbursment (note 4) (920,429 ) — Foreign exchange loss (189,122 ) (7,757 ) Finance costs $ (2,446,279 ) $ (2,772,146 )

Share-based Payments

Share-based Payments	12 Months Ended
	Mar. 31, 2018
Disclosure Share Based Payment Arrangement [Abstract]
Share-based payments	17. Share-based payments: At March 31, 2018, the Corporation had the following share-based payment arrangements: (a) Corporation stock option plan: ( i ) Stock option plan: The Corporation has established a stock option plan for directors, officers, employees and consultants. Awards under the plan grants a participant the right to purchase a certain number of Common Shares, subject to certain conditions described below, at an exercise price equal to at least the Market Price (as defined after) of the Common Shares on the grant date. The “Market Price” of Common Shares as of a particular date shall generally mean the VWAP (volume weighted average trading price of the Common Shares) obtained for such Common Shares on the TSX (and if listed on more than one stock exchange, then the highest of such closing prices) during the last ten (10) Business Days prior to the Grant Date (10-day VWAP). The terms and conditions for exercising options and purchasing the underlying Common Shares are set by the Board of Directors, and subject, among others, to the following limitations: the term of the options cannot exceed ten years and every stock option granted under the stock option plan will be subject to conditions no less restrictive than a minimum vesting period of 18 months and a gradual and equal acquisition of vesting rights at least on a quarterly basis. The Corporation can issue a number of Common Shares not exceeding 15% of the number of Common Shares issued and outstanding at the time of any grant pursuant to the stock option plan. The total number of Common Shares issuable to a single holder pursuant to the stock option plan cannot exceed 5% of the Corporation’s total issued and outstanding Common Shares at the time of the grant, with the maximum of 2% for any one consultant. The number and weighted average exercise prices of stock options are as follows: 2018 2017 Weighted Weighted average average exercise Number of exercise Number of price options price options Options outstanding at April 1, 2017 and March 1, 2016 $ 1.92 3,765,000 $ 2.50 4,242,025 Granted (i) 1.90 7,501,980 1.54 881,000 Exercised (note 12 (d)) 1.72 (149,000 ) — — Forfeited 1.54 (816,434 ) 2.69 (456,461 ) Expired 2.93 (210,000 ) 3.84 (901,564 ) Options outstanding at March 31, 2018 and 2017 $ 1.92 10,091,546 $ 1.92 3,765,000 Options exercisable at March 31, 2018 and 2017 $ 1.97 2,322,668 $ 2.07 2,115,666 (i) Of the 7,501,980 options granted, 2,095,333 options have restrictions on their exercise subject to shareholder approval as required by the rules of the Toronto Stock Exchange. 2018 Options outstanding Exercisable options Weighted remaining Weighted Weighted contractual Number of number of average Exercise life options options exercise price outstanding outstanding exercisable price $1.24 - $1.82 3.47 1,825,973 672,668 $ 1.66 $1.83 - $1.91 4.35 420,000 350,000 1.83 $1.92 - $2.05 4.69 6,470,573 — — $2.06 - $2.15 4.70 75,000 — — $2.16 3.64 1,300,000 1,300,000 2.16 4.32 10,091,546 2,322,668 $ 1.97 The fair value of options granted, including 2,095,333 options issued during the year ended March 31, 2018 for which the fair value is revaluated at each reporting date until shareholder approval, has been estimated according to the Black-Scholes option pricing model and based on the weighted average of the following assumptions for options granted to employees during the year ended March 31, 2018 and the thirteen-month period ended March 31, 2017: 2018 2017 Exercise price $ 1.90 $ 1.54 Share price $ 1.81 $ 1.54 Dividend ‒ ‒ Risk-free interest 1.50 % 0.67 % Estimated life (years) 3.93 3.50 Expected volatility 48.60 % 49.46 % The weighted average fair value of the options granted to employees during the year ended March 31, 2018 is $0.68 ($0.56 for the thirteen-month period ended March 31, 2017). No options were granted to non-employees during the year ended March 31, 2018 and the thirteen-month period ended March 31, 2017. Stock-based compensation recognized under this plan amounted to $1,334,817 for the year ended March 31, 2018 ($768,368 for the thirteen-month period ended March 31, 2017). (ii) Performance options: On October 16, 2015, the Corporation granted 625,000 performance options under the Corporation stock option plan at an exercise price of $1.55 per share expiring on October 16, 2020. The options vest after a two-year minimum service period and the attainment of market performance conditions within the following three years. As at March 31, 2018, all performance options were vested. The number and weighted average exercise prices of performance options are as follows: 2018 2017 Weighted Weighted average average exercise Number of exercise Number of price options price options Options outstanding at April 1, 2017 and March 1, 2016 $ 1.55 475,000 $ 1.55 625,000 Forfeited 1.55 (150,000 ) 1.55 (150,000 ) Options outstanding at March 31, 2018 and 2017 $ 1.55 325,000 $ 1.55 475,000 Options exercisable at March 31, 2018 and 2017 $ 1.55 325,000 $ — — 2018 Options outstanding Exercisable options Weighted remaining Weighted Weighted contractual Number of number of average Exercise life options options exercise price outstanding outstanding exercisable price $1.55 2.55 325,000 325,000 $ 1.55 Stock-based compensation recognized under this plan amounted to ($17,485) for the year ended March 31, 2018 ($187,649 for the thirteen-month period ended March 31, 2017). (b) Deferred Share Unit (‘’DSUs’’): The Corporation has established an equity incentive plan for employees, directors and consultants of the Corporation. The plan provides for the issuance of restricted share units, performance share units, restricted shares, deferred share units and other share-based awards, subject to restricted conditions as may be determined by the Board of Directors. Upon fulfillment of the restricted conditions, as the case may be, the plan provides for settlement of the awards outstanding through shares. 2018 2017 Weighted Weighted average average exercise Number of exercise Number of price DSUs price DSUs DSUs outstanding at April1, 2017 and March 1, 2016 $ 1.60 425,354 $ 1.72 75,000 Granted 1.27 201,342 1.57 350,354 Released through the issuance of common shares (note 12 (c)) 1.43 (55,944 ) — — DSUs outstanding at March 31, 2018 and 2017 $ 1.50 570,752 $ 1.60 425,354 DSUs exercisable at March 31, 2018 and 2017 $ 1.48 374,670 $ 1.59 240,004 Of the 570,752 DSUs outstanding as at March 31, 2018, 160,000 DSUs vest upon achievement of performance conditions to be achieved no later than June 30, 2019, which were modified during the year to change the performance conditions and vesting period, 72,164 DSUs vest upon services to be rendered during a period of twelve months from date of grant, 263,588 vested DSUs were granted for past services and 75,000 DSUs were in compensation for consulting services rendered by a member of the Board of Directors and are fully vested. However, the shares will be delivered when the consultant ceases to be a member of the board. The fair value of the DSUs is determined to be the share price at the date of grant and is recognized as stock-based compensation, through contributed surplus, over the vesting period. The weighted average fair value of the DSUs granted during the year ended March 31, 2018 was $1.27 ($1.57 for the thirteen-month period ended March 31, 2017). Stock-based compensation recognized under this plan amounted to $305,813 for the year ended March 31, 2018 ($384,307 for the thirteen-month period ended March 31, 2017). (c) Corporation warrants: As part of the NeuroBioPharm Plan of Arrangement for the acquisition by Neptune of all of the issued and outstanding shares of NeuroBioPharm in February 2015, the rights over NeuroBioPharm warrants and call-options were exchanged for Neptune warrants. The number and weighted average exercise prices of warrants are as follows: 2018 2017 Weighted Weighted average average exercise Number of exercise Number of price warrants price warrants Warrants outstanding at April 1, 2017 and March 1, 2016 $ 21.50 24,174 $ 12.84 292,047 Forfeited 21.50 (465 ) 11.86 (129,122 ) Expired 21.50 (23,709 ) 12.25 (138,751 ) Warrants outstanding and exercisable at March 31, 2018 and 2017 $ — — $ 21.50 24,174 (d) Acasti stock option plan: Stock-based compensation recognized under Acasti’s stock option plan amounted to $660,611 for the year ended March 31, 2018 ($674,578 for the thirteen-month period ended March 31, 2017). The amounts for the year ended March 31, 2018 and the thirteen-month period ended March 31, 2017 are included in the ‟share-based payment transactions’’ of the equity attributable to non-controlling interest.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2018
Disclosure Of Income Tax [Abstract]
Income Taxes	18. Current income taxes expense (recovery): 2018 2017 Current $ — $ 2,294,471 Adjustment of prior year income taxes expense (recovery) (1,932,831 ) — Current income taxes expense (recovery) $ (1,932,831 ) $ 2,294,471 Deferred taxes expense: 2018 2017 Recognition of previously unrecognized deductible temporary differences and tax losses of prior periods $ (114,226 ) $ (129,362 ) Origination and reversal of temporary differences (1,772,883 ) (434,615 ) Change in unrecognized deductible temporary differences 2,179,740 623,134 Deferred tax expense $ 292,631 $ 59,157 Reconciliation of effective tax rate: 2018 2017 Income before income taxes $ 7,699,183 $ 3,233,477 Basic combined Canadian statutory income tax rate 1 26.78 % 26.87 % Income tax $ 2,061,841 $ 868,835 Increase (decrease) resulting from: Recognition of previously unrecognized deductible temporary differences and tax losses of prior periods (114,226 ) (129,362 ) Change in unrecognized deductible temporary differences 2,179,736 623,134 Gain on loss of control of Acasti (2,352,252 ) — Non taxable gain on sale of assets (4,304,482 ) — Non-deductible stock-based compensation 611,590 538,145 Non-deductible change in fair value 9,733 70,929 Permanent differences and other 210,449 37,786 Change in statutory income tax rate 57,411 344,161 Total tax expense (recovery) $ (1,640,200 ) $ 2,353,628 1 The Canadian combined statutory income tax rate has decreased due to a reduction in the provincial statutory income tax rate. Recognized deferred tax assets and liabilities: The details of changes of deferred income taxes are as follows for the year ended March 31, 2018: Balance as at Balance as at March 31, Recognized in Recognized in March 31, 2017 equity net income 2018 Tax losses carried forward $ 1,376,971 $ — $ 5,964,843 $ 7,341,814 Research and development expenses 245,399 — (222 ) 245,177 Intangible assets (1,309,688 ) — 112,806 (1,196,882 ) Property, plant and equipment (6,513 ) — (4,457,302 ) (4,463,815 ) Tax credits receivable (40,708 ) — — (40,708 ) Prepaid royalty income — — (1,912,756 ) (1,912,756 ) $ 265,461 $ — $ (292,631 ) $ (27,170 ) The details of changes of deferred income taxes are as follows for the thirteen-month period ended March 31, 2017: Balance as at Balance as at February 29, Recognized in Recognized in March 31, 2016 equity net income 2017 Tax losses carried forward $ 1,769,506 $ – $ (392,535 ) $ 1,376,971 Research and development expenses 247,409 – (2,010 ) 245,399 Intangible assets (1,549,950 ) – 240,262 (1,309,688 ) Property, plant and equipment 136,166 – (142,679 ) (6,513 ) Tax credits receivable (149,151 ) – 108,443 (40,708 ) Unsecured convertible debentures – (129,362 ) 129,362 – $ 453,980 $ (129,362 ) $ (59,157 ) $ 265,461 As at March 31, 2018, the amounts and expiry dates of tax attributes and temporary differences, for which no tax assets have been recognized, which are available to reduce future years’ taxable income were as follows. Deferred tax assets have not been recognized in respect of these items because it is not probable that future taxable profit will be available against which the Corporation can utilise the benefits there from. Federal Provincial Tax losses carried forward 2035 $ 5,812,000 $ 1,298,000 2036 3,052,000 3,052,000 2037 9,050,000 10,499,000 2038 754,000 754,000 $ 18,668,000 $ 15,603,000 Research and development expenses, without time limitation $ 10,906,000 $ 15,574,000 Tax credits receivable and recoverable: Tax credits receivable comprise research and development investment tax credits receivable from the provincial government amounting to $49,597 ($139,932 as at March 31, 2017) which relate to qualifiable research and development expenditures under the applicable tax laws. Tax credits recoverable comprise research and development investment tax credits recoverable against income taxes otherwise payable to the federal government. Unused federal Research and Development investment tax credits of the nutraceutical segment, for which no benefit has been recognized, may be used to reduce future federal income taxes payable and expire as follows: 2022 $ 76,000 2023 217,000 2024 75,000 2025 53,000 2026 91,000 2027 145,000 2028 64,000 2029 107,000 2030 206,000 2031 244,000 2032 129,000 2033 124,000 2034 106,000 2035 281,000 2036 210,000 2037 141,000 $ 2,269,000 As at March 31, 2017, the Corporation had determined that there was reasonable assurance of realizing some federal tax credits generated by the nutraceutical business, prior to their scheduled expiry dates, given the income taxes on the net income of the nutraceutical segment for the thirteen-month period ended March 31, 2017. The Corporation then recognized tax credits recoverable of $1,966,757 at March 31, 2017. During the year ended The amounts recorded as tax credits receivable or recoverable are subject to a government tax audit and the final amount received may differ from those recorded.

Income per share

Income per share	12 Months Ended
	Mar. 31, 2018
Reconciliation Of Number Of Shares Outstanding [Abstract]
Income per share	19. The following table provides a reconciliation between the number of basic and diluted shares outstanding: 2018 2017 Weighted average number of common shares 78,599,208 77,945,548 Dilutive effect of deferred share units 373,039 200,339 Dilutive effect of stock options 387,049 — Weighted average number of diluted shares 79,359,296 78,145,887 Number of anti-dilutive stock options, warrants and deferred share units excluded from diluted earnings per share calculation 8,798,979 5,232,178 Stock options, deferred share units and warrants could be dilutive in the future.

Supplemental Cash Flow Disclosu

Supplemental Cash Flow Disclosure	12 Months Ended
	Mar. 31, 2018
Disclosure Of Supplementary Cash Flow Information [Abstract]
Supplemental Cash Flow Disclosure	20. Supplemental cash flow disclosure: (a) Changes in operating assets and liabilities: March 31, March 31, 2018 2017 Trade and other receivables $ 10,547,497 $ (7,026,796 ) Tax credits receivable 108,821 645,334 Prepaid expenses (981,444 ) 500,968 Inventories (5,581,135 ) 4,619,832 Trade and other payables 3,312,306 (521,119 ) Deferred revenues 109,950 206,036 Changes in operating assets and liabilities $ 7,515,995 $ (1,575,745 ) (b) Non-cash transactions: March 31, March 31, 2018 2017 Acquired property, plant and equipment included in trade and other payables $ 456,774 $ 308,218 Intangible assets included in trade and other payables 453,436 140,731 Intangible assets included in trade and other receivables (note 14) — 3,546,400 Intangible assets included in long-term payable 249,714 795,072 Liability settlement in shares 858,000 — Acasti convertible debenture interest paid in shares of subsidiary 56,984 — Reduction in goodwill on reduction of balance of purchase price — 65,513 Acasti equity settled share-based payment included in equity and unsecured convertible debentures — 94,200 Acasti issuance of broker warrants included in net proceeds from Acasti public offering — 143,932 Acasti public offering transactions costs included in trade and other payables — 380,765 Acasti reduction in share issue costs from reduction in trade and other payables — 109,410 Acasti private placement transactions costs included in trade and other payables — 40,305 (c) Reconciliation of movements of liabilities to cash flows arising from financing activities: Cash (used in) provided by financing activities Non-cash changes Balance as at March 31, 2017 Proceeds Repayments Settlement of cross currency swap Accretion of interest Effect of foreign currency exchange rate changes Financing and discounted fees Changes in fair value Balance as at March 31, 2018 Loan $ 5,429,852 $ – $ (1,571,432 ) $ – $ 32,657 $ – $ – $ – $ 3,891,077 Balance of purchase price 3,202,612 – (2,941,016 ) – – – – – 261,596 Bank line of credit – 490,000 – – – – – – 490,000 Finance lease liabilities 44,644 – (25,961 ) – – – – – 18,683 Loan IQ 8,347,506 – (8,593,775 ) – 47,242 – 199,027 – – Loan in GBP (1) 3,562,814 – (3,456,910 ) – 16,594 (225,384 ) 102,886 – – Refundable contribution 2,344,116 – (2,800,004 ) – 100,855 – 355,033 – – Total long-term debt $ 22,931,544 $ 490,000 $ (19,389,098 ) $ – $ 197,348 $ (225,384 ) $ 656,946 $ – $ 4,661,356 Interest rate swap liability (asset) used for hedging $ 7,298 $ – $ – $ – $ – $ – $ – $ (26,388 ) $ (19,090 ) Cross currency swap liability $ 207,839 $ – $ – $ (58,999 ) $ – $ 7,499 $ – $ (156,339 ) $ – (1)

Financial Instruments

Financial Instruments	12 Months Ended
	Mar. 31, 2018
Disclosure Of Financial Instruments [Abstract]
Financial instruments	21. (a) Financial instruments – carrying values and fair values: Financial assets and liabilities measured at fair value on a recurring basis are the investment in BlueOcean Nutrascience Inc. (“BlueOcean”) until the sale of common shares, the derivative warrant liabilities until December 27, 2017, the investment in Acasti since the loss of control (note 13) and derivative swap agreements. (i) Other investment: In January 2018, the Corporation sold all units it held in the publicly traded shares of BlueOcean for total proceeds of $104,110. Prior to the sale, the investment was measured at fair value using its stock market price, a level 1 input, with changes in fair value recorded through other comprehensive income. The fair value of the investment at time of sale was $104,110 or $0.21 per share ($65,745 or $0.135 per share as at March 31, 2017). The change in fair value recorded through other comprehensive income amounted to a gain of $38,365 for the year ended March 31, 2018 (ii) Derivative warrant liabilities: Warrants issued as part of a public offering of units of Acasti composed of Class A shares and Class A share purchase warrants of Acasti in 2014 were derivative liabilities for accounting purposes due to the currency of the exercise price being different from Acasti’s functional currency until December 27, 2017, date of loss of control. The Corporation measured its derivative warrant liabilities at fair value on a recurring basis. These financial liabilities were measured using a level 3 input. The reconciliation of changes in fair value measurements of financial liabilities as at December December 27, March 31, 2017 2017 Opening balance at April 1, 2017 and March 1, 2016 $ 202,610 $ 151,343 Change in fair value (gain) loss (189,001 ) 51,267 Loss of control of subsidiary (note 13) (13,609 ) — Closing balance at December 27, 2017 and March 31, 2017 $ — $ 202,610 (iii) Derivative swap agreements: March 31, March 31, 2018 2017 Non-current asset Interest rate swap contract $ 19,090 $ — $ 19,090 $ — Non-current liabilities Cross currency swap contract $ — $ 207,839 Interest rate swap contract — 7,298 $ — $ 215,137 The Corporation used currency swap agreements to convert a long-term debt in pounds to the US dollar to mitigate its financial liabilities exposure to foreign currency risk as well as mitigate the risk from short-term financial assets denominated in US dollars. The Corporation did not apply hedge accounting to foreign currency differences arising from these agreements. These instruments were recorded into the consolidated statement of financial position at their fair value. The change in fair value of these cross currency swaps amounted to a gain of $156,339 for the year ended March 31, 2018 and is accounted for in change in fair value of derivative assets and liabilities. The cross currency swaps were cancelled and settled for $58,999 following the transaction with Aker BioMarine (see note 4). The Corporation uses interest rate swap agreement to lock-in a portion of its debt cost and reduce its exposure to the variability of interest rates by exchanging variable rate payments for fixed rate payments. The Corporation has designated its interest rate swap as cash flow hedge for which it uses hedge accounting. Details of the interest rate swap is as follows: Fixed rate Notional March 31, March 31, % amount Maturity 2018 2017 Interest rate swap agreement 2.94 $ 3,883,923 Dec. 27, 2018 $ 19,090 $ (7,298 ) The level 2 fair value determination of the interest rate swap is measured using a generally accepted valuation technique which is the discounted value of the difference between the value of the swap based on variable interest rates (estimated using the yield curve for anticipated interest rates) and the value of the swap based on the swap’s fixed interest rate. The Corporation’s and the counterparty’s credit risk is also taken into consideration in determining fair value. The interest rate swap is decreasing at the same proportion of the debt covered. The change in fair value is recognized in other comprehensive income. An assumed 1% change in the interest rate would not have a material effect on the net income. The Corporation has determined that the carrying values of its short-term financial assets and liabilities approximate their fair value given the short-term nature of these instruments. The carrying value of the restricted short-term investment also approximates its fair value given the short-term maturity of the reinvested funds. For variable rate loans and borrowings, the fair value is considered to approximate the carrying amount. The fair value of the fixed rate loans and borrowings is determined by discounting future cash flows using a rate that the Corporation could obtain for loans with similar terms, conditions and maturity dates. The fair value of these instruments approximates the carrying amounts and was measured using level 3 inputs. (b) Management of risks arising from financial instruments: In the normal course of business, the Corporation is subject to various risks relating to credit, foreign exchange, interest rate and liquidity. The Corporation manages these risk exposures on an ongoing basis. The Corporation’s management is responsible for determining the acceptable level of risk and only uses derivative financial instruments to manage existing or anticipated risks, commitments or obligations based on its past experience. The following analysis provides a measurement of risks arising from financial instruments. (i) Credit risk: Credit risk is the risk of a loss if a customer or counterparty to a financial asset fails to meet its contractual obligations, and arises primarily from the Corporation’s trade receivables. The Corporation may also have credit risk relating to cash and cash equivalents and restricted short-term investments, which are managed by dealing only with highly-rated Canadian institutions. The carrying amount of these financial assets, as disclosed in the consolidated statements of financial position, represents the Corporation’s credit exposure at the reporting date. The Corporation’s trade receivables and credit exposure fluctuate throughout the year. The Corporation’s average trade receivables and credit exposure during the year may be higher than the balance at the end of that reporting period. Most sales' payment terms are set in accordance with industry practice. As at March 31, 2018, two customers accounted for respectively 19.7% and 10.8% of total trade accounts included in trade and other receivables. As at March 31, 2017, four customers accounted for respectively 13.3%, 13.1%, 12.7% and 10.6% of total trade accounts included in trade and other receivables. As a consequence of the sale of assets to Aker, most of the trade receivables as at March 31, 2018 are related to Biodroga’s customer. Most of the Corporation's customers are distributors for a given territory and are privately-held enterprises. The profile and credit quality of the Corporation’s customers vary significantly. Adverse changes in a customer’s financial position could cause the Corporation to limit or discontinue conducting business with that customer, require the Corporation to assume more credit risk relating to that customer’s future purchases or result in uncollectible accounts receivable from that customer. Such changes could have a material adverse effect on business, consolidated results of operations, financial condition and cash flows. Customers do not provide collateral in exchange for credit, except in unusual circumstances. Receivables from selected customers are covered by credit insurance, with coverage amount usually of 100% of the invoicing, with the exception of some customers under specific terms. The information available through the insurers is the main element in the decision process to determine the credit limits assigned to customers. The Corporation’s extension of credit to customers involves considerable judgment and is based on an evaluation of each customer’s financial condition and payment history. The Corporation has established various internal controls designed to mitigate credit risk, including a credit analysis by the insurer which recommends customers' credit limits and payment terms that are reviewed and approved by the Corporation. The Corporation reviews periodically the insurer's maximum credit quotation for each of its clients. New clients are subject to the same process as regular clients. The Corporation has also established procedures to obtain approval by senior management to release goods for shipment when customers have fully-utilized approved insurers credit limits. From time to time, the Corporation will temporarily transact with customers on a prepayment basis where circumstances warrant. The Corporation’s credit controls and processes cannot eliminate credit risk. The Corporation provides for trade receivable accounts to their expected realizable value as soon as the account is determined not to be fully collectible, with such write-offs charged to consolidated earnings unless the loss has been provided for in prior periods, in which case the write-off is applied to reduce the allowance for doubtful accounts. The Corporation updates its estimate of the allowance for doubtful accounts, based on evaluations of the collectibility of trade receivable balances at each reporting date, taking into account amounts which are past due, and any available information indicating that a customer could be experiencing liquidity or going concern problems. The aging of trade receivable balances and the allowance for doubtful accounts as at March 31, 2018 and 2017 were as follows: March 31, March 31, 2018 2017 Current $ 3,908,804 $ 6,244,434 Past due 0-30 days 950,417 818,318 Past due 31-120 days 66,546 326,053 Past due over 121 days 606,829 625,752 Trade receivables 5,532,596 8,014,557 Less allowance for doubtful accounts (605,964 ) (623,856 ) $ 4,926,632 $ 7,390,701 The allowance for doubtful accounts is for customer accounts over 121 days past due that are not expected to be collected. The movement in allowance for doubtful accounts in respect of trade receivables was as follows: March 31, March 31, 2018 2017 Balance, beginning of year $ 623,856 $ 5,613,365 Bad debt expenses — 30,847 Foreign exchange (gain) loss (17,892 ) (6,811 ) Write-off against reserve — (5,013,545 ) Balance, end of year $ 605,964 $ 623,856 As at March 31, 2018, the allowance for doubtful accounts on other receivables is in the amount of $265,676 ($33,139 as at March 31, 2017), with the difference recorded as bad debt expense in the current year. (ii) Foreign exchange rate risk: The Corporation is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign currency risk is limited to the portion of the Corporation's business transactions denominated in currencies other than the Canadian dollar. Fluctuations related to foreign exchange rates could cause unforeseen fluctuations in the Corporation's operating results. Approximately 63% (2017 - 67%) of the Corporation’s revenues are in US dollars and 2% (2017 - 7%) are in Euros. A small portion of the expenses, except for the purchase of raw materials, which are predominantly in US dollars, is made in foreign currencies. There is a financial risk related to the fluctuation in the value of the US dollar in relation to the Canadian dollar. The following table provides an indication of the Corporation’s significant foreign exchange currency exposures as stated in Canadian dollars at the following dates: March 31, March 31, 2018 2017 US$ US$ EURO GBP Cash and cash equivalents $ 1,120,711 $ 5,204,124 $ 15,997 $ 1,778 Trade and other receivables 3,125,286 13,146,332 1,390,984 36,239 Trade and other payables (1,338,182 ) (6,566,584 ) (463,134 ) — Long-term payable (483,549 ) (795,072 ) — — Derivative financial liability swap — (30,741 ) — — Long-term debt (1) — (3,682,294 ) — — $ 2,424,266 $ 7,275,765 $ 943,847 $ 38,017 (1) The following exchange rates are those applicable for the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017: March 31, March 31, 2018 2017 Average Reporting Average Reporting US$ per CAD 1.2834 1.2900 1.3134 1.3299 EURO per CAD 1.5008 1.5898 1.4424 1.4251 GBP per CAD 1.7022 1.8079 1.7275 1.6700 Based on the Corporation’s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar, Euro and GBP would have increased the net profit as follows, assuming that all other variables remained constant: March 31, March 31, 2018 2017 US$ US$ EURO GBP Increase in net profit $ 121,212 $ 363,787 $ 47,192 $ 1,901 An assumed 5% weakening of the foreign currency would have had an equal but opposite effect on the basis that all other variables remained constant. In addition to the derivative swap agreements (refer to note 21 (a)(iii)), from time to time, the Corporation enters into currency forwards to purchase or sell amounts of foreign currency in the future at predetermined exchange rates. The purpose of these currency forwards is to fix the risk of fluctuations in future exchange rates. (iii) Interest rate risk: Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates. The Corporation’s exposure to interest rate risk as at March 31, 2018 and 2017 is as follows: Cash and cash equivalents Short-term fixed interest rate Restricted short-term investments Short-term fixed interest rate Loans and borrowings Fixed and variable interest rates Unsecured convertible debentures until the loss on control of Acasti Fixed interest rates The risk that the Corporation will realize a loss as a result of the decline in the fair value of its short-term investments is limited because these short-term investments have short-term maturities and are generally held to maturity. The capacity of the Corporation to reinvest the short-term amounts with equivalent returns will be impacted by variations in short-term fixed interest rates available in the market. The fixed rate borrowings expose the Corporation to a fair value risk but not cash flow interest rate risk. The Corporation uses interest rate swap agreement to lock-in a portion of its debt cost and reduce its exposure to the variability of interest rates by exchanging variable rate payments for fixed rate payments. The Corporation has designated its interest rate swap as cash flow hedge for which it uses hedge accounting (refer to note 21 (a)(iii)). Based on currently outstanding loans and borrowings at variable rates and interest rate swap, an assumed 0.5% interest rate increase during the year ended March 31, 2018 would have decreased consolidated net income by $10,652 with an equal opposite effect for an assumed 0.5% decrease. (iv) Liquidity risk: Liquidity risk is the risk that the Corporation will not be able to meet its financial obligations as they fall due. The Corporation manages liquidity risk through the management of its capital structure and financial leverage, as outlined in note 24. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Audit Committee and the Board of Directors review and approve the Corporation's operating budgets, and review the most important material transactions outside the normal course of business. The following are the contractual maturities of financial liabilities as at March 31, 2018 and 2017: March 31, 2018 Required payments per year Carrying Contractual Less than 1 to More than (in thousands of dollars) amount cash flows 1 year 5 years 5 years Trade and other payables and long-term payable $ 6,998 $ 6,998 $ 6,748 $ 250 $ – Loans and borrowings * 4,661 4,818 4,818 – – $ 11,659 $ 11,816 $ 11,566 $ 250 $ – * Includes interest payments to be made at the contractual rate. March 31, 2017 Required payments per year Carrying Contractual Less than 1 to More than (in thousands of dollars) amount cash flows 1 year 5 years 5 years Trade and other payables and long-term payable $ 10,788 $ 10,788 $ 9,993 $ 795 $ – Loans and borrowings * 22,932 26,459 8,681 17,778 – Unsecured convertible debentures * 1,406 2,463 160 2,303 – Interest rate swap 7 7 7 – – Cross currency rate swap 208 208 208 – – $ 35,341 $ 39,925 $ 19,049 $ 20,876 $ – * Includes interest payments to be made at the contractual rate.

Operating Leases

Operating Leases	12 Months Ended
	Mar. 31, 2018
Operating Leases [Abstract]
Operating leases	22. Operating leases: The Corporation rents its premises pursuant to operating leases expiring at different dates from May 31, 2018 to September 30, 2022. During the year ended March 31, 2018, an amount of $615,989 was recognized as an expense in respect of operating leases. An amount of $264,137 has been recorded in selling, general and administrative expenses ($377,941 for the thirteen-month period ended March 31, 2017), $143,087 ($305,458 for the thirteen-month period ended March 31, 2017) has been recorded in cost of sales and $208,765 has been recorded in research and development (nil for the thirteen-month period ended March 31, 2017). Included in these amounts are the Corporation’s share of operating costs and taxes under the terms of the leases, in the amount of $72,020 and $110,234, respectively ($76,987 and $117,800, respectively, for the thirteen-month period ended March 31, 2017). Minimum lease payments for the next five years are $453,219 in 2019, $381,727 in 2020, $336,174 in 2021, $336,174 in 2022 and $168,087 in 2023.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Mar. 31, 2018
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and contingencies	23. Commitments and contingencies: (a) Commitments: ( i ) As at September 30, 2016, Neptune has entered into an exclusive commercial agreement for a speciality ingredient (note 11). According to this agreement, Neptune has to pay royalties on sales. To maintain the exclusivity, Neptune must reach minimum annual volumes of sales for the duration of the agreement of 11 years with a corresponding total remaining amount of minimum royalties of $5,800,000 (US$4,500,000). (ii) A capital expenditure of $5,000,000 was approved by the Board of the Corporation to make its production facility ready and compliant for the extraction of cannabis oil. As at March 31, 2018, Neptune signed various capital expenditure contracts amounting to $4,043,487 of which $349,012 is included in trade and other payables and $507,983 has been paid. (iii) As at March 31, 2018, t (vi) As at March 31, 2018, t (b) Contingencies: In the normal course of operations, the Corporation is involved in various claims and legal proceedings. The most significant of which are as follows: ( i ) A former CEO of the Corporation is claiming the payment of approximately $8,500,000 and the issuance of equity instruments. As the Corporation’s management believes that these claims are not valid, no provision has been recognized. As of the date of these consolidated financial statements, no agreement has been reached. Neptune also filed an additional claim to recover certain amounts from this former officer. All outstanding share-based payments held by the former CEO have been cancelled during the year ended February 28, 2015. (ii) Under the terms of an agreement entered into with a corporation controlled by the former CEO of the Corporation, the Corporation should pay royalties of 1% of its krill oil revenues in semi-annual instalments, for an unlimited period. Neptune filed a motion challenging the validity of certain clauses of the agreement. (iii) The Corporation initiated arbitration against a customer that owed approximately $4,773,000 (US$3,700,000). The full amount receivable has been written-off. This customer is counterclaiming a sum in damages. As the Corporation’s management believes that this counterclaim is not valid, no additional provision has been recognized. Although the outcome of the these and various other claims and legal proceedings against the Corporation as at March 31, 2018 cannot be determined with certainty, based on currently available information, management believes that the ultimate outcome of these matters, individually and in aggregate, would not have a material adverse effect on the Corporation’s financial position or overall trends in results of operations.

Capital Management

Capital Management	12 Months Ended
	Mar. 31, 2018
Capital Management [Abstract]
Capital Management	24. Capital management: The Corporation’s objective in managing capital is to ensure sufficient liquidity to develop its technologies and commercialize its products, finance its research and development activities, including the cannabis project, selling, general and administrative expenses, its overall capital expenditures and those related to its debt reimbursement. The Corporation is not exposed to external requirements by regulatory agencies regarding its capital. The Corporation is subject to certain financial covenants under its secured loan. As of March 31, 2018, the Corporation was in compliance with these financial covenants. Since inception, the Corporation has financed its liquidity needs primarily through the cash coming from the sale of the krill business, cash flows from operating activities and liquidities, as well as the issuance of debt and common shares. The Corporation optimizes its liquidity needs by non-dilutive sources whenever possible, including research tax credits, investment tax credits, interest income and revenues from strategic partnerships, collaboration agreements and government assistance. The Corporation defines capital as being the total of shareholders’ equity and loans and borrowings. The Corporation’s primary objectives when managing capital are to: • Ensure that the Corporation will continue as a going concern while providing an appropriate investment return to its shareholders; • Optimize leverage position of the nutraceutical segment by generating positive cash flows and reducing the long-term debt; • Preserve its financial flexibility in order to continue to develop unique extracts and formulations in high potential growth segments such as medical and wellness cannabinoid-based products. Cash, cash equivalents and restricted short-term investments: As at March 31, 2018 cash amounted to $5,784,810 (March 31, 2017 – $12,808,173), and cash equivalents amounted to $18,502,297 (March 31, 2017 – $2,994,190). The Corporation cash equivalents and restricted short-term investments as at March 31, 2018 and 2017 are as follows: March 31, March 31, 2018 2017 Maturity Maturity date Rate Amount date Rate Amount Term deposit (1) April 27, 2018 1.12% $ 18,502,297 April 11, 2017 0.52% $ 1,662,375 Term deposit (1) — — — April 25, 2017 0.53% 1,331,815 Restricted short-term investment as pledge for the acquisition of Biodroga May 28, 2018 1.20% 2,350,000 June 1, 2017 1.05% 2,350,000 Restricted short-term investment Dec. 11, 2018 0.90% 60,000 Dec. 11, 2017 0.85% 72,000 Restricted short-term investment as pledge for cross currency swaps — — — April 4, 2018 — 323,000 (1)

Operating segments

Operating segments	12 Months Ended
	Mar. 31, 2018
Disclosure Of Operating Segments [Abstract]
Operating Segments	25. Operating segments: In prior periods and until the loss of control of the subsidiary Acasti on December 27, 2017, the Corporation had two reportable segments which were the Corporation’s strategic business units. As at March 31, 2018, the cardiovascular segment that develops pharmaceutical products for cardiovascular diseases is no longer a strategic business unit for Neptune. The nutraceutical segment, that produces and commercializes nutraceutical products and turnkey solutions for primarly omega-3 softgel capsules and liquids, which includes the results of Biodroga for the year and the results of krill oil manufacturing and distribution activities until its sale (see note 4), and the cannabis oil extraction project which began in October 2017 are now the strategic business segments of the Corporation. Information regarding the results of each reportable segment is included below. The cardiovascular results are presented until the loss of control. Performance is measured based on segment net income (loss), as included in the internal management reports that are reviewed by the Corporation’s Chief Operating Decision Maker. Segment income (loss) is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries. Transfer pricing is based on predetermined rates accepted by all parties involved. The reportable segment assets of the Cardiovascular segment as at March 31, 2018 consists of the investment in Acasti (note 13). Differences between the sums of all segments and consolidated balances are explained primarily by the cardiovascular segment operating under license issued by the nutraceutical segment, the ultimate owner of the original intellectual property used in pharmaceutical applications. The amortization charge of the intangible license asset of the cardiovascular segment is eliminated upon consolidation. As disclosed in note 4, the Sherbrooke facility has been repurposed from the krill oil activities and will be used for the development of unique extractions targeted towards high potential growth segments such as the cannabis industry and therefore, is now presented under the cannabis segment information. The nutraceutical segment is the primary obligor of corporate expenses of the Corporation. Prior to the loss of control of Acasti, all material corporate expenses were allocated to each reportable segment in a fraction that is commensurate to the estimated fraction of services or benefits received by each segment. These charges may not have represented the cost that the segments would otherwise need to incur, should they not have received these services or benefits through the shared resources of the Corporation or received financing from the nutraceutical segment. Subsequent to the loss of control of Acasti, all corporate expenses are presented within the nutraceutical segment as it is the primary obligator for these expenses and corporate costs have not been allocated for internal purpose. (a) Information about reportable segments: Year ended March 31, 2018: Cardiovascular Intersegment Nutraceutical Cannabis ( i ) eliminations Total Revenue from external sales and royalties $ 27,645,582 $ — $ — $ — $ 27,645,582 Gross margin 6,324,292 — — — 6,324,292 Research and development expenses (895,944 ) (3,566,223 ) (9,675,625 ) 1,742,121 (12,395,671 ) Research tax credits and grants (1,836,071 ) — 84,119 — (1,751,952 ) Selling, general and administrative expenses (11,946,772 ) — (2,761,478 ) — (14,708,250 ) Other income – net gain on sale of assets 23,702,312 — — — 23,702,312 Income (loss) from operating activities 15,347,817 (3,566,223 ) (12,352,984 ) 1,742,121 1,170,731 Gain on loss of control of subsidiary 8,783,613 — — — 8,783,613 Finance income 188,828 — 38,637 — 227,465 Finance costs (2,090,867 ) — (355,412 ) — (2,446,279 ) Change in fair value of derivative assets and liabilities and loss on sale of available-for-sale investment (225,348 ) — 195,740 (6,739 ) (36,347 ) Income (loss) before income tax 22,004,043 (3,566,223 ) (12,474,019 ) 1,735,382 7,699,183 Income tax recovery 1,640,200 — — — 1,640,200 Net income (loss) 23,644,243 (3,566,223 ) (12,474,019 ) 1,735,382 9,339,383 Depreciation and amortization (2,224,814 ) (1,054,170 ) (2,005,019 ) 1,742,121 (3,541,882 ) Stock-based compensation (1,371,382 ) (251,763 ) (660,611 ) — (2,283,756 ) Reportable segment assets 51,057,311 40,953,903 6,585,740 — 98,596,954 Reportable segment liabilities 11,057,797 1,005,387 — — 12,063,184 (i) Results of operations for the period starting April 1 st Thirteen-month period ended March 31, 2017: Intersegment Nutraceutical Cardiovascular eliminations Total Revenue from external sales and royalties $ 46,809,586 $ 7,797 $ – $ 46,817,383 Revenue from transactions to Cardiovascular segment 112,500 — (112,500 ) — Gross margin 12,792,785 7,797 1,230 12,801,812 Research and development expenses (1,774,038 ) (7,991,232 ) 2,516,397 (7,248,873 ) Research tax credits and grants 2,078,047 330,330 — 2,408,377 Selling, general and administrative expenses (13,503,643 ) (3,557,209 ) — (17,060,852 ) Other income – royalty settlement 15,301,758 — — 15,301,758 Income (loss) from operating activities 14,894,909 (11,210,314 ) 2,517,627 6,202,222 Finance income 31,180 124,509 (89,153 ) 66,536 Finance costs (2,623,073 ) (238,226 ) 89,153 (2,772,146 ) Change in fair value of derivative assets and liabilities (211,869 ) (52,974 ) 1,708 (263,135 ) Income (loss) before income tax 12,091,147 (11,377,005 ) 2,519,335 3,233,477 Income taxes (expense) recovery (2,482,990 ) 129,362 — (2,353,628 ) Net income (loss) 9,608,157 (11,247,643 ) 2,519,335 879,849 Depreciation and amortization (3,596,088 ) (2,737,109 ) 2,516,397 (3,816,800 ) Stock-based compensation (1,340,324 ) (674,578 ) — (2,014,902 ) Reportable segment assets 98,163,888 25,454,825 (12,398,597 ) 111,220,116 Reportable segment liabilities 32,685,762 3,752,298 (18,182 ) 36,419,878 (b) Geographic information: Most of the Corporation’s assets are located in Canada. The Corporation’s revenue from sales are attributed based on destination: 2018 2017 (12 months) (13 months) Canada $ 11,494,565 $ 15,793,572 United States 11,581,085 23,795,544 Belgium — 2,363,275 China 1,254,964 1,493,165 France 467,473 809,127 Uruguay 779,613 51,144 Other countries 590,769 1,428,534 $ 26,168,469 $ 45,734,361 (c) Information about major customers: During the year ended March 31, 2018, the Corporation realized sales from the nutraceutical segment amounting to $4,529,350 from one customer accounting for 17.26% of consolidated revenues. During the thirteen-month period ended March 31, 2017, the Corporation realized sales from the nutraceutical segment amounting to $7,478,492 from one customer accounting for 16.35% of consolidated revenues.

Related Parties

Related Parties	12 Months Ended
	Mar. 31, 2018
Disclosure Of Transactions Between Related Parties [Abstract]
Related parties	26. Related parties: Key management personnel compensation: The key management personnel are the officers of the Corporation and members of the Board of Directors. They control 9% of the voting shares of the Corporation. Key management personnel compensation includes the following for the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017: 2018 2017 (12 months) (13 months) Short-term benefits (1) $ 3,361,371 $ 2,988,124 Share-based compensation costs (2) 1,879,459 1,605,103 $ 5,240,830 $ 4,593,227 (1) An amount of $735,244 is included related to key management personnel of Acasti for fees incurred before the loss of control of the subsidiary ($756,405 for the thirteen-month period ended March 31, 2017). (2) An amount of $444,556 is included related to key management personnel of Acasti for fees incurred before the loss of control of the subsidiary ($544,703 for the thirteen-month period ended March 31, 2017).

Significant Accounting Polici33

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Basis of consolidation	(a) Basis of consolidation: ( i ) Business combinations and related goodwill: Business combinations are accounted for using the acquisition method as at the acquisition date, when control is transferred. The consideration transferred for the acquisition of a business is the fair value of the assets transferred, and any liability and equity interests issued by the Corporation on the date control of the acquired company is obtained. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are generally measured initially at their fair values at the acquisition date. The Corporation measures goodwill as the fair value for the consideration transferred including the recognized amount of any non-controlling interest in the acquiree, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured at the acquisition date. If this consideration is lower than the fair value of the net assets of the business acquired, the difference is recognized immediately in the consolidated statement of earnings and comprehensive loss as a gain from a bargain purchase. Restructuring, transaction costs other than those associated with the issue of debt or equity securities, and other direct costs of a business combination are not considered part of the business acquisition transaction and are expensed as incurred. Subsequent recognition of goodwill: After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but tested for impairment at least annually and upon occurrence of an indication of impairment. The impairment testing process is described in the appropriate section of these accounting policies. Subsidiaries: Subsidiaries are entities controlled by the Corporation. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Control exists when the Corporation is exposed to, or has the right to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. (ii) Transactions eliminated on consolidation: Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. (iii) Subsidiary warrants, options and other equity: Subsidiary warrants, options and other equity are comprised of equity-classified warrants, rights and options issued by the subsidiary, as well as options and rights issued by the Corporation over the subsidiary’s equity instruments. Because they do not represent outstanding participating non-controlling interests, they are recorded at cost and remain presented as a sub-component of non-controlling interest until such time they are exercised or expire. (iv) Acquisitions and dispositions of non-controlling interests while retaining control: Acquisitions and dispositions of non-controlling interests while retaining control are accounted for as transactions with equity holders in their capacity as equity holders; therefore, no goodwill is recognized as a result of acquisitions and no gain or loss is recognized in connection with dispositions. Upon acquisition or disposition of non-controlling interests while retaining control, the Corporation adjusts non-controlling interests to reflect the relative change in its interest in the subsidiary’s equity, before giving effect of the elimination of the intra-group balances. Any difference between the amount by which non-controlling interest is adjusted and the fair value of consideration paid or received is recognized directly in equity attributable to shareholders of the Corporation. The fair value of consideration paid includes the cost of any subsidiary warrants, options and other equity exercised as part of the operation. Subsidiary warrants, options and other equity that expire unexercised are transferred to equity attributable to shareholders of the Corporation. (v) Attribution of profit or loss: Profit or loss of the subsidiaries is attributed to the Corporation’s shareholders and to non-controlling interests based on their respective share of participating equity instruments in each subsidiary outstanding during the period. This allocation is made giving effect to subsidiary profit and loss and before the elimination of intra-group balances.
Financial instruments	(b) Financial instruments: ( i ) Non-derivative financial assets: The Corporation has the following non-derivative financial assets: cash and cash equivalents, restricted short-term investments, trade and other receivables and other assets. Financial assets and liabilities are offset and the net amount presented in the consolidated statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Loans and receivables Loans and receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses. Loans and receivables comprise cash and cash equivalents, trade and other receivables and restricted short-term investments. Cash and cash equivalents comprise cash balances and highly liquid investments purchased three months or less from maturity. Bank overdrafts that are repayable on demand form an integral part of the Corporation’s cash management and are included as a component of cash and cash equivalents for the purpose of the consolidated statements of cash flows. Available-for-sale financial assets Available-for-sale financial assets are non-derivative financial assets that are designated as available-for-sale or are not classified in any of the other categories of financial assets. These assets are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at fair value and changes therein, are recognized in other comprehensive income (loss) and presented in accumulated other comprehensive income (loss) in equity. When an available-for-sale financial asset is derecognized, the gain or loss accumulated other comprehensive income (loss) in equity is reclassified to income or loss. The Corporation’s available-for-sale financial asset is comprised only of quoted equity securities and is presented as Other Assets. (ii) Non-derivative financial liabilities: The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire. The Corporation has the following non-derivative financial liabilities: loans and borrowings, trade and other payables and long-term payables. Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method. (iii) Share capital: Common shares are classified as equity. Incremental costs directly attributable to the issue of common shares are recognized as a deduction from equity, net of any tax effects. (iv) Compound financial instruments: Compound financial instruments are instruments that can be converted to share capital at the option of the holder, and the number of shares to be issued is fixed. The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not remeasured subsequent to initial recognition. (v) Derivative financial instruments and hedge accounting: Derivative financial instruments: The Corporation has issued liability-classified derivatives over its own equity. Embedded derivative is separated from the host contract and accounted for separately if the economic characteristics and risks of the host contract and the embedded derivative are not closely related, a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative, and the combined instrument is not measured at fair value through profit or loss. Derivatives and separable embedded derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives and separable embedded derivatives are measured at fair value, and all changes in their fair value are recognized immediately in profit or loss. Hedge accounting: Derivatives that qualify as hedging instruments must be designated as either a “cash flow hedge”, when the hedged risk is a variability in the future cash flows of the hedged item, or a “fair value hedge”, when the hedged risk is a variability in the fair value of the hedged item. Any derivative instrument that does not qualify for hedge accounting is marked-to-market at each reporting date and the gains or losses are included in income. Cash flow hedges: For derivative financial instruments designated as cash flow hedges, the effective portion of changes in their fair value is recognized in other comprehensive income in the consolidated statement of comprehensive income and presented in the cash flow hedges reserve in equity. Any ineffectiveness is recognized in income immediately as it arises in the same consolidated statement of earnings and comprehensive loss account as the hedged item when realized. Should a cash flow hedging relationship become ineffective or the hedging relationship be terminated, previously unrealized gains and losses remain within the cash flows hedges reserve until the hedged item is settled and any future changes in value of the derivative are recognized in income prospectively. When the hedged item is realized, amounts recognized in the cash flow hedge reserve are reclassified to the same consolidated statement of earnings and comprehensive loss account or reclassified to the related non-financial asset in which the hedged item is recorded. If the hedged item ceases to exist before the hedging instrument expires, the unrealized gains or losses within the cash flow hedge reserve are immediately reclassified to income. Use of derivative financial instruments: Derivative financial instruments are utilized, from time to time, by the Corporation in the management of its foreign currency exposures and interest-rate market risks. These derivative financial instruments are used as a method for meeting the risk reduction objectives of the Corporation by generating offsetting cash flows related to the underlying position in respect of amount and timing of forecasted foreign currency cash flows and interest payments. The Corporation uses interest rate swap agreements to lock-in a portion of its debt cost and reduce its exposure to the variability of interest rates by exchanging variable rate payments for fixed rate payments. The Corporation has designated its interest rate swaps as cash flow hedges for which it uses hedge accounting. When it utilizes derivatives in hedge accounting relationships, the Corporation formally documents and designates all of its eligible hedging relationships. This process involves associating all derivatives to specific assets and liabilities on the consolidated statement of financial position or with forecasted or probable transactions. The Corporation also formally assesses the effectiveness of hedging relationships at inception and on an on-going basis. (vi) Other equity instruments: Warrants, options and rights over the Corporation’s equity issued outside of share-based payment transactions that do not meet the definition of a liability instrument are recognized in equity.
Inventories	(c) Inventories: Inventories are measured at the lower of cost and net realizable value. The cost of raw materials, supplies and spare parts is based on the weighted-average cost method. The cost of finished goods and work in progress includes expenditures incurred in acquiring the inventories, production or conversion costs, sub-contractors costs and other costs incurred in bringing them to their existing location and condition, as well as production overheads based on normal operating capacity. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.
Property, plant and equipment	(d) Property, plant and equipment: ( i ) Recognition and measurement: Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labour, any other costs directly attributable to bringing the assets to a working condition for their intended use, the costs of dismantling and removing the items and restoring the site on which they are located and borrowing costs on qualifying assets. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. When parts of an item of property, plant and equipment have significantly different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized in net profit (loss). (ii) Subsequent costs: The cost of replacing a part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property, plant and equipment are recognized in profit or loss as incurred. (iii) Depreciation: Depreciation is calculated over the depreciable amount, which is the cost of an asset less its residual value. Depreciation is recognized in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item of property, plant and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows: Asset Method Period/Rate Building and building components Straight-line 20 to 40 years Laboratory, R&D and plant equipment Straight-line 10 to 20 years Furniture and office equipment Declining balance 20% to 30% Computer equipment Straight-line 2 to 5 years Depreciation methods, useful lives and residual values are reviewed at each financial year-end and adjusted prospectively, if appropriate.
Intangible assets	(e) Intangible assets: ( i ) Research and development: Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditure is recognized in profit or loss as incurred. Capitalized development expenditure is measured at cost less accumulated amortization and accumulated impairment losses. (ii) Other intangible assets: Non-compete agreements Non-compete agreements were valued as part of business acquisitions and are amortized on a straight-line basis over a period of 3 Customer relationships Customer relationships were acquired as part of business acquisitions and are amortized on a straight-line basis over a period of 10 Patent costs Patents for technologies that are no longer in the research phase are recorded at cost. The patent costs include legal fees to obtain patents and patent application fees. When the technology is still in the research phase, those costs are expensed as incurred. Patent costs are amortized on a straight-line basis over a period of 20 years. License agreements License agreements are mainly comprised of a license agreement acquired separately or as part of business acquisitions and are amortized on a straight-line basis between a period of 12 or 13 years from the acquisition date according to the licence agreement. Trademarks Trademarks have indefinite useful lives considering that they can be renewed at a minimal cost and are not amortized. They are tested for impairment annually, or more frequently if events or changes in circumstances indicate that they might be impaired. Any impairment is recognized in profit or loss. (iii) Subsequent expenditure: Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred. (iv) Amortization: Amortization is calculated over the cost of the asset less its residual value. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, other than trademarks, from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are described above.
Impairment	(f) Impairment: ( i ) Financial assets (including receivables): A financial asset not carried at fair value through profit or loss is assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, restructuring of an amount due to the Corporation on terms that the Corporation would not consider otherwise, indications that a debtor or issuer will enter bankruptcy, or the disappearance of an active market for a security. The Corporation considers evidence of impairment for receivables at both a specific asset and collective level. All individually significant receivables are assessed for specific impairment. All individually significant receivables found not to be specifically impaired are then collectively assessed for any impairment that has been incurred but not yet identified. Receivables that are not individually significant are collectively assessed for impairment by grouping together receivables with similar risk characteristics. In assessing collective impairment, the Corporation uses historical trends of the probability of default, timing of recoveries and the amount of loss incurred, adjusted for management’s judgment as to whether current economic and credit conditions are such that the actual losses are likely to be greater or less than suggested by historical trends. An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. Impairment losses on available-for-sale financial assets are recognized by reclassifying the losses accumulated in accumulated other comprehensive income to profit or loss. The amount reclassified is the difference between the acquisition cost and the current fair value, less any impairment loss previously recognized in profit or loss. (ii) Non-financial assets: The carrying amounts of the Corporation’s non-financial assets, and other than inventories, tax credits receivable and recoverable and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. For intangible assets that have indefinite useful lives or that are not yet available for use, the recoverable amount is estimated each year at the same date. The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the ''cash-generating unit'', or ''CGU''). An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill: Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired. Impairment is determined for goodwill by assessing the recoverable amount of each CGU to which the goodwill relates. The Corporation defines its CGUs based on the way it internally monitors and derives economic benefits from the acquired goodwill. Impairment losses for a CGU is first allocated to reduce goodwill. An impairment loss in respect of goodwill is not reversed in future periods.
Provisions	(g) Provisions: A provision is recognized if, as a result of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost. ( i ) Onerous contracts: A provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract. (ii) Contingent liability: A contingent liability is a possible obligation that arises from past events and of which the existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not within the control of the Corporation; or a present obligation that arises from past events (and therefore exists), but is not recognized because it is not probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation, or the amount of the obligation cannot be estimated reliably .
Revenue	(h) Revenue: ( i ) Sale of goods: Revenue from the sale of goods in the course of ordinary activities is measured at the fair value of the consideration received or receivable, net of returns. Revenue is recognized on delivery when the significant risks and rewards of ownership have been transferred to the buyer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. The Corporation considers delivery to have occurred upon shipment, or in some cases, upon reception by the customer. If it is probable that discounts will be granted and the amount can be measured reliably, then the discount is recognized as a reduction of revenue as the sales are recognized. (ii) Royalty revenues: Royalties are earned under the terms of the applicable agreement and are generally recognized on this basis. Royalty revenues are recognized when it is probable that the economic benefits associated with the transaction will be received and the amount can be measured reliably.
Government grants	( i ) Government grants: Government grants, consisting of grants and investment tax credits, are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Corporation has met or will meet the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset.
Lease payments	(j) Lease payments: Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease. Contingent lease payments are accounted for in the period in which they are incurred.
Foreign currency	(k) Foreign currency: Transactions in foreign currencies are translated to the respective functional currency at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on retranslation are recognized in profit or loss.
Employee benefits	(l) Employee benefits: ( i ) Short-term employee benefits: Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Corporation has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably. (ii) Share-based payment transactions: The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in contributed surplus and subsidiary warrants and options, as applicable, over the period that the employees unconditionally become entitled to the awards. The grant date fair value takes into consideration market performance conditions when applicable. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. The fair value of the share-based payment transactions is measured based on valuation models. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility), weighted average expected life of the instruments (based on contractual life, tranche vesting term and general option holder behaviour), expected dividends, and the risk-free interest rate (based on government bonds). Service and non-market performance conditions attached to the transactions, if any, are not taken into account in determining fair value. (iii) Termination benefits: Termination benefits are recognized as an expense when the Corporation is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to
Finance income and finance costs	(m) Finance income and finance costs: Finance income comprises interest income on funds invested. Interest income is recognized as it accrues in profit or loss, using the effective interest method. Finance costs comprise interest expense and accretion on borrowings, unwinding of the discount on provisions, financing costs, penalty on debt reimbursement, impairment losses recognized on financial assets and bank charges. Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognized in profit or loss using the effective interest method. Foreign currency gains and losses are reported on a net basis. The Corporation recognizes interest income as a component of investing activities and interest cost as a component of financing activities in the consolidated statements of cash flows.
Income tax	(n) Income tax: Income tax expense comprises current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to a business combination, or items recognized directly in equity or in other comprehensive income. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.
Earnings per share	(o) Earnings per share: The Corporation presents basic and diluted earnings per share ("EPS'') data for its common shares. Basic EPS is calculated by dividing the profit or loss attributable to common shareholders of the Corporation by the weighted average number of common shares outstanding during the period, adjusted for own shares held. Diluted EPS is determined by adjusting the profit or loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for own shares held, for the effects of all dilutive potential common shares, which comprise warrants, share options and deferred share units granted to employees.
Segment reporting	(p) Segment reporting: An operating segment is a component of the Corporation that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Corporation’s other components. All operating segments’ operating results are reviewed regularly by the Corporation’s CEO to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available.
New standard and interpretation adopted during the year	(q) New standard and interpretation adopted during the year: Statement of Cash Flows: In January 2016, the IASB amended IAS 7, Statement of Cash Flows
New standards and interpretations not yet adopted	(r) New standards and interpretations not yet adopted: A number of new standards, and amendments to standards and interpretations, are not yet effective for the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017, and have not been applied in preparing these consolidated financial statements. ( i ) Financial instruments: On July 24, 2014, the IASB issued the complete IFRS 9, Financial Instruments “ ” The Corporation expects no significant impact on its consolidated financial statements from the transition to the classification and measurement requirements of IFRS 9. On transition to IFRS 9, the Corporation must either designate the investment in Acasti as a financial asset measured at fair value through profit and loss or as an investment in an equity instrument measured at fair value through other comprehensive income. In the former case, changes in fair value to March 31, 2018 of $506,469, would be reclassified from accumulated other comprehensive income to reduce the deficit on initial application, with subsequent changes in fair value recognized in net income. In the latter case, the change in fair value would continue to be recognized in other comprehensive income and would never be reclassified to net income. Management has not yet completed its IFRS 9 analysis and therefore has not finalized the accounting designation for the investment in Acasti. IFRS requires the Corporation to record expected credit losses on all its trade receivables and other financial assets, either on a 12-month or lifetime basis. The Corporation does not expect the potential impact to be significant on its consolidated financial statements. The Corporation believes that the existing hedge relationship that is currently designated in an effective hedging relationship will still qualify for hedge accounting under IFRS 9. As IFRS 9 does not change the general principles of how an entity accounts for effective hedges, the adoption of IFRS 9 is not expected to have a significant impact on the Corporation’s hedge accounting. (ii) Revenue: On May 28, 2014, the IASB issued IFRS 15, Revenue from Contracts with Customers Revenue The Corporation expects no significant impact on its consolidated financial statements, other than the disclosure requirements noted below. The majority of the Corporation’s contracts are contracts with customers in which the sale of goods is generally expected to be the only performance obligation. The Corporation expects the revenue recognition to occur at a point in time when control of the assets is transferred to the customer, generally on delivery of the goods, consistent with its current practice. IFRS 15 provides presentation and disclosure requirements, which are more detailed than under current IFRS. The presentation requirements represent a significant change from current practice and is expected to significantly increase the volume of disclosures required in the Corporation’s consolidated financial statements. The Corporation is currently developing processes necessary to collect and disclose the required information. The Corporation will be providing the required disclosure in its quarterly and annual consolidated financial statements for the year ended March 31, 2019. (iii) Leases: In January 2016, the IASB issued IFRS 16, Leases Leases (iv) Amendments to IFRS 2 – Classification and Measurement of Share-Based Payment Transactions : On June 20, 2016, the IASB issued amendments to IFRS 2, Share-Based Payment (v) Income tax: On June 7, 2017, the IASB issued IFRIC 23 – Uncertainty over Income Tax Treatments The Interpretation requires an entity to: • Contemplate whether uncertain tax treatments should be considered separately, or together as a group, based on which approach provides better predictions of the resolution; • Reflect an uncertainty in the amount of income tax payable (recoverable) if it is probable that it will pay (or recover) an amount for the uncertainty; and • Measure a tax uncertainty based on the most likely amount or expected value depending on whichever method better predicts the amount payable (recoverable). The Corporation intends to adopt the Interpretation in its consolidated financial statements for the annual period beginning on April 1, 2019. The extent of the impact of adoption of the Interpretation has not yet been determined.

Significant Accounting Polici34

Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Significant Accounting Policies [Abstract]
Schedule of Estimated Useful Lives	The estimated useful lives for the current and comparative periods are as follows: Asset Method Period/Rate Building and building components Straight-line 20 to 40 years Laboratory, R&D and plant equipment Straight-line 10 to 20 years Furniture and office equipment Declining balance 20% to 30% Computer equipment Straight-line 2 to 5 years

Sale of Assets (Tables)

Sale of Assets (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Sale Of Assets [Abstract]
Schedule of Reconciliation of Net Gain on Sale of Assets	The following table presents a reconciliation of the net gain on sale of assets for the year ended March 31, 2018 and the full impact of the sale transaction and concurrent debt reimbursements on the net income of the Corporation: August 7, 2017 Total transaction proceeds $ 43,075,587 Inventory sold (11,185,572 ) Net intangible assets sold (5,791,710 ) Write-off of assets, severance costs, transaction costs and costs for activities relating to exiting the bulk krill oil business (i) (2,395,993 ) Net gain on sale of assets as presented in the consolidated statement of earnings $ 23,702,312 Impairment loss in inventories – presented in cost of sales (note 6) (2,376,969 ) Penalty on reimbursement, loss on financing fees and reversal of accretion from non-interest bearing debt reimbursed – presented in finance costs (note 16) (920,429 ) Total impact of the transaction on the net income before tax $ 20,404,914 (i) Including non-cash write-off of assets of $554,044, employee severance of $1,063,790 and transaction costs of $497,811.

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	12 Months Ended
	Mar. 31, 2018
Trade And Other Current Receivables [Abstract]
Summary of Trade and Other Receivables	March 31, March 31, 2018 2017 Trade receivables $ 4,926,632 $ 7,390,701 Sales taxes receivable 215,184 153,652 Accrued and other receivables 426,488 6,015,116 Grants receivables 22,543 — $ 5,590,847 $ 13,559,469

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Mar. 31, 2018
Classes Of Inventories [Abstract]
Schedule of Inventories	March 31, March 31, 2018 2017 Raw materials $ 3,358,264 $ 5,539,437 Work in progress 474,057 3,154,833 Finished goods 675,031 3,807,455 Supplies and spare parts 753,977 741,010 $ 5,261,329 $ 13,242,735

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Property Plant And Equipment [Abstract]
Summary of Property Plant and Equipment	Building Laboratory, Furniture and building R&D and plant and office Computer Land components equipment equipment equipment Total Cost: Balance at February 29, 2016 $ 228,630 $ 23,009,625 $ 26,073,781 $ 499,159 $ 281,766 $ 50,092,961 Additions – 6,231 2,953,611 9,710 88,820 3,058,372 Disposals – – (8,995 ) (45,102 ) – (54,097 ) Balance at March 31, 2017 228,630 23,015,856 29,018,397 463,767 370,586 53,097,236 Additions – 147,263 1,182,102 – 86,555 1,415,920 Loss of control of Acasti (note 13) – – (3,299,059 ) (18,407 ) (13,759 ) (3,331,225 ) Balance at March 31, 2018 $ 228,630 $ 23,163,119 $ 26,901,440 $ 445,360 $ 443,382 $ 51,181,931 Accumulated depreciation: Balance at February 29, 2016 – 1,721,529 2,358,964 258,377 206,426 4,545,296 Disposals – – (8,995 ) (45,102 ) – (54,097 ) Depreciation for the thirteen-month period – 899,412 1,743,346 57,439 41,473 2,741,670 Balance at March 31, 2017 – 2,620,941 4,093,315 270,714 247,899 7,232,869 Loss of control of Acasti (note 13) – – (529,344 ) (13,070 ) (7,017 ) (549,431 ) Depreciation for the year – 830,850 1,712,516 37,820 36,460 2,617,646 Balance at March 31, 2018 $ – $ 3,451,791 $ 5,276,487 $ 295,464 $ 277,342 $ 9,301,084 Net carrying amounts: March 31, 2017 $ 228,630 $ 20,394,915 $ 24,925,082 $ 193,053 $ 122,687 $ 45,864,367 March 31, 2018 228,630 19,711,328 21,624,953 149,896 166,040 41,880,847
Summary of Depreciation Expense of Property Plant and Equipment	Depreciation expense has been recorded in the following accounts in the consolidated statements of earnings and comprehensive income: March 31, March 31, 2018 2017 (12 months) (13 months) Cost of sales $ 1,067,629 $ 2,264,748 Research and development expenses 1,321,145 229,541 Selling, general and administrative expenses 228,872 247,381 $ 2,617,646 $ 2,741,670

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Intangible Assets And Goodwill [Abstract]
Schedule of Reconciliation of Changes in Intangible Assets and Goodwill	Non-compete Customer License agreements relationships Patents agreements Trademarks Total Cost: Balance at February 29, 2016 $ 400,000 $ 4,100,000 $ 1,544,467 $ 1,552,334 $ 150,289 $ 7,747,090 Additions — — 2,126 6,182,604 12,937 6,197,667 Balance at March 31, 2017 400,000 4,100,000 1,546,593 7,734,938 163,226 13,944,757 Additions — — — 772 3,844 4,616 Sale to Aker BioMarine (note 4) — — (1,185,773 ) (5,553,524 ) (167,070 ) (6,906,367 ) Balance at March 31, 2018 $ 400,000 $ 4,100,000 $ 360,820 $ 2,182,186 $ — $ 7,043,006 Accumulated depreciation: Balance at February 29, 2016 $ 22,000 $ 68,200 $ 814,174 $ 17,560 $ — $ 921,934 Amortization for the thirteen- month period 143,000 443,300 108,400 380,430 — 1,075,130 Balance at March 31, 2017 165,000 511,500 922,574 397,990 — 1,997,064 Sale to Aker BioMarine (note 4) — — (576,458 ) (538,199 ) — (1,114,657 ) Amortization for the year 132,111 409,267 14,704 368,154 — 924,236 Balance at March 31, 2018 $ 297,111 $ 920,767 $ 360,820 $ 227,945 $ — $ 1,806,643 Net carrying amounts: March 31, 2017 $ 235,000 $ 3,588,500 $ 624,019 $ 7,336,948 $ 163,226 $ 11,947,693 March 31, 2018 102,889 3,179,233 — 1,954,241 — 5,236,363

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Mar. 31, 2018
Trade And Other Current Payables [Abstract]
Summary of Trade and Other Payables	March 31, March 31, 2018 2017 Trade payables $ 2,425,617 $ 4,344,557 Accrued liabilities and other payables 2,773,043 3,757,436 Employee salaries and benefits payable 1,549,229 1,891,026 $ 6,747,889 $ 9,993,019

Loans and Borrowings (Tables)

Loans and Borrowings (Tables)	12 Months Ended
	Mar. 31, 2018
Borrowings [Abstract]
Summary of Contractual Terms of Corporation's Loans and Borrowings	This note provides information about the contractual terms of the Corporation’s loans and borrowings, which are measured at amortized cost. March 31, March 31, 2018 2017 Loans and borrowings: Loan, bearing interest at prime rate plus 2.5% (plus 3.25% before October 14, 2016), secured through a first-ranking mortgage on all movable assets of Biodroga current and future, corporeal and incorporeal, and tangible and intangible, reimbursable in monthly principal payments of $89,286 and a final payment of $3,314,276 on December 2018. The interest risk of the loan is mitigated by an interest rate swap. The Corporation has reserved $2,350,000 of short-term investments as pledge for the loan. Amounts received are net of transaction costs of $197,789. $ 3,891,077 $ 5,429,852 Balance of purchase price due to previous owners of Biodroga bearing interest at 5% until December 2018, reimbursable in quarterly principal payments of $93,750 from March 2016 to September 2018, with a final payment of $74,096. An amount of $2,501,016 bearing interest at 7% was reimbursed during the year. Payments under these agreements are only payable if covenants on the loan at prime plus 2.5% above are respected. 261,596 3,202,612 Authorized bank line of credit of $1,800,000 bearing interest at prime rate plus 1%, expiring on August 31, 2018. 490,000 — Finance lease liabilities, interest rate from 6.25% to 7.13%, payable in monthly instalments of $2,345, maturing in November 2018 and March 2019. 18,683 44,644 Secured loan from Investissement Québec (“IQ”), principal balance authorized of $12,500,000, bearing interest at 8%, reimbursed during the year. — 8,347,506 Loan, principal amount of 2.1 million GBP ($3,822,000), bearing interest at 12%, reimbursed during the year. — 3,562,814 Refundable contribution obtained from a federal program, principal balance authorized of $3,500,000, without collateral or interest, reimbursed during the year. — 2,344,116 4,661,356 22,931,544 Less current portion of loans and borrowings 4,661,356 7,192,315 Loans and borrowings $ — $ 15,739,229

Capital and Other Components 42

Capital and Other Components of Equity (Tables)	12 Months Ended
	Mar. 31, 2018
Default Root [Abstract]
Summary of Warrants	(e) Warrants: The warrants of the Corporation are composed of the following as at March 31, 2018 and 2017: March 31, March 31, 2018 2017 Number Number outstanding outstanding and exercisable Amount and exercisable Amount Warrants IQ financing (i) 750,000 $ 648,820 750,000 $ 648,820 ( i ) Exercise price of $3.37 per share and expiring on December 12, 2019.

Non-controlling Interests ("N43

Non-controlling Interests ("NCI") (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Significant Investments In Subsidiaries [Abstract]
Summary of reconciliation of gain on loss of control in subsidiary	The following table presents a reconciliation of the gain on loss of control for the year ended March 31, 2018: December 27, 2017 Investment in Acasti at fair value $ 6,079,271 Non-controlling interest 2,233,973 Acasti's assets before deconsolidation (7,143,171 ) Acasti's liabilities before deconsolidation 7,613,540 Gain on loss on control of Acasti $ 8,783,613

Personnel Expense (Table)

Personnel Expense (Table)	12 Months Ended
	Mar. 31, 2018
Personnel Expenses [Abstract]
Disclosure of Employee Related Expense Explanatory	March 31, March 31, 2018 2017 (12 months) (13 months) Salaries and other short-term employee benefits $ 9,833,691 $ 12,196,987 Severance 813,365 83,879 Share-based compensation 2,283,756 2,014,902 $ 12,930,812 $ 14,295,768

Finance Costs (Tables)

Finance Costs (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Finance Income And Costs [Abstract]
Summary of Finance Costs	March 31, March 31, 2018 2017 (12 months) (13 months) Interest charges and other finance costs $ (1,061,588 ) $ (2,764,389 ) Interest expense on unsecured convertible debentures (275,140 ) — Penalty on reimbursment, loss on financing and discounted fees on debt reimbursment (note 4) (920,429 ) — Foreign exchange loss (189,122 ) (7,757 ) Finance costs $ (2,446,279 ) $ (2,772,146 )

Share-based Payments (Tables)

Share-based Payments (Tables)	12 Months Ended
	Mar. 31, 2018
Stock Option Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Number and Weighted Average Exercise Price	The number and weighted average exercise prices of stock options are as follows: 2018 2017 Weighted Weighted average average exercise Number of exercise Number of price options price options Options outstanding at April 1, 2017 and March 1, 2016 $ 1.92 3,765,000 $ 2.50 4,242,025 Granted (i) 1.90 7,501,980 1.54 881,000 Exercised (note 12 (d)) 1.72 (149,000 ) — — Forfeited 1.54 (816,434 ) 2.69 (456,461 ) Expired 2.93 (210,000 ) 3.84 (901,564 ) Options outstanding at March 31, 2018 and 2017 $ 1.92 10,091,546 $ 1.92 3,765,000 Options exercisable at March 31, 2018 and 2017 $ 1.97 2,322,668 $ 2.07 2,115,666 (i) Of the 7,501,980 options granted, 2,095,333 options have restrictions on their exercise subject to shareholder approval as required by the rules of the Toronto Stock Exchange.
Schedule of Number and Contractual Life	2018 Options outstanding Exercisable options Weighted remaining Weighted Weighted contractual Number of number of average Exercise life options options exercise price outstanding outstanding exercisable price $1.24 - $1.82 3.47 1,825,973 672,668 $ 1.66 $1.83 - $1.91 4.35 420,000 350,000 1.83 $1.92 - $2.05 4.69 6,470,573 — — $2.06 - $2.15 4.70 75,000 — — $2.16 3.64 1,300,000 1,300,000 2.16 4.32 10,091,546 2,322,668 $ 1.97
Summary of Assumptions Used to Determine Fair Value of Options Granted	The fair value of options granted, including 2,095,333 options issued during the year ended March 31, 2018 for which the fair value is revaluated at each reporting date until shareholder approval, has been estimated according to the Black-Scholes option pricing model and based on the weighted average of the following assumptions for options granted to employees during the year ended March 31, 2018 and the thirteen-month period ended March 31, 2017: 2018 2017 Exercise price $ 1.90 $ 1.54 Share price $ 1.81 $ 1.54 Dividend ‒ ‒ Risk-free interest 1.50 % 0.67 % Estimated life (years) 3.93 3.50 Expected volatility 48.60 % 49.46 %
Performance Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Number and Contractual Life	2018 Options outstanding Exercisable options Weighted remaining Weighted Weighted contractual Number of number of average Exercise life options options exercise price outstanding outstanding exercisable price $1.55 2.55 325,000 325,000 $ 1.55
Schedule of Number and Weighted Average Exercise Price	The number and weighted average exercise prices of performance options are as follows: 2018 2017 Weighted Weighted average average exercise Number of exercise Number of price options price options Options outstanding at April 1, 2017 and March 1, 2016 $ 1.55 475,000 $ 1.55 625,000 Forfeited 1.55 (150,000 ) 1.55 (150,000 ) Options outstanding at March 31, 2018 and 2017 $ 1.55 325,000 $ 1.55 475,000 Options exercisable at March 31, 2018 and 2017 $ 1.55 325,000 $ — —
Deferred Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Number and Weighted Average Exercise Price	2018 2017 Weighted Weighted average average exercise Number of exercise Number of price DSUs price DSUs DSUs outstanding at April1, 2017 and March 1, 2016 $ 1.60 425,354 $ 1.72 75,000 Granted 1.27 201,342 1.57 350,354 Released through the issuance of common shares (note 12 (c)) 1.43 (55,944 ) — — DSUs outstanding at March 31, 2018 and 2017 $ 1.50 570,752 $ 1.60 425,354 DSUs exercisable at March 31, 2018 and 2017 $ 1.48 374,670 $ 1.59 240,004
Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Schedule of Number and Weighted Average Exercise Price	The number and weighted average exercise prices of warrants are as follows: 2018 2017 Weighted Weighted average average exercise Number of exercise Number of price warrants price warrants Warrants outstanding at April 1, 2017 and March 1, 2016 $ 21.50 24,174 $ 12.84 292,047 Forfeited 21.50 (465 ) 11.86 (129,122 ) Expired 21.50 (23,709 ) 12.25 (138,751 ) Warrants outstanding and exercisable at March 31, 2018 and 2017 $ — — $ 21.50 24,174

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Income Tax [Abstract]
Schedule of Current Income Taxes Expense	Current income taxes expense (recovery): 2018 2017 Current $ — $ 2,294,471 Adjustment of prior year income taxes expense (recovery) (1,932,831 ) — Current income taxes expense (recovery) $ (1,932,831 ) $ 2,294,471
Schedule of Deferred Taxes Expense (Income)	Deferred taxes expense: 2018 2017 Recognition of previously unrecognized deductible temporary differences and tax losses of prior periods $ (114,226 ) $ (129,362 ) Origination and reversal of temporary differences (1,772,883 ) (434,615 ) Change in unrecognized deductible temporary differences 2,179,740 623,134 Deferred tax expense $ 292,631 $ 59,157
Schedule of Reconciliation of Effective Tax Rate	Reconciliation of effective tax rate: 2018 2017 Income before income taxes $ 7,699,183 $ 3,233,477 Basic combined Canadian statutory income tax rate 1 26.78 % 26.87 % Income tax $ 2,061,841 $ 868,835 Increase (decrease) resulting from: Recognition of previously unrecognized deductible temporary differences and tax losses of prior periods (114,226 ) (129,362 ) Change in unrecognized deductible temporary differences 2,179,736 623,134 Gain on loss of control of Acasti (2,352,252 ) — Non taxable gain on sale of assets (4,304,482 ) — Non-deductible stock-based compensation 611,590 538,145 Non-deductible change in fair value 9,733 70,929 Permanent differences and other 210,449 37,786 Change in statutory income tax rate 57,411 344,161 Total tax expense (recovery) $ (1,640,200 ) $ 2,353,628 1 The Canadian combined statutory income tax rate has decreased due to a reduction in the provincial statutory income tax rate.
Schedule of Recognized Deferred Tax Assets and Liabilities	The details of changes of deferred income taxes are as follows for the year ended March 31, 2018: Balance as at Balance as at March 31, Recognized in Recognized in March 31, 2017 equity net income 2018 Tax losses carried forward $ 1,376,971 $ — $ 5,964,843 $ 7,341,814 Research and development expenses 245,399 — (222 ) 245,177 Intangible assets (1,309,688 ) — 112,806 (1,196,882 ) Property, plant and equipment (6,513 ) — (4,457,302 ) (4,463,815 ) Tax credits receivable (40,708 ) — — (40,708 ) Prepaid royalty income — — (1,912,756 ) (1,912,756 ) $ 265,461 $ — $ (292,631 ) $ (27,170 ) The details of changes of deferred income taxes are as follows for the thirteen-month period ended March 31, 2017: Balance as at Balance as at February 29, Recognized in Recognized in March 31, 2016 equity net income 2017 Tax losses carried forward $ 1,769,506 $ – $ (392,535 ) $ 1,376,971 Research and development expenses 247,409 – (2,010 ) 245,399 Intangible assets (1,549,950 ) – 240,262 (1,309,688 ) Property, plant and equipment 136,166 – (142,679 ) (6,513 ) Tax credits receivable (149,151 ) – 108,443 (40,708 ) Unsecured convertible debentures – (129,362 ) 129,362 – $ 453,980 $ (129,362 ) $ (59,157 ) $ 265,461
Schedule of Tax Losses Carried Forward	As at March 31, 2018, the amounts and expiry dates of tax attributes and temporary differences, for which no tax assets have been recognized, which are available to reduce future years’ taxable income were as follows. Deferred tax assets have not been recognized in respect of these items because it is not probable that future taxable profit will be available against which the Corporation can utilise the benefits there from. Federal Provincial Tax losses carried forward 2035 $ 5,812,000 $ 1,298,000 2036 3,052,000 3,052,000 2037 9,050,000 10,499,000 2038 754,000 754,000 $ 18,668,000 $ 15,603,000 Research and development expenses, without time limitation $ 10,906,000 $ 15,574,000
Schedule of Unused Tax Credits	Unused federal Research and Development investment tax credits of the nutraceutical segment, for which no benefit has been recognized, may be used to reduce future federal income taxes payable and expire as follows: 2022 $ 76,000 2023 217,000 2024 75,000 2025 53,000 2026 91,000 2027 145,000 2028 64,000 2029 107,000 2030 206,000 2031 244,000 2032 129,000 2033 124,000 2034 106,000 2035 281,000 2036 210,000 2037 141,000 $ 2,269,000

Income per share (Tables)

Income per share (Tables)	12 Months Ended
	Mar. 31, 2018
Reconciliation Of Number Of Shares Outstanding [Abstract]
Summary of Reconciliation of Number of Shares Outstanding	The following table provides a reconciliation between the number of basic and diluted shares outstanding: 2018 2017 Weighted average number of common shares 78,599,208 77,945,548 Dilutive effect of deferred share units 373,039 200,339 Dilutive effect of stock options 387,049 — Weighted average number of diluted shares 79,359,296 78,145,887 Number of anti-dilutive stock options, warrants and deferred share units excluded from diluted earnings per share calculation 8,798,979 5,232,178

Supplemental Cash Flow Disclo49

Supplemental Cash Flow Disclosure (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Supplementary Cash Flow Information [Abstract]
Summary of Supplemental Cash Flow Disclosure	(a) Changes in operating assets and liabilities: March 31, March 31, 2018 2017 Trade and other receivables $ 10,547,497 $ (7,026,796 ) Tax credits receivable 108,821 645,334 Prepaid expenses (981,444 ) 500,968 Inventories (5,581,135 ) 4,619,832 Trade and other payables 3,312,306 (521,119 ) Deferred revenues 109,950 206,036 Changes in operating assets and liabilities $ 7,515,995 $ (1,575,745 ) (b) Non-cash transactions: March 31, March 31, 2018 2017 Acquired property, plant and equipment included in trade and other payables $ 456,774 $ 308,218 Intangible assets included in trade and other payables 453,436 140,731 Intangible assets included in trade and other receivables (note 14) — 3,546,400 Intangible assets included in long-term payable 249,714 795,072 Liability settlement in shares 858,000 — Acasti convertible debenture interest paid in shares of subsidiary 56,984 — Reduction in goodwill on reduction of balance of purchase price — 65,513 Acasti equity settled share-based payment included in equity and unsecured convertible debentures — 94,200 Acasti issuance of broker warrants included in net proceeds from Acasti public offering — 143,932 Acasti public offering transactions costs included in trade and other payables — 380,765 Acasti reduction in share issue costs from reduction in trade and other payables — 109,410 Acasti private placement transactions costs included in trade and other payables — 40,305
Summary of Reconciliation of Liabilities to Cash Flows from Financing Activities	(c) Reconciliation of movements of liabilities to cash flows arising from financing activities: Cash (used in) provided by financing activities Non-cash changes Balance as at March 31, 2017 Proceeds Repayments Settlement of cross currency swap Accretion of interest Effect of foreign currency exchange rate changes Financing and discounted fees Changes in fair value Balance as at March 31, 2018 Loan $ 5,429,852 $ – $ (1,571,432 ) $ – $ 32,657 $ – $ – $ – $ 3,891,077 Balance of purchase price 3,202,612 – (2,941,016 ) – – – – – 261,596 Bank line of credit – 490,000 – – – – – – 490,000 Finance lease liabilities 44,644 – (25,961 ) – – – – – 18,683 Loan IQ 8,347,506 – (8,593,775 ) – 47,242 – 199,027 – – Loan in GBP (1) 3,562,814 – (3,456,910 ) – 16,594 (225,384 ) 102,886 – – Refundable contribution 2,344,116 – (2,800,004 ) – 100,855 – 355,033 – – Total long-term debt $ 22,931,544 $ 490,000 $ (19,389,098 ) $ – $ 197,348 $ (225,384 ) $ 656,946 $ – $ 4,661,356 Interest rate swap liability (asset) used for hedging $ 7,298 $ – $ – $ – $ – $ – $ – $ (26,388 ) $ (19,090 ) Cross currency swap liability $ 207,839 $ – $ – $ (58,999 ) $ – $ 7,499 $ – $ (156,339 ) $ – (1)

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Financial Instruments [Line Items]
Schedule of Reconciliation of Changes in Fair Value Measurement of Financial Liabilities	The reconciliation of changes in fair value measurements of financial liabilities as at December December 27, March 31, 2017 2017 Opening balance at April 1, 2017 and March 1, 2016 $ 202,610 $ 151,343 Change in fair value (gain) loss (189,001 ) 51,267 Loss of control of subsidiary (note 13) (13,609 ) — Closing balance at December 27, 2017 and March 31, 2017 $ — $ 202,610
Schedule of Derivative Swap Agreements	(iii) Derivative swap agreements: March 31, March 31, 2018 2017 Non-current asset Interest rate swap contract $ 19,090 $ — $ 19,090 $ — Non-current liabilities Cross currency swap contract $ — $ 207,839 Interest rate swap contract — 7,298 $ — $ 215,137
Schedule of Maturity Analysis Associated with Interest Rate Swap Agreement Used to Manage Interest Risk Associated with Long-Term Debt	Details of the interest rate swap is as follows: Fixed rate Notional March 31, March 31, % amount Maturity 2018 2017 Interest rate swap agreement 2.94 $ 3,883,923 Dec. 27, 2018 $ 19,090 $ (7,298 )
Schedule of Aging of Trade Receivable Balances and Allowance for Doubtful Accounts	The aging of trade receivable balances and the allowance for doubtful accounts as at March 31, 2018 and 2017 were as follows: March 31, March 31, 2018 2017 Current $ 3,908,804 $ 6,244,434 Past due 0-30 days 950,417 818,318 Past due 31-120 days 66,546 326,053 Past due over 121 days 606,829 625,752 Trade receivables 5,532,596 8,014,557 Less allowance for doubtful accounts (605,964 ) (623,856 ) $ 4,926,632 $ 7,390,701
Schedule of Movement of Trade Receivable Allowance for Doubtful Accounts	The movement in allowance for doubtful accounts in respect of trade receivables was as follows: March 31, March 31, 2018 2017 Balance, beginning of year $ 623,856 $ 5,613,365 Bad debt expenses — 30,847 Foreign exchange (gain) loss (17,892 ) (6,811 ) Write-off against reserve — (5,013,545 ) Balance, end of year $ 605,964 $ 623,856
Schedule of Contractual Maturities of Financial Liabilities	The following are the contractual maturities of financial liabilities as at March 31, 2018 and 2017: March 31, 2018 Required payments per year Carrying Contractual Less than 1 to More than (in thousands of dollars) amount cash flows 1 year 5 years 5 years Trade and other payables and long-term payable $ 6,998 $ 6,998 $ 6,748 $ 250 $ – Loans and borrowings * 4,661 4,818 4,818 – – $ 11,659 $ 11,816 $ 11,566 $ 250 $ – * Includes interest payments to be made at the contractual rate. March 31, 2017 Required payments per year Carrying Contractual Less than 1 to More than (in thousands of dollars) amount cash flows 1 year 5 years 5 years Trade and other payables and long-term payable $ 10,788 $ 10,788 $ 9,993 $ 795 $ – Loans and borrowings * 22,932 26,459 8,681 17,778 – Unsecured convertible debentures * 1,406 2,463 160 2,303 – Interest rate swap 7 7 7 – – Cross currency rate swap 208 208 208 – – $ 35,341 $ 39,925 $ 19,049 $ 20,876 $ – * Includes interest payments to be made at the contractual rate.
Foreign Exchange Rate Risk
Disclosure Of Financial Instruments [Line Items]
Schedule of Effect of Changes in Foreign Exchange Currency	The following table provides an indication of the Corporation’s significant foreign exchange currency exposures as stated in Canadian dollars at the following dates: March 31, March 31, 2018 2017 US$ US$ EURO GBP Cash and cash equivalents $ 1,120,711 $ 5,204,124 $ 15,997 $ 1,778 Trade and other receivables 3,125,286 13,146,332 1,390,984 36,239 Trade and other payables (1,338,182 ) (6,566,584 ) (463,134 ) — Long-term payable (483,549 ) (795,072 ) — — Derivative financial liability swap — (30,741 ) — — Long-term debt (1) — (3,682,294 ) — — $ 2,424,266 $ 7,275,765 $ 943,847 $ 38,017 (1) The following exchange rates are those applicable for the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017: March 31, March 31, 2018 2017 Average Reporting Average Reporting US$ per CAD 1.2834 1.2900 1.3134 1.3299 EURO per CAD 1.5008 1.5898 1.4424 1.4251 GBP per CAD 1.7022 1.8079 1.7275 1.6700 Based on the Corporation’s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar, Euro and GBP would have increased the net profit as follows, assuming that all other variables remained constant: March 31, March 31, 2018 2017 US$ US$ EURO GBP Increase in net profit $ 121,212 $ 363,787 $ 47,192 $ 1,901
Interest rate risk [member]
Disclosure Of Financial Instruments [Line Items]
Summary of Corporation’s Exposure to Interest Rate Risk	The Corporation’s exposure to interest rate risk as at March 31, 2018 and 2017 is as follows: Cash and cash equivalents Short-term fixed interest rate Restricted short-term investments Short-term fixed interest rate Loans and borrowings Fixed and variable interest rates Unsecured convertible debentures until the loss on control of Acasti Fixed interest rates

Capital Management (Tables)

Capital Management (Tables)	12 Months Ended
	Mar. 31, 2018
Capital Management [Abstract]
Summary of Cash Equivalents and Restricted Short-term Investments	The Corporation cash equivalents and restricted short-term investments as at March 31, 2018 and 2017 are as follows: March 31, March 31, 2018 2017 Maturity Maturity date Rate Amount date Rate Amount Term deposit (1) April 27, 2018 1.12% $ 18,502,297 April 11, 2017 0.52% $ 1,662,375 Term deposit (1) — — — April 25, 2017 0.53% 1,331,815 Restricted short-term investment as pledge for the acquisition of Biodroga May 28, 2018 1.20% 2,350,000 June 1, 2017 1.05% 2,350,000 Restricted short-term investment Dec. 11, 2018 0.90% 60,000 Dec. 11, 2017 0.85% 72,000 Restricted short-term investment as pledge for cross currency swaps — — — April 4, 2018 — 323,000 (1)

Operating segments (Tables)

Operating segments (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Operating Segments [Abstract]
Summary of Information About Reportable Segments	(a) Information about reportable segments: Year ended March 31, 2018: Cardiovascular Intersegment Nutraceutical Cannabis ( i ) eliminations Total Revenue from external sales and royalties $ 27,645,582 $ — $ — $ — $ 27,645,582 Gross margin 6,324,292 — — — 6,324,292 Research and development expenses (895,944 ) (3,566,223 ) (9,675,625 ) 1,742,121 (12,395,671 ) Research tax credits and grants (1,836,071 ) — 84,119 — (1,751,952 ) Selling, general and administrative expenses (11,946,772 ) — (2,761,478 ) — (14,708,250 ) Other income – net gain on sale of assets 23,702,312 — — — 23,702,312 Income (loss) from operating activities 15,347,817 (3,566,223 ) (12,352,984 ) 1,742,121 1,170,731 Gain on loss of control of subsidiary 8,783,613 — — — 8,783,613 Finance income 188,828 — 38,637 — 227,465 Finance costs (2,090,867 ) — (355,412 ) — (2,446,279 ) Change in fair value of derivative assets and liabilities and loss on sale of available-for-sale investment (225,348 ) — 195,740 (6,739 ) (36,347 ) Income (loss) before income tax 22,004,043 (3,566,223 ) (12,474,019 ) 1,735,382 7,699,183 Income tax recovery 1,640,200 — — — 1,640,200 Net income (loss) 23,644,243 (3,566,223 ) (12,474,019 ) 1,735,382 9,339,383 Depreciation and amortization (2,224,814 ) (1,054,170 ) (2,005,019 ) 1,742,121 (3,541,882 ) Stock-based compensation (1,371,382 ) (251,763 ) (660,611 ) — (2,283,756 ) Reportable segment assets 51,057,311 40,953,903 6,585,740 — 98,596,954 Reportable segment liabilities 11,057,797 1,005,387 — — 12,063,184 (i) Results of operations for the period starting April 1 st Thirteen-month period ended March 31, 2017: Intersegment Nutraceutical Cardiovascular eliminations Total Revenue from external sales and royalties $ 46,809,586 $ 7,797 $ – $ 46,817,383 Revenue from transactions to Cardiovascular segment 112,500 — (112,500 ) — Gross margin 12,792,785 7,797 1,230 12,801,812 Research and development expenses (1,774,038 ) (7,991,232 ) 2,516,397 (7,248,873 ) Research tax credits and grants 2,078,047 330,330 — 2,408,377 Selling, general and administrative expenses (13,503,643 ) (3,557,209 ) — (17,060,852 ) Other income – royalty settlement 15,301,758 — — 15,301,758 Income (loss) from operating activities 14,894,909 (11,210,314 ) 2,517,627 6,202,222 Finance income 31,180 124,509 (89,153 ) 66,536 Finance costs (2,623,073 ) (238,226 ) 89,153 (2,772,146 ) Change in fair value of derivative assets and liabilities (211,869 ) (52,974 ) 1,708 (263,135 ) Income (loss) before income tax 12,091,147 (11,377,005 ) 2,519,335 3,233,477 Income taxes (expense) recovery (2,482,990 ) 129,362 — (2,353,628 ) Net income (loss) 9,608,157 (11,247,643 ) 2,519,335 879,849 Depreciation and amortization (3,596,088 ) (2,737,109 ) 2,516,397 (3,816,800 ) Stock-based compensation (1,340,324 ) (674,578 ) — (2,014,902 ) Reportable segment assets 98,163,888 25,454,825 (12,398,597 ) 111,220,116 Reportable segment liabilities 32,685,762 3,752,298 (18,182 ) 36,419,878
Summary of Revenue from Sales Based on Destination	The Corporation’s revenue from sales are attributed based on destination: 2018 2017 (12 months) (13 months) Canada $ 11,494,565 $ 15,793,572 United States 11,581,085 23,795,544 Belgium — 2,363,275 China 1,254,964 1,493,165 France 467,473 809,127 Uruguay 779,613 51,144 Other countries 590,769 1,428,534 $ 26,168,469 $ 45,734,361

Related Parties (Tables)

Related Parties (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Transactions Between Related Parties [Abstract]
Summary of Key Management Personnel Compensation	Key management personnel compensation includes the following for the year ended March 31, 2018 and for the thirteen-month period ended March 31, 2017: 2018 2017 (12 months) (13 months) Short-term benefits (1) $ 3,361,371 $ 2,988,124 Share-based compensation costs (2) 1,879,459 1,605,103 $ 5,240,830 $ 4,593,227

Significant Accounting Polici54

Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	12 Months Ended
	Mar. 31, 2018
Building and building components
Disclosure Of Significant Accounting Policies [Line Items]
Method	Straight-line
Period/Rate	20 to 40 years
Laboratory, R&D and plant equipment
Disclosure Of Significant Accounting Policies [Line Items]
Method	Straight-line
Period/Rate	10 to 20 years
Furniture and office equipment
Disclosure Of Significant Accounting Policies [Line Items]
Method	Declining balance
Period/Rate	20% to 30%
Computer equipment
Disclosure Of Significant Accounting Policies [Line Items]
Method	Straight-line
Computer equipment | Bottom of range
Disclosure Of Significant Accounting Policies [Line Items]
Period/Rate	2 years
Computer equipment | Top of range
Disclosure Of Significant Accounting Policies [Line Items]
Period/Rate	5 years

Significant Accounting Polici55

Significant Accounting Policies - Additional Information (Details)	Mar. 31, 2018CAD ($)
Acasti
Disclosure Of Significant Accounting Policies [Line Items]
Fair value of financial asset reclassified from accumulated other comprehensive income to deficit on initial application of IFRS 9	$ 506,469

Sale of Assets - Additional Inf

Sale of Assets - Additional Information (Details) $ in Millions	Oct. 06, 2017CAD ($)	Aug. 07, 2017CAD ($)	Aug. 07, 2017USD ($)	Mar. 31, 2018CAD ($)	Mar. 31, 2017CAD ($)
Disclosure Of Sale Of Assets [Line Items]
Acquisition for cash consideration		$ 43,075,587		$ 43,075,587
Penalty on debt reimbursement				263,483
Impairment loss on inventories				$ 2,376,969	$ 256,913
Revaluation of useful life				no
Impairment of plant and related equipment				$ 0
Krill Oil
Disclosure Of Sale Of Assets [Line Items]
Manufacturing and distribution sale				3,200,000	21,500,000
Impairment loss on inventories				2,400,000
Gross margin, excluding impairment loss on inventories				$ 1,200,000	$ 6,200,000
Aker BioMarine Antarctic AS
Disclosure Of Sale Of Assets [Line Items]
Acquisition for cash consideration		43,075,587	$ 34
Debt reimbursement		11,175,466
Penalty on debt reimbursement		$ 263,483
Additional debt reimbursement	$ 2,391,673

Sale of Assets - Schedule of Re

Sale of Assets - Schedule of Reconciliation of Net Gain on Sale of Assets (Details) - CAD ($)	Aug. 07, 2017	Mar. 31, 2018
Disclosure Of Sale Of Assets [Line Items]
Acquisition for cash consideration	$ 43,075,587	$ 43,075,587
Inventory sold	(11,185,572)
Net intangible assets sold	(5,791,710)
Net gain on sale of assets as presented in the consolidated statement of earnings	23,702,312
Impairment loss in inventories - presented in cost of sales	(2,376,969)
Penalty on reimbursement, loss on financing fees and reversal of accretion from non-interest bearing debt reimbursed – presented in finance costs	(920,429)
Total impact of the transaction on the net income before tax	20,404,914
Krill Oil
Disclosure Of Sale Of Assets [Line Items]
Write-off of assets, severance costs, transaction costs and costs for activities relating to exiting the bulk krill oil business	$ (2,395,993)

Sale of Assets - Schedule of 58

Sale of Assets - Schedule of Reconciliation of Net Gain on Sale of Assets (Parenthetical) (Details)	Aug. 07, 2017CAD ($)
Disclosure Of Sale Of Assets [Abstract]
Non-cash write-off assets	$ 554,044
Employee severance cost	1,063,790
Transaction costs	$ 497,811

Trade and Other Receivables - S

Trade and Other Receivables - Summary of Trade and Other Receivables (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017
Trade And Other Current Receivables [Abstract]
Trade receivables	$ 4,926,632	$ 7,390,701
Sales taxes receivable	215,184	153,652
Accrued and other receivables	426,488	6,015,116
Grants receivables	22,543
Trade and other receivables	$ 5,590,847	$ 13,559,469

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017
Classes Of Inventories [Abstract]
Raw materials	$ 3,358,264	$ 5,539,437
Work in progress	474,057	3,154,833
Finished goods	675,031	3,807,455
Supplies and spare parts	753,977	741,010
Inventories	$ 5,261,329	$ 13,242,735

Inventories - Additional Inform

Inventories - Additional Information (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Inventories [Line Items]
Cost of sales	$ 21,321,290	$ 34,015,571
Inventory cost	18,359,553	33,334,255
Other inventory costs	584,768	424,403
Impairment loss on inventories	2,376,969	256,913
Inventory sold	26,168,469	$ 45,734,361
Aker BioMarine (“Aker”)
Disclosure Of Inventories [Line Items]
Inventory sold	$ 11,185,572

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property Plant and Equipment (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	$ 45,864,367
Loss of control of Acasti	8,783,613
Depreciation for the period	2,617,646	$ 2,741,670
Ending Balance	41,880,847	45,864,367
Gross Carrying Amount
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	53,097,236	50,092,961
Additions	1,415,920	3,058,372
Disposals		(54,097)
Ending Balance	51,181,931	53,097,236
Gross Carrying Amount | Acasti
Disclosure Of Property Plant And Equipment [Line Items]
Loss of control of Acasti	(3,331,225)
Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	7,232,869	4,545,296
Disposals		(54,097)
Depreciation for the period	2,617,646	2,741,670
Ending Balance	9,301,084	7,232,869
Accumulated Depreciation | Acasti
Disclosure Of Property Plant And Equipment [Line Items]
Loss of control of Acasti	(549,431)
Land
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	228,630
Ending Balance	228,630	228,630
Land | Gross Carrying Amount
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	228,630	228,630
Ending Balance	228,630	228,630
Building and Building Components
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	20,394,915
Ending Balance	19,711,328	20,394,915
Building and Building Components | Gross Carrying Amount
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	23,015,856	23,009,625
Additions	147,263	6,231
Ending Balance	23,163,119	23,015,856
Building and Building Components | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	2,620,941	1,721,529
Depreciation for the period	830,850	899,412
Ending Balance	3,451,791	2,620,941
Laboratory, R&D and Plant Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	24,925,082
Ending Balance	21,624,953	24,925,082
Laboratory, R&D and Plant Equipment | Gross Carrying Amount
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	29,018,397	26,073,781
Additions	1,182,102	2,953,611
Disposals		(8,995)
Ending Balance	26,901,440	29,018,397
Laboratory, R&D and Plant Equipment | Gross Carrying Amount | Acasti
Disclosure Of Property Plant And Equipment [Line Items]
Loss of control of Acasti	(3,299,059)
Laboratory, R&D and Plant Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	4,093,315	2,358,964
Disposals		(8,995)
Depreciation for the period	1,712,516	1,743,346
Ending Balance	5,276,487	4,093,315
Laboratory, R&D and Plant Equipment | Accumulated Depreciation | Acasti
Disclosure Of Property Plant And Equipment [Line Items]
Loss of control of Acasti	(529,344)
Furniture and Office Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	193,053
Ending Balance	149,896	193,053
Furniture and Office Equipment | Gross Carrying Amount
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	463,767	499,159
Additions		9,710
Disposals		(45,102)
Ending Balance	445,360	463,767
Furniture and Office Equipment | Gross Carrying Amount | Acasti
Disclosure Of Property Plant And Equipment [Line Items]
Loss of control of Acasti	(18,407)
Furniture and Office Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	270,714	258,377
Disposals		(45,102)
Depreciation for the period	37,820	57,439
Ending Balance	295,464	270,714
Furniture and Office Equipment | Accumulated Depreciation | Acasti
Disclosure Of Property Plant And Equipment [Line Items]
Loss of control of Acasti	(13,070)
Computer equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	122,687
Ending Balance	166,040	122,687
Computer equipment | Gross Carrying Amount
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	370,586	281,766
Additions	86,555	88,820
Ending Balance	443,382	370,586
Computer equipment | Gross Carrying Amount | Acasti
Disclosure Of Property Plant And Equipment [Line Items]
Loss of control of Acasti	(13,759)
Computer equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning Balance	247,899	206,426
Depreciation for the period	36,460	41,473
Ending Balance	277,342	$ 247,899
Computer equipment | Accumulated Depreciation | Acasti
Disclosure Of Property Plant And Equipment [Line Items]
Loss of control of Acasti	$ (7,017)

Property, Plant and Equipment63

Property, Plant and Equipment - Additional Information (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Property Plant And Equipment [Abstract]
Property, plant and equipment, not yet in service	$ 1,152,814	$ 172,142

Property, Plant and Equipment64

Property, Plant and Equipment - Summary of Depreciation Expense of Property Plant and Equipment (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation expense	$ 2,617,646	$ 2,741,670
Cost of sales
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation expense	1,067,629	2,264,748
Research and development expenses
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation expense	1,321,145	229,541
Selling, general and administrative expenses
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation expense	$ 228,872	$ 247,381

Intangible Assets and Goodwil65

Intangible Assets and Goodwill - Schedule of Reconciliation of Changes in Intangible Assets and Goodwill - (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	$ 11,947,693
Ending Balance	5,236,363	$ 11,947,693
Gross Carrying Amount
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	13,944,757	7,747,090
Additions	4,616	6,197,667
Sale to Aker BioMarine (note 4)	(6,906,367)
Ending Balance	7,043,006	13,944,757
Accumulated Depreciation
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	1,997,064	921,934
Sale to Aker BioMarine (note 4)	(1,114,657)
Amortization	924,236	1,075,130
Ending Balance	1,806,643	1,997,064
Non-Compete Agreements
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	235,000
Ending Balance	102,889	235,000
Non-Compete Agreements | Gross Carrying Amount
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	400,000	400,000
Ending Balance	400,000	400,000
Non-Compete Agreements | Accumulated Depreciation
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	165,000	22,000
Amortization	132,111	143,000
Ending Balance	297,111	165,000
Customer Relationships
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	3,588,500
Ending Balance	3,179,233	3,588,500
Customer Relationships | Gross Carrying Amount
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	4,100,000	4,100,000
Ending Balance	4,100,000	4,100,000
Customer Relationships | Accumulated Depreciation
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	511,500	68,200
Amortization	409,267	443,300
Ending Balance	920,767	511,500
Patents
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	624,019
Ending Balance		624,019
Patents | Gross Carrying Amount
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	1,546,593	1,544,467
Additions		2,126
Sale to Aker BioMarine (note 4)	(1,185,773)
Ending Balance	360,820	1,546,593
Patents | Accumulated Depreciation
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	922,574	814,174
Sale to Aker BioMarine (note 4)	(576,458)
Amortization	14,704	108,400
Ending Balance	360,820	922,574
License Agreement
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	7,336,948
Ending Balance	1,954,241	7,336,948
License Agreement | Gross Carrying Amount
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	7,734,938	1,552,334
Additions	772	6,182,604
Sale to Aker BioMarine (note 4)	(5,553,524)
Ending Balance	2,182,186	7,734,938
License Agreement | Accumulated Depreciation
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	397,990	17,560
Sale to Aker BioMarine (note 4)	(538,199)
Amortization	368,154	380,430
Ending Balance	227,945	397,990
Trademarks
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	163,226
Ending Balance		163,226
Trademarks | Gross Carrying Amount
Disclosure Of Reconciliation Of Changes In Intangible Assets And Goodwill [Line Items]
Beginning Balance	163,226	150,289
Additions	3,844	12,937
Sale to Aker BioMarine (note 4)	$ (167,070)
Ending Balance		$ 163,226

Intangible Assets and Goodwil66

Intangible Assets and Goodwill - Additional Information - (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Intangible Assets [Line Items]
Discount rate on discounted cash flow	18.20%
Terminal growth rate	2.00%
Selling, general and administrative expenses
Disclosure Of Intangible Assets [Line Items]
Amortization expense	$ 924,236	$ 1,075,130

Trade and Other Payables - Summ

Trade and Other Payables - Summary of Trade and Other Payables (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017
Trade And Other Current Payables [Abstract]
Trade payables	$ 2,425,617	$ 4,344,557
Accrued liabilities and other payables	2,773,043	3,757,436
Employee salaries and benefits payable	1,549,229	1,891,026
Trade and other payables	$ 6,747,889	$ 9,993,019

Loans and Borrowings - Summary

Loans and Borrowings - Summary of Contractual Terms of Corporation's Loans and Borrowings (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Detailed Information About Borrowings [Line Items]
Total loans and borrowings	$ 4,661,356	$ 22,931,544
Loans and borrowings (note 10)	4,661,356	7,192,315
Loans and borrowings (note 10)		15,739,229
2.5% Secured Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans	3,891,077	5,429,852
Balance of Purchase Price
Disclosure Of Detailed Information About Borrowings [Line Items]
Total loans and borrowings	261,596	3,202,612
Authorized bank line of credit
Disclosure Of Detailed Information About Borrowings [Line Items]
Total loans and borrowings	490,000
Finance Lease Liabilities
Disclosure Of Detailed Information About Borrowings [Line Items]
Finance lease liabilities, interest rate from 6.25% to 7.13%, payable in monthly instalments of $2,345, maturing in November 2018 and March 2019.	$ 18,683	44,644
8% Secured Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans		8,347,506
12% Secured Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans		3,562,814
Refundable Contribution
Disclosure Of Detailed Information About Borrowings [Line Items]
Total loans and borrowings		$ 2,344,116

Loans and Borrowings - Summar69

Loans and Borrowings - Summary of Contractual Terms of Corporation's Loans and Borrowings (Parenthetical) (Details) £ in Millions	12 Months Ended	13 Months Ended
	Mar. 31, 2018CAD ($)	Mar. 31, 2017	Mar. 31, 2018GBP (£)
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, principal amount	$ 3,500,000
2.5% Secured Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, reimbursable monthly principal payments	89,286
Short-term investments pledged for loan	2,350,000
Loans, transaction costs	$ 197,789
2.5% Secured Loan | Prime Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, adjustment to interest rate basis	2.50%	3.25%	2.50%
2.5% Secured Loan | December 2018
Disclosure Of Detailed Information About Borrowings [Line Items]
Loan final payment	$ 3,314,276
Balance of Purchase Price Amount Bearing 5% Interest
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, interest rate	5.00%		5.00%
Balance of Purchase Price Amount Bearing 5% Interest | March 2016 to Septmber 2018
Disclosure Of Detailed Information About Borrowings [Line Items]
Loan final payment	$ 74,096
Borrowings, reimbursable quarterly principal payments	$ 93,750
Balance of Purchase Price Amount Bearing 7% Interest
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, adjustment to interest rate basis	2.50%		2.50%
Loans and borrowings, interest rate	7.00%		7.00%
Loans and borrowings, principal amount	$ 2,501,016
Authorized bank line of credit
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, principal amount	$ 1,800,000
Borrowings expiration date	Aug. 31, 2018	Aug. 31, 2018
Authorized bank line of credit | Prime Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, adjustment to interest rate basis	1.00%		1.00%
Finance Lease Liabilities
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings, payable in monthly instalments	$ 2,345
Borrowings maturity	November 2018 and March 2019	November 2018 and March 2019
Finance Lease Liabilities | Bottom of range
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, interest rate	6.25%	7.13%	6.25%
8% Secured Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, interest rate	8.00%		8.00%
Loans and borrowings, principal amount	$ 12,500,000
12% Secured Loan
Disclosure Of Detailed Information About Borrowings [Line Items]
Loans and borrowings, interest rate	12.00%		12.00%
Loans and borrowings, principal amount	$ 3,822,000		£ 2.1

Loans and Borrowings - Addition

Loans and Borrowings - Additional Information (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Detailed Information About Borrowings [Abstract]
Interest recognized	$ 986,986	$ 2,592,659

Long-term-Payable - Additional

Long-term-Payable - Additional Information (Detail)	12 Months Ended
	Mar. 31, 2018CAD ($)	Mar. 31, 2017CAD ($)	Sep. 30, 2016CAD ($)	Sep. 30, 2016USD ($)
Noncurrent Payables [Abstract]
Intangible assets	$ 5,236,363	$ 11,947,693		$ 850,000
Intangible assets fair value			$ 935,804
Royalty fee payable	$ 372,592	115,870
Description of payment terms	In connection with this agreement, Neptune must also pay royalties based on sales, using this specialty ingredient. Minimum annual volumes must be reached for the duration of the agreement of 11 years.
Royalty agreement term	11 years
Short term payable	$ 558,045	215,095
Long term payable	$ 249,714	$ 795,072

Capital and Other Components 72

Capital and Other Components of Equity - Additional Information (Details)	May 09, 2017CAD ($)$ / sharesshares	May 09, 2017USD ($)shares	Mar. 31, 2018CAD ($)shares$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Percentage of dividend issued on paid up capital			5.00%
Liability settled in shares, shares	630,681	630,681
Share Issue Price Per Share | $ / shares	$ 1.35		$ 1.43
Share issued on settlement of liability, value	$ 858,000	$ 625,000	$ 858,000
Share issue costs | $	$ 9,930
DSU released, shares			55,944
Proceeds from exercise of options | $			$ 256,616
Share Option Exercise
Disclosure Of Classes Of Share Capital [Line Items]
Share Issue Price Per Share | $ / shares			$ 1.72
Number of options excercised			149,000
Proceeds from exercise of options | $			$ 256,616
Preference shares [member]
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares issued			0
Number of shares outstanding			0

Capital and Other Components 73

Capital and Other Components of Equity - Summary of Warrants (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Share Capital Reserves And Other Equity Interest [Abstract]
Number of warrants outstanding and exercisable	750,000	750,000
Warrants amount	$ 648,820	$ 648,820

Capital and Other Components 74

Capital and Other Components of Equity - Summary of Warrants (Parenthetical) (Details) - Warrants I Q Financing	12 Months Ended
	Mar. 31, 2018$ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Warrants exercise price	$ 3.37
Warrants expiring date	Dec. 12, 2019

Non-controlling Interests ("N75

Non-controlling Interests ("NCI") - Additional Information (Details) - CAD ($)	Dec. 27, 2017	Feb. 21, 2017	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Transaction costs			$ 2,446,279		$ 2,772,146
Acasti
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Percentage of subsidiary owned	33.96%		19.78%
Proportion of ownership interests held by non-controlling interests on a fully diluted basis	20.39%				34.45%
Proportion of voting right held by non-controlling interests on a fully diluted basis	12.12%				23.28%
Number of shares owned in subsidiary	5,064,694
Fair value of investment	$ 6,079,271		$ 6,585,740
Fair value of investment, per share	$ 1.20		$ 1.30
Gain on loss of control of subsidiary	$ 8,783,613		$ 506,469
Principal amount of unsecured debentures and contingent warrant issued		$ 2,000,000
Number of contingent warrants to acquire common shares		1,052,630
Acasti | Public Offering
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Number of shares issued		3,930,518
Share issued price		$ 1.45
Gross proceeds from issuing units		$ 5,699,251
Transaction costs		$ 1,190,730
Acasti | Non-controlling Interest
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Impact of expiry of Acasti options and call-options			(1,466,459)		$ (3,059,035)
Impact on non-controlling interest resulting from exercise of broker warrants			228,530
Impact on non-controlling interest resulting from financing fees related to past financing			(102,011)
Impact on non-controlling interest resulting from issue of shares to settle convertible debentures interest			$ 51,965
Impact of expiry of Acasti options and call-options				$ 3,059,035
The change in equity resulting from the public offering				5,681,990
Impact of private placement				$ 308,907

Non-controlling Interests ("N76

Non-controlling Interests ("NCI") - Summary of reconciliation of gain on loss of control in subsidiary (Details) - CAD ($)	Dec. 27, 2017	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Non-controlling interest			$ 11,052,812
Acasti
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Investment in Acasti at fair value	$ 6,079,271
Non-controlling interest	2,233,973
Acasti's assets before deconsolidation	(7,143,171)
Acasti's liabilities before deconsolidation	7,613,540
Gain on loss on control of Acasti	$ 8,783,613	$ 506,469

Other Income - Additional Infor

Other Income - Additional Information (Details)	Mar. 31, 2017CAD ($)	Mar. 31, 2017USD ($)	Sep. 30, 2016USD ($)	Mar. 31, 2018CAD ($)	Mar. 31, 2017CAD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2017USD ($)
Disclosure Of Other Income [Line Items]
Royalty settlement income				$ 1,477,113	$ 1,083,022
Intangible assets	$ 11,947,693		$ 850,000	$ 5,236,363	11,947,693
Neptune and Aker BioMarine (“Aker”)
Disclosure Of Other Income [Line Items]
Royalty payment			10,000,000
Royalty settlement income					13,117,000	$ 10,000,000
Intangible assets	5,246,800				$ 5,246,800		$ 4,000,000
Neptune and Aker BioMarine (“Aker”) | krill oil-related patent portfolio
Disclosure Of Other Income [Line Items]
Royalty payment			$ 4,000,000
Neptune and Enzymotec Ltd (“Enzymotec”)
Disclosure Of Other Income [Line Items]
Royalty payment		$ 1,630,000
Royalty settlement income	$ 2,184,758

Personnel Expenses - Schedule o

Personnel Expenses - Schedule of Personnel Expenses (Detail) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Personnel Expenses [Abstract]
Salaries and other short-term employee benefits	$ 9,833,691	$ 12,196,987
Severance	813,365	83,879
Share-based compensation	2,283,756	2,014,902
Total personnel expense	$ 12,930,812	$ 14,295,768

Finance Costs - Summary of Fina

Finance Costs - Summary of Finance Costs (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Finance Income And Costs [Abstract]
Interest charges and other finance costs	$ (1,061,588)	$ (2,764,389)
Interest expense on unsecured convertible debentures	(275,140)
Penalty on reimbursment, loss on financing and discounted fees on debt reimbursment (note 4)	(920,429)
Foreign exchange loss	(189,122)	(7,757)
Finance costs	$ (2,446,279)	$ (2,772,146)

Share-based Payments - Addition

Share-based Payments - Additional Information (Details)	Jun. 30, 2019shares	Oct. 16, 2015CAD ($)shares	Mar. 31, 2018CAD ($)sharesyrmo	Mar. 31, 2017CAD ($)shares	Feb. 29, 2016shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Stock-based compensation recognized			$ 2,283,756	$ 2,014,902
Stock Option Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Maximum percent of option issuable			2.00%
Number of options, Restriction | shares			2,095,333
Weighted average fair value of options granted to employees			$ 0.68	$ 0.56
Number of options granted | shares			7,501,980	881,000
Stock-based compensation recognized			$ 1,334,817	$ 768,368
Weighted average exercise price, Granted			$ 1.90	$ 1.54
Stock Option Plan | Non Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options granted | shares			0	0
Stock Option Plan | Top of range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Options term | yr			10
Percentage of common shares issued and outstanding			15.00%
Percent of stock common shares issuable to single holder			5.00%
Stock Option Plan | Bottom of range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period | mo			18
Performance Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options granted | shares		625,000
Stock-based compensation recognized			$ 17,485	$ 187,649
Weighted average exercise price, Granted		$ 1.55
Expiration date		Oct. 16, 2020
Vesting period		2 years
Description of vesting requirements for share-based payment arrangement			The options vest after a two-year minimum service period and the attainment of market performance conditions within the following three years.
Deferred Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of share options outstanding in share-based payment arrangement | shares			570,752	425,354	75,000
Number of other equity instruments exercised or vested in share-based payment arrangement | shares	160,000		263,588	72,164
Number of share fully vested | shares			75,000
Weighted average fair value			$ 1.27	$ 1.57
Stock-based compensation recognized			305,813	384,307
Acasti Stock Option Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Stock-based compensation recognized			$ 660,611	$ 674,578

Share-based Payments - Schedule

Share-based Payments - Schedule of Number and Weighted Average Exercise Price of Stock Options (Details) - Stock Option Plan	12 Months Ended	13 Months Ended
	Mar. 31, 2018CAD ($)shares	Mar. 31, 2017CAD ($)shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted average exercise price, Beginning balance | $	$ 1.92	$ 2.50
Weighted average exercise price, Granted | $	1.90	1.54
Weighted average exercise price, Exercised | $	1.72
Weighted average exercise price, Forfeited | $	1.54	2.69
Weighted average exercise price, Expired | $	2.93	3.84
Weighted average exercise price, Ending balance | $	1.92	1.92
Weighted average exercise price, Exercisable | $	$ 1.97	$ 2.07
Number of options outstanding, Beginning balance | shares	3,765,000	4,242,025
Number of options, Granted | shares	7,501,980	881,000
Number of options, Exercised | shares	(149,000)
Number of options, Forfeited | shares	(816,434)	(456,461)
Number of options, Expired | shares	(210,000)	(901,564)
Number of options outstanding, Ending balance | shares	10,091,546	3,765,000
Number of options, Exercisable | shares	2,322,668	2,115,666

Share-based Payments - Schedu82

Share-based Payments - Schedule of Number and Weighted Average Exercise Price of Stock Options (Parenthetical) (Details) - Stock Option Plan - shares	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options, Granted	7,501,980	881,000
Number of options, Restriction	2,095,333

Share-based Payments - Schedu83

Share-based Payments - Schedule of Number and Contractual Life of Options (Details) - Stock Option Plan	Mar. 31, 2018CAD ($)sharesyr	Mar. 31, 2017CAD ($)shares	Feb. 29, 2016shares
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options outstanding, Weighted remaining contractual life outstanding | yr	4.32
Options outstanding, Number of options outstanding | shares	10,091,546	3,765,000	4,242,025
Exercisable options, Weighted number of options exercisable | shares	2,322,668	2,115,666
Weighted average exercise price, Exercisable	$ 1.97	$ 2.07
$1.24 - $1.82
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options outstanding, Weighted remaining contractual life outstanding | yr	3.47
Options outstanding, Number of options outstanding | shares	1,825,973
Exercisable options, Weighted number of options exercisable | shares	672,668
Weighted average exercise price, Exercisable	$ 1.66
$1.24 - $1.82 | Bottom of range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	1.24
$1.24 - $1.82 | Top of range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	$ 1.82
$1.83 - $1.91
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options outstanding, Weighted remaining contractual life outstanding | yr	4.35
Options outstanding, Number of options outstanding | shares	420,000
Exercisable options, Weighted number of options exercisable | shares	350,000
Weighted average exercise price, Exercisable	$ 1.83
$1.83 - $1.91 | Bottom of range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	1.83
$1.83 - $1.91 | Top of range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	$ 1.91
$1.92 - $2.05
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options outstanding, Weighted remaining contractual life outstanding | yr	4.69
Options outstanding, Number of options outstanding | shares	6,470,573
$1.92 - $2.05 | Bottom of range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	$ 1.92
$1.92 - $2.05 | Top of range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	$ 2.05
$2.06 - $2.15
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Options outstanding, Weighted remaining contractual life outstanding | yr	4.70
Options outstanding, Number of options outstanding | shares	75,000
$2.06 - $2.15 | Bottom of range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	$ 2.06
$2.06 - $2.15 | Top of range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	2.15
$ 2.16
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price	$ 2.16
Options outstanding, Weighted remaining contractual life outstanding | yr	3.64
Options outstanding, Number of options outstanding | shares	1,300,000
Exercisable options, Weighted number of options exercisable | shares	1,300,000
Weighted average exercise price, Exercisable	$ 2.16

Share-based Payments - Summary

Share-based Payments - Summary of Assumptions Used to Determine Fair Value of Options Granted (Details) - Stock Option Plan - Black Scholes Option Pricing Model	12 Months Ended	13 Months Ended
	Mar. 31, 2018CAD ($)yr	Mar. 31, 2017CAD ($)yr
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise price	$ 1.90	$ 1.54
Share price	$ 1.81	$ 1.54
Risk-free interest	1.50%	0.67%
Estimated life (years) | yr	3.93	3.50
Expected volatility	48.60%	49.46%

Share-based Payments - Schedu85

Share-based Payments - Schedule of Number and Weighted Average Exercise Price of Performance Options (Details) - Performance Options	12 Months Ended	13 Months Ended
	Mar. 31, 2018CAD ($)shares	Mar. 31, 2017CAD ($)shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options outstanding, Beginning balance | shares	475,000	625,000
Number of options, Forfeited | shares	(150,000)	(150,000)
Number of options outstanding, Ending balance | shares	325,000	475,000
Number of options, Exercisable | shares	325,000
Weighted average exercise price, Beginning balance | $	$ 1.55	$ 1.55
Weighted average exercise price, Forfeited | $	1.55	1.55
Weighted average exercise price, Ending balance | $	1.55	$ 1.55
Weighted average exercise price, Exercisable | $	$ 1.55

Share-based Payments - Schedu86

Share-based Payments - Schedule of Number and Contractual Life of Performance Options (Details) - Performance Options	Mar. 31, 2018CAD ($)sharesyr	Mar. 31, 2017shares	Feb. 29, 2016shares
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Exercise price | $	$ 1.55
Options outstanding, Weighted remaining contractual life outstanding | yr	2.55
Options outstanding, Number of options outstanding | shares	325,000	475,000	625,000
Exercisable options, Weighted number of options exercisable | shares	325,000
Weighted average exercise price, Exercisable | $	$ 1.55

Share-based Payments - Schedu87

Share-based Payments - Schedule of Number and Weighted Average Exercise Price of Deferred Share Units (Details)	12 Months Ended	13 Months Ended
	Mar. 31, 2018CAD ($)shares	Mar. 31, 2017CAD ($)shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Released through the issuance of common shares	(55,944)
Deferred Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | $	$ 1.60	$ 1.72
Granted | $	1.27	1.57
Released through the issuance of common shares | $	1.43
Ending balance | $	1.50	1.60
Exercisable options | $	$ 1.48	$ 1.59
Beginning balance	425,354	75,000
Granted	201,342	350,354
Released through the issuance of common shares	(55,944)
Ending balance	570,752	425,354
Exercisable options	374,670	240,004

Share-based Payments - Schedu88

Share-based Payments - Schedule of Number and Weighted Average Exercise Price of Warrants (Details) - Warrants	12 Months Ended	13 Months Ended
	Mar. 31, 2018CAD ($)shares	Mar. 31, 2017CAD ($)shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | $	$ 21.50	$ 12.84
Weighted average price, forfeited | $	21.50	11.86
Weighted average price, expired | $	$ 21.50	12.25
Ending balance | $		$ 21.50
Beginning balance | shares	24,174	292,047
Number of warrants, forfeited | shares	(465)	(129,122)
Number of warrants, expired | shares	(23,709)	(138,751)
Ending balance | shares		24,174

Income Taxes - Schedule of Curr

Income Taxes - Schedule of Current Income Taxes Expense (Recovery) (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Income Tax [Abstract]
Current		$ 2,294,471
Adjustment of prior year income taxes expense (recovery)	$ (1,932,831)
Current income taxes expense (recovery)	$ (1,932,831)	$ 2,294,471

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Taxes Expense (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Income Tax [Abstract]
Recognition of previously unrecognized deductible temporary differences and tax losses of prior periods	$ (114,226)	$ (129,362)
Origination and reversal of temporary differences	(1,772,883)	(434,615)
Change in unrecognized deductible temporary differences	2,179,740	623,134
Deferred tax expense	$ 292,631	$ 59,157

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Effective Tax Rate (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Income before income taxes	$ 7,699,183	$ 3,233,477
Basic combined Canadian statutory income tax rate	26.78%	26.87%
Income tax	$ 2,061,841	$ 868,835
Increase (decrease) resulting from:
Recognition of previously unrecognized deductible temporary differences and tax losses of prior periods	(114,226)	(129,362)
Change in unrecognized deductible temporary differences	2,179,736	623,134
Gain on loss of control of Acasti	8,783,613
Non taxable gain on sale of assets	(4,304,482)
Non-deductible stock-based compensation	611,590	538,145
Non-deductible change in fair value	9,733	70,929
Permanent differences and other	210,449	37,786
Change in statutory income tax rate	57,411	344,161
Total tax expense (recovery)	(1,640,200)	$ 2,353,628
Acasti
Increase (decrease) resulting from:
Gain on loss of control of Acasti	$ (2,352,252)

Income Taxes - Summary of Recog

Income Taxes - Summary of Recognized Deferred Tax Assets and Liabilities (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Beginning balance	$ 265,461	$ 453,980
Recognized in equity		(129,362)
Recognized in net income		(59,157)
Ending balance		265,461
Tax losses carried forward
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Beginning balance	1,376,971	1,769,506
Recognized in net income	5,964,843	(392,535)
Ending balance	7,341,814	1,376,971
Research and development expenses
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Beginning balance	245,399	247,409
Recognized in net income	(222)	(2,010)
Ending balance	245,177	245,399
Intangible assets
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Beginning balance	(1,309,688)	(1,549,950)
Recognized in net income	112,806	240,262
Ending balance	(1,196,882)	(1,309,688)
Property, plant and equipment [member]
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Beginning balance	(6,513)	136,166
Recognized in net income	(4,457,302)	(142,679)
Ending balance	(4,463,815)	(6,513)
Tax credits receivable
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Beginning balance	(40,708)	(149,151)
Recognized in net income		108,443
Ending balance	(40,708)	(40,708)
Prepaid royalty income
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Recognized in net income	(1,912,756)
Ending balance	(1,912,756)
Unsecured Convertible Debentures
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Beginning balance	265,461
Recognized in equity		(129,362)
Recognized in net income	(292,631)	129,362
Ending balance	$ (27,170)	$ 265,461

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Income Tax [Line Items]
Deferred tax asset recognized		$ (59,157)
Tax credits receivable	$ 49,597	139,932
Nutraceutical
Disclosure Of Income Tax [Line Items]
Tax credits recoverable recognized in the period		1,966,757
Derecognition of prior period tax credits recoverable	1,932,831
Temporary Differences
Disclosure Of Income Tax [Line Items]
Deferred tax asset recognized	0
Research and development expenses
Disclosure Of Income Tax [Line Items]
Deferred tax asset recognized	(222)	(2,010)
Tax credits receivable	$ 49,597	$ 139,932

Income Taxes - Summary of Tax L

Income Taxes - Summary of Tax Losses Carried Forward (Details)	Mar. 31, 2018CAD ($)
Federal
Tax losses carried forward
Tax losses carried forward	$ 18,668,000
Research and development expenses, without time limitation	10,906,000
Federal | 2035
Tax losses carried forward
Tax losses carried forward	5,812,000
Federal | 2036
Tax losses carried forward
Tax losses carried forward	3,052,000
Federal | 2037
Tax losses carried forward
Tax losses carried forward	9,050,000
Federal | 2038
Tax losses carried forward
Tax losses carried forward	754,000
Provincial
Tax losses carried forward
Tax losses carried forward	15,603,000
Research and development expenses, without time limitation	15,574,000
Provincial | 2035
Tax losses carried forward
Tax losses carried forward	1,298,000
Provincial | 2036
Tax losses carried forward
Tax losses carried forward	3,052,000
Provincial | 2037
Tax losses carried forward
Tax losses carried forward	10,499,000
Provincial | 2038
Tax losses carried forward
Tax losses carried forward	$ 754,000

Income Taxes - Schedule of Futu

Income Taxes - Schedule of Future Federal Income Taxes Payable and Expire (Details) - Federal - Nutraceutical - Research and development expenses	Mar. 31, 2018CAD ($)
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	$ 2,269,000
2,022
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	76,000
2,023
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	217,000
2,024
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	75,000
2,025
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	53,000
2,026
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	91,000
2,027
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	145,000
2,028
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	64,000
2,029
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	107,000
2,030
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	206,000
2,031
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	244,000
2,032
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	129,000
2,033
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	124,000
2,034
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	106,000
2,035
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	281,000
2,036
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	210,000
2,037
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Unused tax credits for which no deferred tax asset recognised	$ 141,000

Income Per Share - Summary of R

Income Per Share - Summary of Reconciliation of Number of Shares Outstanding (Details) - shares	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Reconciliation Of Number Of Shares Outstanding [Abstract]
Weighted average number of common shares	78,599,208	77,945,548
Dilutive effect of deferred share units	373,039	200,339
Dilutive effect of stock options	387,049
Weighted average number of diluted shares	79,359,296	78,145,887
Number of anti-dilutive stock options, warrants and deferred share units excluded from diluted earnings per share calculation	8,798,979	5,232,178

Supplemental Cash Flow Disclo97

Supplemental Cash Flow Disclosure - Summary of Supplemental Cash Flow Disclosure - Changes in Operating Assets and Liabilities (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Supplementary Cash Flow Information [Abstract]
Trade and other receivables	$ 10,547,497	$ (7,026,796)
Tax credits receivable	108,821	645,334
Prepaid expenses	(981,444)	500,968
Inventories	(5,581,135)	4,619,832
Trade and other payables	3,312,306	(521,119)
Deferred revenues	109,950	206,036
Changes in operating assets and liabilities	$ 7,515,995	$ (1,575,745)

Supplemental Cash Flow Disclo98

Supplemental Cash Flow Disclosure - Summary of Supplemental Cash Flow Disclosure - Non-cash Transactions (Details)	May 09, 2017CAD ($)	May 09, 2017USD ($)	Mar. 31, 2018CAD ($)	Mar. 31, 2017CAD ($)
Disclosure Of Supplementary Cash Flow Information [Abstract]
Acquired property, plant and equipment included in trade and other payables			$ 456,774	$ 308,218
Intangible assets included in trade and other payables			453,436	140,731
Intangible assets included in trade and other receivables (note 14)				3,546,400
Intangible assets included in long-term payable			249,714	795,072
Liability settlement in shares	$ 858,000	$ 625,000	858,000
Acasti convertible debenture interest paid in shares of subsidiary			$ 56,984
Reduction in goodwill on reduction of balance of purchase price				65,513
Acasti equity settled share-based payment included in equity and unsecured convertible debentures				94,200
Acasti issuance of broker warrants included in net proceeds from Acasti public offering				143,932
Acasti public offering transactions costs included in trade and other payables				380,765
Acasti reduction in share issue costs from reduction in trade and other payables				109,410
Acasti private placement transactions costs included in trade and other payables				$ 40,305

Supplemental Cash Flow Disclo99

Supplemental Cash Flow Disclosure - Summary of Reconciliation of Liabilities to Cash Flows from Financing Activities (Detail) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Supplementary Cash Flow Information [Line Items]
Increase in long-term debt, net of finance costs		$ 3,666,311
Repayments From Cash (used in) provided by financing activities	$ 19,389,098	7,654,363
Loan
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	5,429,852
Repayments From Cash (used in) provided by financing activities	(1,571,432)
Non-cash Changes Accretion of Interest	32,657
Ending Balance	3,891,077	5,429,852
Balance of Purchase Price
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	3,202,612
Repayments From Cash (used in) provided by financing activities	(2,941,016)
Ending Balance	261,596	3,202,612
Bank Line of Credit
Disclosure Of Supplementary Cash Flow Information [Line Items]
Increase in long-term debt, net of finance costs	490,000
Ending Balance	490,000
Finance Lease Liabilities
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	44,644
Repayments From Cash (used in) provided by financing activities	(25,961)
Ending Balance	18,683	44,644
Loan IQ
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	8,347,506
Repayments From Cash (used in) provided by financing activities	(8,593,775)
Non-cash Changes Accretion of Interest	47,242
Non-cash changes financing and discounted fees	199,027
Ending Balance		8,347,506
Loan in GBP
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	3,562,814
Repayments From Cash (used in) provided by financing activities	(3,456,910)
Non-cash Changes Accretion of Interest	16,594
Non-cash changes effect of foreign currency exchange rate changes	(225,384)
Non-cash changes financing and discounted fees	102,886
Ending Balance		3,562,814
Refundable Contribution
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	2,344,116
Repayments From Cash (used in) provided by financing activities	(2,800,004)
Non-cash Changes Accretion of Interest	100,855
Non-cash changes financing and discounted fees	355,033
Ending Balance		2,344,116
Long-term Debt
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	22,931,544
Increase in long-term debt, net of finance costs	490,000
Repayments From Cash (used in) provided by financing activities	(19,389,098)
Non-cash Changes Accretion of Interest	197,348
Non-cash changes effect of foreign currency exchange rate changes	(225,384)
Non-cash changes financing and discounted fees	656,946
Ending Balance	4,661,356	22,931,544
Interest Rate Swap Liability (Asset) Used for Hedging
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	7,298
Non-cash changes in fair value	(26,388)
Ending Balance	(19,090)	7,298
Cross Currency Swap Liability
Disclosure Of Supplementary Cash Flow Information [Line Items]
Beginning Balance	207,839
Settlement of Cross Currency Swap From Cash (Used in) Provided by Financing Activities	(58,999)
Non-cash changes effect of foreign currency exchange rate changes	7,499
Non-cash changes in fair value	$ (156,339)
Ending Balance		$ 207,839

Supplemental Cash Flow Discl100

Supplemental Cash Flow Disclosure - Summary of Reconciliation of Liabilities to Cash Flows from Financing Activities (Parentheical) (Details)	12 Months Ended
	Mar. 31, 2018CAD ($)
Disclosure Of Supplementary Cash Flow Information [Line Items]
Penalty on debt reimbursement	$ 263,483
Loan in GBP
Disclosure Of Supplementary Cash Flow Information [Line Items]
Penalty on debt reimbursement	$ 263,483

Financial Instruments - Additio

Financial Instruments - Additional Information (Details)	Aug. 07, 2017CAD ($)	Jan. 31, 2018USD ($)	Mar. 31, 2018CAD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Jan. 03, 2018USD ($)$ / shares	Mar. 31, 2017CAD ($)	Mar. 31, 2017USD ($)$ / shares
Disclosure Of Financial Instruments [Line Items]
Proceeds on sale of assets (note 4)	$ 43,075,587		$ 43,075,587
Settlement of derivative swap agreements			$ 58,999
Assumed foreign exchange rate			1.00%	1.00%
Allowance for doubtful accounts other receivables			$ 265,676				$ 33,139
Credit Risk
Disclosure Of Financial Instruments [Line Items]
Percentage of credit insurance on invoicing			100.00%	100.00%
Credit Risk | Customer One
Disclosure Of Financial Instruments [Line Items]
Percentage of trade accounts			19.70%	19.70%	13.30%
Credit Risk | Customer Two
Disclosure Of Financial Instruments [Line Items]
Percentage of trade accounts			10.80%	10.80%	13.10%
Credit Risk | Customer Three
Disclosure Of Financial Instruments [Line Items]
Percentage of trade accounts					12.70%
Credit Risk | Customer Four
Disclosure Of Financial Instruments [Line Items]
Percentage of trade accounts					10.60%
Foreign Exchange Rate Risk | U S Dollars
Disclosure Of Financial Instruments [Line Items]
Percentage of revenues by geographical area			63.00%	63.00%	67.00%
Foreign Exchange Rate Risk | Euro
Disclosure Of Financial Instruments [Line Items]
Percentage of revenues by geographical area			2.00%	2.00%	7.00%
Interest rate risk [member]
Disclosure Of Financial Instruments [Line Items]
Decrease in net profit				$ 10,652
Cross Currency Swap
Disclosure Of Financial Instruments [Line Items]
Non-cash changes in fair value			$ 156,339
Settlement of derivative swap agreements			$ 58,999
Blue Ocean Nutrascience Inc
Disclosure Of Financial Instruments [Line Items]
Proceeds on sale of assets (note 4)		$ 104,110
Fair value of investment						$ 104,110		$ 65,745
Fair value of investment, per share | $ / shares						$ 0.21		$ 0.135
Losses on change In fair value of investment				$ 38,365	$ 104,705
Change in fair value of derivative assets and liabilities					$ 381,687

Financial Instruments - Schedul

Financial Instruments - Schedule of Reconciliation of Changes in Fair Value Measurement of Financial Liabilities (Details) - CAD ($)	12 Months Ended		13 Months Ended
	Mar. 31, 2018	Dec. 27, 2017	Mar. 31, 2017
Disclosure Of Reconciliation Of Changes In Fair Value Measurement Liabilities [Line Items]
Opening balance, financial liabilities	$ 36,419,878
Loss of control of subsidiary	8,783,613
Closing balance, financial liabilities	12,063,184		$ 36,419,878
Level 3 of Fair Value Hierarchy | Financial Liabilities
Disclosure Of Reconciliation Of Changes In Fair Value Measurement Liabilities [Line Items]
Opening balance, financial liabilities	$ 202,610	$ 202,610	151,343
Change in fair value (gain) loss		(189,001)	51,267
Loss of control of subsidiary		$ (13,609)
Closing balance, financial liabilities			$ 202,610

Financial Instruments - Sche103

Financial Instruments - Schedule of Derivative Swap Agreements (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Financial Instruments [Line Items]
Non-current asset	$ 19,090
Non-current liabilities		$ 215,137
Cross Currency Swap Contract
Disclosure Of Financial Instruments [Line Items]
Non-current liabilities		207,839
Interest Rate Swap Contract
Disclosure Of Financial Instruments [Line Items]
Non-current asset	$ 19,090
Non-current liabilities		$ 7,298

Financial Instruments - Sche104

Financial Instruments - Schedule of Maturity Analysis Associated with Interest Rate Swap Agreement - Long-Term Debt (Details)	12 Months Ended
	Mar. 31, 2018CAD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2017CAD ($)	Mar. 31, 2017USD ($)
Disclosure Of Financial Instruments [Line Items]
Loans and borrowings, Notional amount	$ 3,500,000
Loans and borrowings, Long-term debt	$ 4,661,356		$ 22,931,544
Interest Rate Swap Contract
Disclosure Of Financial Instruments [Line Items]
Loans and borrowings, Notional amount		$ 3,883,923
Loans and borrowings, Maturity	Dec. 27, 2018
Loans and borrowings, Long-term debt		$ 19,090		$ (7,298)
Interest Rate Swap Contract | Fixed Rate
Disclosure Of Financial Instruments [Line Items]
Loans and borrowings, Fixed rate	2.94%	2.94%

Financial Instruments - Summary

Financial Instruments - Summary of Aging of Trade Receivable Balances (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017	Feb. 29, 2016
Disclosure Of Financial Instruments [Line Items]
Trade receivables	$ 5,532,596	$ 8,014,557
Less allowance for doubtful accounts	(605,964)	(623,856)	$ (5,613,365)
Current Trade Receivables Net Of Allowance	4,926,632	7,390,701
Current
Disclosure Of Financial Instruments [Line Items]
Trade receivables	3,908,804	6,244,434
Past due 0-30 days
Disclosure Of Financial Instruments [Line Items]
Trade receivables	950,417	818,318
Past due 31-120 days
Disclosure Of Financial Instruments [Line Items]
Trade receivables	66,546	326,053
Past due over 121 days
Disclosure Of Financial Instruments [Line Items]
Trade receivables	$ 606,829	$ 625,752

Financial Instruments - Sche106

Financial Instruments - Schedule of Movement of Trade Receivable Allowance for Doubtful Accounts (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Financial Instruments [Abstract]
Balance, beginning of year	$ 623,856	$ 5,613,365
Bad debt expenses		30,847
Foreign exchange (gain) loss	(17,892)	(6,811)
Write-off against reserve		(5,013,545)
Balance, end of year	$ 605,964	$ 623,856

Financial Instruments - Summ107

Financial Instruments - Summary of Effect of Changes in Foreign Exchange Currency (Details)		12 Months Ended	13 Months Ended
		Mar. 31, 2018CAD ($)$ / shares	Mar. 31, 2017CAD ($)$ / shares	Mar. 31, 2018USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	Mar. 31, 2017GBP (£)$ / shares	Mar. 31, 2017EUR (€)$ / shares	Feb. 29, 2016CAD ($)
Disclosure Of Financial Instruments [Line Items]
Cash and cash equivalents		$ 24,287,107	$ 15,802,363					$ 5,472,927
Long-term debt		$ (4,661,356)	$ (22,931,544)
Foreign Exchange Rate Risk
Disclosure Of Financial Instruments [Line Items]
Cash and cash equivalents				$ 1,120,711	$ 5,204,124	£ 1,778	€ 15,997
Trade and other receivables				3,125,286	13,146,332	36,239	1,390,984
Trade and other payables				(1,338,182)	(6,566,584)		(463,134)
Long-term payable				(483,549)	(795,072)
Derivative financial liability swap					(30,741)
Long-term debt	[1]				(3,682,294)
Financial assets				$ 2,424,266	$ 7,275,765	£ 38,017	€ 943,847
Foreign Exchange Rate Risk | U S Dollars
Disclosure Of Financial Instruments [Line Items]
Average | $ / shares		1.2834	1.3134
Reporting | $ / shares		1.2900	1.3299	1.2900	1.3299	1.3299	1.3299
Foreign Exchange Rate Risk | U S Dollars | 5% Strengthening of Currency
Disclosure Of Financial Instruments [Line Items]
Increase in net profit		$ 121,212	$ 363,787
Foreign Exchange Rate Risk | Euro
Disclosure Of Financial Instruments [Line Items]
Average | $ / shares		1.5008	1.4424
Reporting | $ / shares		1.5898	1.4251	1.5898	1.4251	1.4251	1.4251
Foreign Exchange Rate Risk | Euro | 5% Strengthening of Currency
Disclosure Of Financial Instruments [Line Items]
Increase in net profit			$ 47,192
Foreign Exchange Rate Risk | GBP
Disclosure Of Financial Instruments [Line Items]
Average | $ / shares		1.7022	1.7275
Reporting | $ / shares		1.8079	1.6700	1.8079	1.6700	1.6700	1.6700
Foreign Exchange Rate Risk | GBP | 5% Strengthening of Currency
Disclosure Of Financial Instruments [Line Items]
Increase in net profit			$ 1,901
[1]	This reflects the cross currency swap agreements applied to the debt in GBP.

Financial Instruments - Summ108

Financial Instruments - Summary of Corporation's Exposure to Interest Rate Risk (Details) - Interest rate risk [member]	12 Months Ended
	Mar. 31, 2018
Cash and Cash Equivalents
Disclosure Of Financial Instruments [Line Items]
Borrowings, interest rate basis	Short-term fixed interest rate
Restricted Short-term Investments
Disclosure Of Financial Instruments [Line Items]
Borrowings, interest rate basis	Short-term fixed interest rate
Long-term Debt
Disclosure Of Financial Instruments [Line Items]
Borrowings, interest rate basis	Fixed and variable interest rates
Unsecured Convertible Debentures
Disclosure Of Financial Instruments [Line Items]
Borrowings, interest rate basis	Fixed interest rates

Financial Instruments - Summ109

Financial Instruments - Summary of Contractual Maturities of Financial Liabilities (Details) - Liquidity Risk - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Financial Instruments [Line Items]
Carrying amount	$ 11,659	$ 35,341
Contractual cash flows	11,816	39,925
Less than 1 year
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows	11,566	19,049
1 to 5 years
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows	250	20,876
Trade and Other Payables And Long-term Payable
Disclosure Of Financial Instruments [Line Items]
Carrying amount	6,998	10,788
Contractual cash flows	6,998	10,788
Trade and Other Payables And Long-term Payable | Less than 1 year
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows	6,748	9,993
Trade and Other Payables And Long-term Payable | 1 to 5 years
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows	250	795
Long-term Debt
Disclosure Of Financial Instruments [Line Items]
Carrying amount	4,661	22,932
Contractual cash flows	4,818	26,459
Long-term Debt | Less than 1 year
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows	$ 4,818	8,681
Long-term Debt | 1 to 5 years
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows		17,778
Unsecured Convertible Debentures
Disclosure Of Financial Instruments [Line Items]
Carrying amount		1,406
Contractual cash flows		2,463
Unsecured Convertible Debentures | Less than 1 year
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows		160
Unsecured Convertible Debentures | 1 to 5 years
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows		2,303
Interest Rate Swap Contract
Disclosure Of Financial Instruments [Line Items]
Carrying amount		7
Contractual cash flows		7
Interest Rate Swap Contract | Less than 1 year
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows		7
Cross Currency Swap Contract
Disclosure Of Financial Instruments [Line Items]
Carrying amount		208
Contractual cash flows		208
Cross Currency Swap Contract | Less than 1 year
Disclosure Of Financial Instruments [Line Items]
Contractual cash flows		$ 208

Operating Leases - Additional I

Operating Leases - Additional Information (Details) - Lease One - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating Leases [Line Items]
Minimum operating lease payments recognised as expense	$ 615,989
Operating costs of lease	72,020	$ 76,987
Tax on lease	110,234	117,800
Less than 1 year
Operating Leases [Line Items]
Minimum lease payments	453,219
2,020
Operating Leases [Line Items]
Minimum lease payments	381,727
2,021
Operating Leases [Line Items]
Minimum lease payments	336,174
2,022
Operating Leases [Line Items]
Minimum lease payments	336,174
2,023
Operating Leases [Line Items]
Minimum lease payments	168,087
Selling, general and administrative expenses
Operating Leases [Line Items]
Minimum operating lease payments recognised as expense	264,137	377,941
Cost of sales
Operating Leases [Line Items]
Minimum operating lease payments recognised as expense	143,087	305,458
Research and development expenses
Operating Leases [Line Items]
Minimum operating lease payments recognised as expense	$ 208,765	$ 0
Bottom of range
Operating Leases [Line Items]
Operating lease expiration terms	May 31, 2018
Top of range
Operating Leases [Line Items]
Operating lease expiration terms	Sep. 30, 2022

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	1 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2018CAD ($)	Mar. 31, 2018USD ($)	Mar. 31, 2018USD ($)
Disclosure Of Commitments And Contingencies [Line Items]
Term of minimum annual volume of sales to maintain exclusivity of speciality ingredient	11 years
Capital expenditure obligations		$ 5,000,000
Capital expenditure		4,043,487
Capital expenditure included in trade and other payables		349,012
Payment of capital expenditure		507,983
Capital commitments		234,914
Capital commitment included in trade and other payable		35,765
Payment of capital commitments		134,839
Research and development projects, remaining amount		428,000
Amount owed from customer		4,773,000	$ 3,700,000
CEO
Disclosure Of Commitments And Contingencies [Line Items]
Claims by former CEO		8,500,000
Provisions recognized on claims		$ 0
Percentage of royalties payable		1.00%	1.00%
Bottom of range
Disclosure Of Commitments And Contingencies [Line Items]
Total remaining amount of royalties		$ 5,800,000		$ 4,500,000

Capital Management - Additional

Capital Management - Additional Information (Details) - CAD ($)	Mar. 31, 2018	Mar. 31, 2017
Capital Management [Abstract]
Cash	$ 5,784,810	$ 12,808,173
Cash equivalents	$ 18,502,297	$ 2,994,190

Capital Management - Summary of

Capital Management - Summary of Cash Equivalents and Restricted Short-term Investments (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Capital Management [Line Items]
Cash equivalents	$ 18,502,297	$ 2,994,190
Restricted short-term investments maturity date	Dec. 11, 2018	Dec. 11, 2017
Restricted short-term investments interest rate	0.90%	0.85%
Restricted short-term investments	$ 60,000	$ 72,000
Biodroga Nutraceuticals Inc
Disclosure Of Capital Management [Line Items]
Restricted short-term investments maturity date	May 28, 2018	Jun. 1, 2017
Restricted short-term investments interest rate	1.20%	1.05%
Restricted short-term investments	$ 2,350,000	$ 2,350,000
Cross Currency Swap
Disclosure Of Capital Management [Line Items]
Restricted short-term investments maturity date		Apr. 4, 2018
Restricted short-term investments		$ 323,000
Term Deposits One
Disclosure Of Capital Management [Line Items]
Maturity dates of term deposits	Apr. 27, 2018	Apr. 11, 2017
Term deposits interest rate	1.12%	0.52%
Cash equivalents	$ 18,502,297	$ 1,662,375
Term Deposits Two
Disclosure Of Capital Management [Line Items]
Maturity dates of term deposits		Apr. 25, 2017
Term deposits interest rate		0.53%
Cash equivalents		$ 1,331,815

Operating segments - Additional

Operating segments - Additional Information (Details)	Dec. 27, 2017Segment	Mar. 31, 2018CAD ($)Customer	Mar. 31, 2017CAD ($)Customer
Disclosure Of Operating Segments [Line Items]
Description of factors used to identify entity's reportable segments		In prior periods and until the loss of control of the subsidiary Acasti on December 27, 2017, the Corporation had two reportable segments which were the Corporation’s strategic business units.
Number of Segments | Segment	2
Revenues		$ 27,645,582	$ 46,817,383
Major Customer One | Nutraceutical
Disclosure Of Operating Segments [Line Items]
Revenues		$ 4,529,350	$ 7,478,492
Number of customers representing ten percent or more of sales | Customer		1	1
Percentage of entity's revenue		17.26%	16.35%

Operating segments - Summary of

Operating segments - Summary of Information About Reportable Segments (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Operating Segments [Line Items]
Revenue from external sales and royalties	$ 27,645,582	$ 46,817,383
Gross margin	6,324,292	12,801,812
Research and development expenses	(12,395,671)	(7,248,873)
Research tax credits and grants	(1,751,952)	2,408,377
Selling, general and administrative expenses	(14,708,250)	(17,060,852)
Other income – net gain on sale of assets	23,702,312
Other income – royalty settlement		15,301,758
Income from operating activities	1,170,731	6,202,222
Gain on loss of control of subsidiary	8,783,613
Finance income	227,465	66,536
Finance costs	(2,446,279)	(2,772,146)
Change in fair value of derivative assets and liabilities and loss on sale of available-for-sale investment	(36,347)
Change in fair value of derivative assets and liabilities		(263,135)
Income before income taxes	7,699,183	3,233,477
Income taxes (expense) recovery	1,640,200	(2,353,628)
Net income	9,339,383	879,849
Depreciation and amortization	(3,541,882)	(3,816,800)
Stock-based compensation	(2,283,756)	(2,014,902)
Reportable segment assets	98,596,954	111,220,116
Reportable segment liabilities	12,063,184	36,419,878
Nutraceutical
Disclosure Of Operating Segments [Line Items]
Revenue from external sales and royalties	27,645,582	46,809,586
Revenue from transactions to Cardiovascular segment		112,500
Gross margin	6,324,292	12,792,785
Research and development expenses	(895,944)	(1,774,038)
Research tax credits and grants	(1,836,071)	2,078,047
Selling, general and administrative expenses	(11,946,772)	(13,503,643)
Other income – net gain on sale of assets	23,702,312
Other income – royalty settlement		15,301,758
Income from operating activities	15,347,817	14,894,909
Gain on loss of control of subsidiary	8,783,613
Finance income	188,828	31,180
Finance costs	(2,090,867)	(2,623,073)
Change in fair value of derivative assets and liabilities and loss on sale of available-for-sale investment	(225,348)
Change in fair value of derivative assets and liabilities		(211,869)
Income before income taxes	22,004,043	12,091,147
Income taxes (expense) recovery	1,640,200	(2,482,990)
Net income	23,644,243	9,608,157
Depreciation and amortization	(2,224,814)	(3,596,088)
Stock-based compensation	(1,371,382)	(1,340,324)
Reportable segment assets	51,057,311	98,163,888
Reportable segment liabilities	11,057,797	32,685,762
Cannabis
Disclosure Of Operating Segments [Line Items]
Research and development expenses	(3,566,223)
Income from operating activities	(3,566,223)
Income before income taxes	(3,566,223)
Net income	(3,566,223)
Depreciation and amortization	(1,054,170)
Stock-based compensation	(251,763)
Reportable segment assets	40,953,903
Reportable segment liabilities	1,005,387
Cardiovascular
Disclosure Of Operating Segments [Line Items]
Revenue from external sales and royalties		7,797
Gross margin		7,797
Research and development expenses	(9,675,625)	(7,991,232)
Research tax credits and grants	84,119	330,330
Selling, general and administrative expenses	(2,761,478)	(3,557,209)
Income from operating activities	(12,352,984)	(11,210,314)
Finance income	38,637	124,509
Finance costs	(355,412)	(238,226)
Change in fair value of derivative assets and liabilities and loss on sale of available-for-sale investment	195,740
Change in fair value of derivative assets and liabilities		(52,974)
Income before income taxes	(12,474,019)	(11,377,005)
Income taxes (expense) recovery		129,362
Net income	(12,474,019)	(11,247,643)
Depreciation and amortization	(2,005,019)	(2,737,109)
Stock-based compensation	(660,611)	(674,578)
Reportable segment assets	6,585,740	25,454,825
Reportable segment liabilities		3,752,298
Intersegment Elimination
Disclosure Of Operating Segments [Line Items]
Revenue from transactions to Cardiovascular segment		(112,500)
Gross margin		1,230
Research and development expenses	1,742,121	2,516,397
Income from operating activities	1,742,121	2,517,627
Finance income		(89,153)
Finance costs		89,153
Change in fair value of derivative assets and liabilities and loss on sale of available-for-sale investment	(6,739)
Change in fair value of derivative assets and liabilities		1,708
Income before income taxes	1,735,382	2,519,335
Net income	1,735,382	2,519,335
Depreciation and amortization	$ 1,742,121	2,516,397
Reportable segment assets		(12,398,597)
Reportable segment liabilities		$ (18,182)

Operating segments - Summary116

Operating segments - Summary of Revenue from Sales Based on Destination (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Geographical Areas [Line Items]
Inventory sold	$ 26,168,469	$ 45,734,361
Canada
Disclosure Of Geographical Areas [Line Items]
Inventory sold	11,494,565	15,793,572
United States
Disclosure Of Geographical Areas [Line Items]
Inventory sold	11,581,085	23,795,544
Belgium
Disclosure Of Geographical Areas [Line Items]
Inventory sold		2,363,275
China
Disclosure Of Geographical Areas [Line Items]
Inventory sold	1,254,964	1,493,165
France
Disclosure Of Geographical Areas [Line Items]
Inventory sold	467,473	809,127
Uruguay
Disclosure Of Geographical Areas [Line Items]
Inventory sold	779,613	51,144
Other Countries
Disclosure Of Geographical Areas [Line Items]
Inventory sold	$ 590,769	$ 1,428,534

Related Parties - Additional In

Related Parties - Additional Information (Details)	12 Months Ended
	Mar. 31, 2018
Key Management Personnel
Disclosure Of Transactions Between Related Parties [Line Items]
Proportion of voting rights	9.00%

Related Parties - Summary of Ke

Related Parties - Summary of Key Management Personnel Compensation (Details) - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Transactions Between Related Parties [Abstract]
Short-term benefits	$ 3,361,371	$ 2,988,124
Share-based compensation costs	1,879,459	1,605,103
Total compensation of key management personnel	$ 5,240,830	$ 4,593,227

Related Parties - Summary of119

Related Parties - Summary of Key Management Personnel Compensation (Parenthtical) (Details) - Acasti - CAD ($)	12 Months Ended	13 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Transactions Between Related Parties [Line Items]
Short-term benefits	$ 735,244	$ 756,405
Share-based compensation costs	$ 444,556	$ 544,703